

conjugated equine estrogens ("CEE") with medroxyprogesterone acetate ("MPA"), and specifically pointed to claims 21-34, which claim methods using combinations of estrogens and progestins over broad dosage ranges. Plunkett provides lists of possible estrogens and progestins. Tables 1A and 1B disclose twenty estrogens and seventeen progestins respectively and recite the maximum, minimum and preferred dosage levels for each. Plunkett lists CEE/MPA as one of twenty possible estrogen/progestin combinations. (Col. 6 line 46 - Col. 7 line 14).

Applicant's claims are drawn specifically to a method of treating or inhibiting vasomotor symptoms comprising continuously and uninterruptedly providing a daily dosage of about 1.5 mg MPA in combination with a dosage of between about 0.3 and about 0.45 mg CEE, USP. As the Examiner noted, "Plunkett et al. does not particularly teach the dosages of conjugated equine estrogen/medroxyprogesterone claimed herein." (Office Action, p. 3). There is nothing in Plunkett to teach or suggest the selection of 1.5 mg MPA for the treatment of vasomotor symptoms in combination with about 0.3 to about 0.45 mg CEE.

The Examiner states that Applicant has not provided any data demonstrating unexpected results in comparison with Plunkett. As discussed below, the Examiner has not even met the initial burden of presenting a prima facie case of obviousness as required by the case law. Moreover, Applicant respectfully disagrees that Applicant has not provided data demonstrating unexpected results. Plunkett describes 0.600 mg as the preferred dosage of CEE (Table 1A) and 2.5 mg as the preferred dosage of MPA (Table 1B). This preferred combination of CEE and MPA represents the closest teaching within Plunkett to the Applicant's claimed invention. This preferred combination essentially has become the

standard, commercially available dosage -- 0.625 mg CEE in combination with 2.5 mg MPA ("PREMPRO"). Thus, Applicant properly has provided data in the application from a clinical study showing unexpected results of the claimed invention of lower dosages of CEE and MPA in comparison with the preferred dosages of CEE and MPA disclosed in Plunkett. Applicant submits herewith a Declaration under 37 C.F.R. § 1.132 of Rogerio A. Lobo, M.D. to further support its showing of unexpected results.

It was understood by those skilled in the art for the past 20 years that 0.625 mg CEE was the minimum required to relieve vasomotor symptoms ("hot flushes") (Lobo Declaration ¶ 8). The dosage of 2.5 mg was understood as the minimum amount needed to oppose 0.625 mg CEE and protect the endometrium. A double blinded clinical study, the Women's Health, Osteoporosis, Progestin, Estrogen study ("H.O.P.E. study"), was conducted to evaluate the safety and efficacy of lower dosages of CEE and MPA with the standard dosages. The H.O.P.E. study unexpectedly demonstrated that providing a much lower daily dosage of 1.5 mg MPA in combination with 0.45 or 0.30 mg CEE reduced the number and severity of hot flushes to essentially the same extent as the standard, commercially available dose combination of 0.625 mg CEE and 2.5 mg MPA. (Lobo Declaration ¶ 14). It was expected by those skilled in the art that there may be a dose response, such that the lower combination doses of CEE and MPA would exhibit some effect in reducing the number and severity of hot flushes, but far less of an effect than the standard dose of 0.625 mg CEE plus 2.5 mg MPA. (Lobo Declaration ¶ 12). The results of the H.O.P.E. study confounded those expectations.

Additionally, the H.O.P.E. study demonstrated that at these particular low dosage combinations, MPA has an additive effect on the relief of vasomotor symptoms. (Lobo Declaration ¶ 15). Previous studies showed that MPA had no additive effect on vasomotor relief when the common dose of 0.625 mg CEE was used. (See Greendale et al., Obstet. Gynecol., 92:982-988 (1998)). The H.O.P.E. study surprisingly demonstrated that at these low doses MPA may contribute to ameliorating vasomotor symptoms. (Lobo Declaration ¶ 15). Plunkett does not teach that an additive vasomotor effect is exhibited by the low dose of 1.5 mg MPA to the lower doses of about 0.30 to 0.45 mg CEE.

The H.O.P.E. study also demonstrated that providing a daily dosage of 1.5 mg MPA effectively inhibited the development of endometrial hyperplasia when opposing the lower doses, 0.30 to 0.45 mg CEE. (Lobo Declaration ¶ 16). The effect of the endometrium was not significantly different with these lower dosages than the standard combination containing 2.5 mg MPA. Prior to the H.O.P.E. study, the dosage of MPA necessary to provide endometrial protection with lower dosages of CEE was unknown. (Lobo Declaration ¶ 16).

Applicant also maintains that the Examiner has not even met the initial burden of presenting a prima facie case of obviousness. In re Rijckaert, 9 F.3d 1531, 1532, 28 U.S.P.Q.2d 1955, 1956 (Fed. Cir. 1993). To establish prima facie obviousness, the prior art reference(s) must teach or suggest all of the claim limitations. In re Royka, 490 F.2d 981, 180 U.S.P.Q. 580 (C.C.P.A. 1974). Because Plunkett does not teach, or suggest, using 1.5 mg MPA in combination with about 0.3 to about 0.45 mg CEE for relief of vasomotor symptoms of menopause, it is respectfully submitted that Plunkett does not render claim 7

obvious. Plunkett discloses thousands of possible estrogen/progestin combinations. The preferred dosages of MPA and CEE that Plunkett discloses are much higher than the dosages claimed in the present invention. It would not have been obvious at the time of the invention to select the lower dosage combinations claimed herein. Applicant respectfully submits that the Office Action employs a reconstruction based upon improper hindsight reasoning. In re Fine, 837 F.2d 1071, 1075 (Fed. Cir. 1988). At best, it would have been obvious to try the Applicant's claimed combination, but it has long been held that "obvious to try" is not the appropriate standard. Therefore, the Office Action does not reflect the proper evidence to support an obviousness rejection based on the reference relied upon. In any event, as discussed above, in order to facilitate prosecution, the accompanying Lobo Declaration, submitted under 37 C.F.R. § 1.132, is believed to demonstrate convincingly the unexpected results obtained with Applicants' invention.

Claims 11, 12 and 69 depend from claim 7, and it is respectfully submitted that Plunkett does not render obvious these dependent claims for at least the same reasons given above in support of the patentability of claim 7.

It is respectfully submitted that all pending claims are allowable. All issues raised by the Examiner having been addressed, reconsideration and allowance of the claims are respectfully requested. If for any reason the Examiner believes that contact with Applicant's attorney would advance prosecution, he is invited to contact the undersigned at the telephone number given below.

Dated: *April 1, 2003*

Respectfully submitted,



Thomas J. Meloro
Reg. No. 33,538

Kenyon & Kenyon
One Broadway
New York, N.Y. 10004
(212) 425-7200

01855/115
(formerly AM100226)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : PICKAR, J.; DEY, M.
Serial No. : 09/808,878
Filed : March 15, 2001
Title : HORMONE REPLACEMENT THERAPY
Art Unit : 1617
Examiner : M. Bahar

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on

Date: April 1, 2003

Signature: Thomas J. Meloro

Thomas J. Meloro (Reg. No. 33,538)

Commissioner for Patents
Washington, D.C. 20231

REQUEST FOR THREE MONTH EXTENSION OF TIME

Sir:

Applicant hereby requests a **three-month extension of time** for response to the Office Action dated October 1, 2002, which set a three-month period for response. Please charge the extension fee of \$930.00 to the deposit account of Kenyon & Kenyon, deposit account number 11-0600.

The Commissioner is also authorized to charge any additional fees or credit any overpayment to the deposit account of Kenyon & Kenyon, Deposit account No. 11-0600. A duplicate copy of this sheet is enclosed.

Respectfully submitted,
KENYON & KENYON

Dated: April 1, 2003

Thomas J. Meloro
Thomas J. Meloro
Reg. No. 33,538

One Broadway
New York, N.Y. 10004
(212) 425-7200

[AM100226]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S) : PICKAR, J., DEY M.
SERIAL NO. : 09/808,878
FILED : March 15, 2001
TITLE : HORMONE REPLACEMENT THERAPY
ART UNIT : 1617
EXAMINER : M. Bahar
Assistant Commissioner
for Patents
Washington, D.C. 20231

DECLARATION UNDER 37 C.F.R. § 1.132

SIR:

I, ROGERIO A. LOBO, M.D., declare as follows:

1. I am currently a Professor of Obstetrics & Gynecology at the Department of Obstetrics and Gynecology, Columbia University in New York, New York, and I served as Rappleye Professor and Chairman of the Department of Obstetrics and Gynecology from 1995 until July 2002. I received a medical degree from Georgetown University Medical School in 1974. I completed an internship from 1974 to 1975 and a residency from 1975 to 1978 at the University of Chicago, Department of Obstetrics & Gynecology. I was a Clinical Research Fellow at the University of Southern California Medical Center in Los Angeles, California from 1978 to 1980.
2. From 1978 until 1995, I held a number of academic medical positions at the University of Southern California, Los Angeles, California. From 1978 to 1980, I was a Clinical Instructor, Division of Reproductive Endocrinology and Infertility, Department of

Obstetrics and Gynecology. I was an Assistant Professor, Department of Obstetrics & Gynecology from 1980 to 1984, an Associate Professor from 1984 to 1988, and a Professor from 1988 to 1995. From 1984 to 1995, I was Chief and Director of the Division of Reproductive Endocrinology and Infertility.

3. In the past twenty-three years, I have been an author or co-author of at least 313 papers published in peer-reviewed journals, 99 book chapters and 314 abstracts, and have been an editor of 25 books. Many of these publications are in the area of the menopause and treatments of the symptoms of menopause including hormone replacement therapy. (See, e.g., Rogerio A. Lobo, ed., Treatment of the Postmenopausal Woman: Basic and Clinical Aspects (2d ed., Philadelphia, PA: Lippincott Williams & Wilkins 1999)).

4. I am a member of a number of professional societies, including the International Menopause Society and the North American Menopause Society. I have served as a consultant to and have served on the editorial board of numerous medical journal specializing in obstetrics and gynecology, including *Obstetrics and Gynecology*, *The Journal of Reproductive Medicine* and *Fertility and Sterility*. Additional acts about my background and qualifications including a list of my publications are set forth in my curriculum vitae, attached as Exhibit A.

5. My private practice consists of gynecology with a focus on the treatment of premenopausal, menopausal and postmenopausal women. I have also participated in a number of clinical studies evaluating various treatments, including hormone replacement therapy, for the symptoms of menopause including hot flushes and decreased bone density.

6. By way of background, menopause generally refers to the cessation of the menses and ovarian function. In other words, the ovaries no longer produce estrogen. Approximately one-third of a woman's life is spent in the estrogen-deficient postmenopausal

state. Symptoms of estrogen deficiency include hot flashes, vaginal atrophy, depression, decrease in bone mass and changes in blood lipid levels, which may be precursors to cardiovascular diseases. Conjugated equine estrogens ("CEE") have been prescribed for over 50 years to treat these symptoms. However, for a woman with an intact uterus, estrogen therapy has been shown to increase the risk of endometrial hyperplasia (abnormalities in the cells that are a precursor to endometrial carcinoma) and endometrial carcinoma (endometrial cancer). The risk is substantially reduced when a progestin is administered concurrently.

7. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial demonstrated that estrogen-progestin combinations protect against endometrial hyperplasia. (See The Writing Group for the PEPI Trial, "Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial," JAMA 275(5):370-5 (1996)). The PEPI trial involved 596 healthy postmenopausal women aged 45 to 74 years at seven clinical centers in the U.S. from 1987 to 1993. The women were randomly assigned to one of five treatment groups: (1) a placebo; (2) 0.625 mg CEE daily; (3) 0.625 mg CEE daily plus 10 mg of a progestin, medroxyprogesterone acetate ("MPA") for 12 days per month; (4) 0.625 mg CEE daily plus 2.5 mg MPA daily¹; or (5) 0.625 mg of estrogen daily plus 200 mg of a natural (micronized) progesterone for 12 days per month. A large proportion of women with a uterus who received unopposed 0.625 mg CEE developed endometrial hyperplasia. However, the addition of a progestin, 2.5 mg MPA, to the 0.625 mg CEE provided protection of the endometrium.

8. For the past 20 years, 0.625 mg CEE has been accepted as the standard dosage of estrogen necessary to relieve the symptoms of menopause, including hot flashes

¹ This is the regimen used in PREMPRO, Wyeth's commercially-marketed combination low dose hormone replace therapy.

and bone loss. (See, e.g., Lindsay et al., Obstetrics and Gynecology, 63:759-763 (1984)). The dosage of 2.5 mg of MPA has been recognized as the minimum amount needed to oppose 0.625 mg CEE and protect the endometrium. This combination of 0.625 mg CEE plus 2.5 mg MPA daily has been the most commonly prescribed hormone replacement therapy regimen in the United States. (See Archer et al., Fertility and Sterility, 75:1080-1087 (2001)).

9. A double blind clinical study of postmenopausal women was conducted using combinations of conjugated equine estrogens ("CEE") and the progestin, medroxyprogesterone acetate ("MPA"). Patients received continuous and uninterrupted treatment for 13 or 26 cycles. This study is referred to as the Women's Health, Osteoporosis, Progestin, Estrogen study ("H.O.P.E. study"). The study was conducted at 57 centers across the United States and included 2,673 healthy postmenopausal women aged 40 to 65. I worked with other scientists and doctors to develop the clinical protocol for the H.O.P.E. study and was involved as a trial investigator.

10. The objectives of the H.O.P.E. study were to evaluate the safety and efficacy of lower doses of Premarin and MPA in reducing the incidence of endometrial hyperplasia, relieving menopausal symptoms and maintaining an acceptable metabolic profile. Another sub-part of the study focused on bone mineral density and was conducted over a 26 cycle period.

11. The doses used in the H.O.P.E. study consisted of eight regimens administered daily: (1) 0.625 mg CEE; (2) 0.45 mg CEE; (3) 0.3 mg CEE; (4) 0.625 mg CEE plus 2.5 mg MPA ("PREMPRO"); (5) 0.45 mg CEE plus 2.5 mg MPA; (6) 0.45 mg CEE plus 1.5 mg MPA; (7) 0.3 mg CEE plus 1.5 mg MPA; and (8) a placebo.

12. It was conventional wisdom that the dose of 0.625 mg CEE was the minimum effective dose to relieve vasomotor symptoms ("hot flashes"). I and others

expected that the study would show that there would be a dose response such that the lower combination doses of CEE and MPA would have some effect in reducing the number and severity of hot flushes compared with the placebo, but far less of an effect than the standard dose of CEE 0.625 plus 2.5 mg MPA. In fact, I and others were interested in seeing the results of the various lower doses, but doubted the study was worth the economic effort.

13. Relief of vasomotor symptoms was analyzed in patients who experienced at least an average of 7 to 8 moderate-to-severe hot flushes per day during the 7-day period just prior to the initiation of treatment in this study.

14. It was very surprising and unexpected that the data from the H.O.P.E. study demonstrated that all doses of CEE and MPA reduced the number and severity of hot flushes experienced by the women in this study compared with women taking placebo. It was unexpected that providing a daily dosage of 1.5 mg MPA in combination with the lower doses, 0.45 or 0.30 mg, CEE, rapidly reduced the number and severity of hot flushes to the same extent as the much higher and commercially available dose combination containing 0.625 mg CEE and 2.5 mg MPA.

15. Moreover, at these particular low doses of 1.5 mg MPA, an additive effect of vasomotor symptom relief is seen. The H.O.P.E. study demonstrated that dosages of CEE and MPA may be better than equivalent dosages of unopposed CEE for vasomotor symptom relief. Previous studies with various dosages of CEE showed no additive effect of MPA on vasomotor relief. (See Greendale et al., Obstetrics and Gynecology, 92:982-988 (1998)). Instead, the presence of MPA was thought to be merely prophylactic (to prevent endometrial cancer). The H.O.P.E. study surprisingly demonstrated that at these low doses MPA may contribute to ameliorating the vasomotor symptoms.

16. Prior to the H.O.P.E. study, the dosage of MPA necessary to provide endometrial protection with lower dosages of CEE was unknown. We entered uncharted waters in conducting the H.O.P.E. study as to the endometrial risk posed by the lower daily dosage combinations of 0.45 or 0.3 mg CEE and 1.5 mg MPA. The endometrial biopsies² evaluated as part of the H.O.P.E. study demonstrated that providing a daily dosage of 1.5 mg MPA effectively inhibited the development of endometrial hyperplasia when opposing the lower doses, 0.45 or 0.30 mg, CEE. These biopsy results were not statistically different from the higher dose hormone replacement therapy combination containing 2.5 mg MPA.

17. The prior art Plunkett patent cited by the examiner is directed to combinations of various estrogens and progestins. Plunkett lists a myriad of such combinations over a variety of dosage ranges, in both cyclic and continuous regimes. There is nothing in the Plunkett patent that teaches one skilled in the art to select the combination of 1.5 mg MPA and about 0.3 to about 0.45 mg CEE for relief of vasomotor symptoms of menopause from the thousands of possible estrogen-progestin combinations.

18. The preferred dosages of MPA and CEE that Plunkett discloses are 2.5 mg MPA and 0.600 mg CEE. These dosages are much higher than the dosages claimed in the present invention -- 1.5 mg MPA and about 0.3 to about 0.45 mg CEE.

19. Plunkett does not teach the importance of balancing the dosages of MPA and CEE, particularly at very low doses. Specifically, Plunkett does not teach that the selection of 1.5 mg MPA would provide relief of vasomotor symptoms achieved in combination with about 0.3 to about 0.45 mg CEE

20. Further, Plunkett does not teach that an additive vasomotor effect is exhibited by the low dose of MPA to the lower doses of CEE (0.3 to about 0.45 mg CEE).

² An endometrial biopsy is a cell sample of the endometrium taken to evaluate whether any abnormal cells exist.

21. In conclusion, the results of the H.O.P.E. study unexpectedly demonstrated that the combinations of a daily dosage of 1.5 mg MPA with 0.3 or 0.45 mg CEE are effective in treating vasomotor symptoms. In my opinion, these dosage combinations would not have been obvious at the time of the invention to relieve vasomotor symptoms.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the patent or any reexamination certificate issued therefor.

Dated: 4/1/03



ROGERIO A. LOBO, M.D.

Updated: 3/24/03**Curriculum Vitae****ROGERIO A. LOBO, M.D.**

Date of birth: October 26, 1949

Place of birth: Hong Kong

Citizenship: Naturalized United States Citizen

Marital Status: Married (Jessie C. Lobo)

Children: Margaret J. Lobo
Roger R. Lobo

Social Security No.: 579-72-6816

Home Address and Telephone No.: 31 Kent Road
Scarsdale, New York 10583
(914) 723-8925

Business Address and Telephone No. Columbia-Presbyterian Medical Center
Department of Obstetrics & Gynecology
622 West 168th Street
New York, NY 10032
(212) 305-2377

Licensure and Certifications: State of California Medical License
No. G-36128

The University of the State of New York Medical License
No. 198859

DEA No. AL822046

Diplomate, National Board of Medical Examiners, 1975

Diplomate, The American Board of
Obstetrics and Gynecology, Inc. 1981

Diplomate, The American Board
of Obstetrics and Gynecology, Inc.
Division of Reproductive Endocrinology, 1982

Recertified Diplomate, The American
Board of Obstetrics and Gynecology Inc. 1994

Education:

1967-1995

Georgetown University
Washington, D.C.B.Sc. (Cum Laude)
Major: Biology

1970- 1974

Georgetown University Medical School
Washington, D.C.
M.D.***Postgraduate Training:***

1974- 1975

Intern
Department of Obstetrics & Gynecology
The Chicago Lying-In-Hospital
The University of Chicago
Chicago, Illinois

1975- 1978

Resident
Department of Obstetrics and Gynecology
The Chicago Lying-In-Hospital
The University of Chicago
Chicago, Illinois

1978-1980

Infertility

Clinical Research Fellow
Division of Reproductive Endocrinology andDepartment of Obstetrics and Gynecology
Los Angeles County/University of Southern
California Medical Center
Los Angeles, California***Academic Positions:***

1978-1980

Clinical Instructor
Division of Reproductive Endocrinology and Infertility
Department of Obstetrics and Gynecology
University of Southern California
Los Angeles, California

1980-1984

Assistant Professor
Department of Obstetrics and Gynecology
University of Southern California
Los Angeles, California

1984-1988

Associate Professor
Department of Obstetrics & Gynecology
University of Southern California
Los Angeles, California

1988- 1985

Professor
Department of Obstetrics & Gynecology
University of Southern California
Los Angeles, California

1984- 1995

Chief, Division of Reproductive
Endocrinology and Infertility
Department of Obstetrics and Gynecology
Los Angeles County/University of Southern
California Medical Center
Los Angeles, California

1984-1995

Director, Reproductive Endocrinology and Infertility
Training Program Fellows and students directed in training
are underlined under list of publications

1995-2002

Rappleye Professor and Chairman
Department of Obstetrics and Gynecology
Columbia University
College of Physicians and Surgeons
New York, New York

7/1/02-present

Professor of Obstetrics & Gynecology
Department of Obstetrics and Gynecology
Columbia University
College of Physicians and Surgeons
New York, New York

Other Hospital Affiliations:

1980- 1995

Consultant
City of Hope National Medical Center
Duarte, California

1984-1995

California Medical Center
Los Angeles, California

1986-1991

Director
University of Southern California/
California Hospital Reproductive Health Institute
Los Angeles, California

1991- 1995

USC University Hospital
Los Angeles, California

Outside Consultantships:

Abbott Diagnostics
North Chicago, Illinois

Medical Advisory Board
Mead Johnson Laboratories
Princeton, New Jersey

Progynon Associates
Rosemont, Illinois

Division of Endocrinology and Metabolism
Robert Wood Johnson Pharmaceutical Research Institute
New Brunswick, New Jersey

Advisory Board on Hormone Replacement Therapy
Schering Laboratories
Kenilworth, New Jersey

Reproductive Endocrinology Luminary Program
Serono Laboratories
Norwell, Massachusetts

Advisory Board
TAP Pharmaceuticals, Inc.
Deerfield, Illinois

Wyeth-Ayerst Research
Philadelphia, Pennsylvania

Board of Trustees
The Berlex Foundation
Dumont, New Jersey

Advisory Boards:

Solvay
Ortho
Lilly
Merck

Membership in Professional Societies:

International Menopause Society
Pacific Coast Fertility Society
Society for Gynecologic Investigation
The American College of Obstetricians and Gynecologists
American Society for Reproductive Medicine
The American Gynecological and Obstetrical Society
The Endocrine Society
The North American Menopause Society

Membership in Committees:**The Society of Reproductive Endocrinologists**

1983- 1984

**Medical Education Committee
III-year students**

1984-1985

**Grand Rounds Program Coordinator
Department of Obstetrics and Gynecology
Los Angeles County/University of
Southern California Medical Center
Los Angeles, California**

1984- 1987

**Board of Directors
Pacific Coast Fertility Society
Los Angeles, California**

1984

**Awards Committee
Pacific Coast Fertility Society
Los Angeles, California**

1984

**Special Study Section
National Institutes of Health
Bethesda, Maryland**

1984- 1995

**Executive Committee
Department of Obstetrics and Gynecology
Los Angeles County/University of Southern California
Medical Center, Los Angeles, California**

1985- 1986

**Search Committee for Dean
University of Southern California
School of Medicine
Los Angeles, California**

1985- 1995

**Admissions Committee for Students
University of Southern California
School of Medicine
Los Angeles, California**

1986

**External Referee
Medical Research Council of Canada
Ottawa, Canada**

1986- 1995

**Advisory Committee on Policy
American Journal of Obstetrics & Gynecology**

1987

**Program Chairman
Pacific Coast Fertility Society
Los Angeles, California**

1987- 1995	Ad Hoc Committee for Promotions University of Southern California School of Medicine Los Angeles, California
1987- present	Examiner Basic Obstetrics and Gynecology and Reproductive Endocrinology Oral Examinations The American Board of Obstetrics and Gynecology, Inc. Seattle, Washington
1988	Steering Committee National Cholesterol Education Program National Heart, Lung and Blood Institute National Institutes of Health Bethesda, Maryland
1988	Program Chairman Society for Gynecologic Investigation Washington, D.C.
1988	Chairman Poster Prize Presentation Committee The American Fertility Society Birmingham, Alabama
1988-1995	Chairman, Institutional Review Committee California Medical Center Los Angeles, California
1988-1995	Advisory Committee General Clinical Research Center University of Southern California School of Medicine Los Angeles, California
1988-1992	Reproductive Endocrinology Study Section Division of Research Grants National Institutes of Health Bethesda, Maryland
1989- 1995	Secretary-Treasurer Society for Gynecologic Investigation Washington, D.C.
1989	Exhibits Chairman Pacific Coast Fertility Society

1991- 1992	Los Angeles, California Vice President Pacific Coast Fertility Society La Mirada, California
1992- 1993	President Pacific Coast Fertility Society La Mirada, California
1992- 1996	Reviewers Reserve National Institutes of Health Bethesda, Maryland
1992- 1993	Program Chairman The North American Menopause Society Cleveland, Ohio
1993- 1996	Board of Directors The American Fertility Society Birmingham, Alabama
1995-	American Board of Obstetrics & Gynecology Division of Reproductive Endocrinology
1997-1998	President, Society for Gynecologic Investigation

***Committees at Columbia University
College of Physicians and Surgeons:***

CPPN Board
Executive Committee, Medical Board
Surgical Directors Committee
Clinical Chairs Committee
Directors of Service Committee
Dean's Committee on Hospital Appointments

Consultant for the Following Journals:

Acta Endocrinologica
American Journal of Medicine
American Journal of Nephrology
Archives of Internal Medicine
Clinical Chemistry
Contraception
Endocrinology
Epidemiology
European Journal of Obstetrics,
Gynecology and Reproductive Biology
Fertility and Sterility
Gynecologic Oncology
Gynecological Endocrinology
International Journal of Gynaecology and Obstetrics

Journal of Endocrinological Investigation
 Journal of the American Medical Association
 Life Sciences
 New England Journal of Medicine
 Obstetrics and Gynecology
 The Journal of Clinical Endocrinology
 and Metabolism
 The Journal of Reproductive Medicine
 Journal of In Vitro Fertilization and Embryo Transfer
 Proceedings of the National Academy of Science
 Australian Medical Journal

Editorship:

Editor-in-Chief
 Journal of Society for Gynecological Investigation

Journal Editorships/Editorial Board:

Clinical Pathological Conferences in
 Obstetrics and Gynecology

Clinics in Endocrinology and Metabolism

Fertility and Sterility
 (Editorial Board, 1986-1993)

Gynecological Endocrinology
 (Editorial Board)

Journal of the Society for Gynecologic
 Investigation

Menopause Management
 (Editorial Board)
 Seminars in Reproductive Endocrinology

The American Journal of Obstetrics and
 Gynecology, Society for Gynecologic
 Investigation issue (1986-1993)

The Journal of Maternal-Fetal Medicine
 (Editorial Board)

The Journal of Reproductive Medicine
 (Editorial Board)

The Journal of Clinical Endocrinology & Metabolism
 (Editorial Board) (1/1/97-12/31/2000)

Contemporary Clinical Gynecology & Obstetrics

Lectureships:

(Editorial Board) 8/1/2000-

Multiple visiting professorships and speaking engagements. Postgraduate courses and other teaching assignments (medical students, residents, etc) not specifically listed.

Honors and Awards:

Serono Award (In-Training) Paper entitled: The Role of DHEA-S in the Evaluation of Hirsute Women. Presented at the 27th Annual Meeting of the Pacific Coast Fertility Society, October 17-21, 1979, Rancho Mirage, California.

Serono Award (In-Training). Paper entitled: Elevations in Unbound Serum Estradiol as a Possible Mechanism for Inappropriate Gonadotropin Secretion in Women with PCO Presented at the 28th Annual Meeting of the Pacific Coast Fertility Society, October 15-19, 1980, Scottsdale, Arizona.

Wyeth Award. Paper entitled: The Relationship Between Psychological Stress, Neurotransmitters and Androgen Secretion in Women With PCO. Presented at the 29th Annual Meeting of the Pacific Coast Fertility Society. October 14-18, 1981, Rancho Mirage, California

Squibb Award. Paper entitled: Hirsutism in Polycystic Ovary Syndrome (PCO). Presented at the 30th Annual Meeting of the Pacific Coast Fertility Society, October 13-17, 1982, Scottsdale, Arizona

Squibb Award
Paper entitled: The Effects of Spironolactone on Adrenal Steroidogenesis in Hirsute Women
Presented at the 32nd Annual Meeting of the Pacific Coast Fertility Society
September 19-23, 1984, Rancho Mirage, California

Wyeth Award
Paper entitled: Prolactin (PRL) Modulates Peripheral Androgen Metabolism (PAM)
Presented at the 33rd Annual Meeting of the

Pacific Coast Fertility Society
April 24-28, 1985
Las Vegas, Nevada

Wyeth Award

Paper entitled: Acute Modulation of the
Hypothalamic-Pituitary Axis (HPA) by
Testosterone (T) in Normal Women
Presented at the 32nd Annual Meeting of the Society for
Gynecologic Investigation
March 20-23, 1985
Phoenix, Arizona

Lester T. Hibbard Award

Outstanding Faculty, 1985
Department of Obstetrics and Gynecology
Los Angeles County/University of Southern
California Medical Center
Los Angeles, California

Second Prize

Paper entitled: Genital Skin 5α Reductase
Activity (5α RA): A Marker of Androgenicity
in Women
Presented at the 4th Annual Meeting of
The American Gynecological and Obstetrical Society
September 4-7, 1985
Hot Springs, Virginia

Squibb Award

Paper entitled: Clinical Heterogeneity in
Turner's Syndrome
Presented at the 34th Annual Meeting of the
Pacific Coast Fertility Society
April 9-13, 1986
San Diego, California

Special Prize Forum

Paper entitled: Differential Pathways of 3α
Androstanediol Glucuronide (3α diol G)
Formation in Human Skin
Presented at the 34th Annual Meeting of the
Society for Gynecologic Investigation
March 18-21, 1987, Atlanta, Georgia

Special Prize Forum

Paper entitled: Opiates Modulate the
Inhibitory Effects of Androgen on the
Hypothalamic-Pituitary Axis (HPA) of Normal Women
Presented at the 34th Annual Meeting of the
Society for Gynecologic Investigation
March 18-21, 1987, Atlanta, Georgia

Serono Award (1st Prize)
Paper entitled: Adrenal Effects of Short-Term
Administration of Testosterone in Normal Women
Presented at the 35th Annual Meeting of the
Pacific Coast Fertility Society
May 6-10, 1987, Palm Springs, California

Serono Award (2nd Prize)
Paper entitled: Secretory Dynamics of
Bioactive and Immunoreactive PRL in PCO
Presented at the 35th Annual Meeting of the
Pacific Coast Fertility Society, May 6-10, 1987
Palm Springs, California

Outstanding Teacher Award, 1988
Department of Family Medicine
University of Southern California
School of Medicine, Los Angeles, California

Serono Award (2nd Prize). Paper entitled: Decreased
Responses of ACTH to Ovine Corticotropin-Releasing
Factor (OCRF) and Increased Adrenal Insensitivity in
Hyperandrogenic Women
Presented at the 37th Annual Meeting of the
Pacific Coast Fertility Society
April 12-16, 1989, Palm Springs, California

Wyeth Award
Paper entitled: Human Chorionic Gonadotropin (hCG)
Enhances Progesterone Stimulation of Prolactin (PRL)
Production by Human Endometrial Stromal Cells in
Culture: Evidence for Trophoblast-Endometrial
Interaction Presented at the 38th Annual

Paracrine
Meeting of the

Pacific Coast Fertility Society
April 25-29, 1990, Scottsdale, Arizona

Mead Johnson Laboratory/Purvis Martin, M.D.
Research Award
Paper entitled: Insulin Induced Stress
Responses and the Effects of Estrogen and
Progesterone in Postmenopausal Women (PMW)

Presented at the 39th Annual Meeting of the
Pacific Coast Fertility Society, April 10-14, 1991
Indian Wells, California

Serono Award (1st Prize)

Paper entitled: The Synergistic Effects of
Clomiphene Citrate and Human Menopausal
Gonadotropins in Folliculogenesis of Hyperstimulated
Cycles as Assessed by GnRH Antagonist (Nal-Glu)
Presented at the 39th Annual Meeting of the
Pacific Coast Fertility Society, April 10-14, 1991,
Indian Wells, California

Serono Award (1st Prize)

Paper entitled: Assessing the Pharmacodynamic
Properties of Exogenously Administered Progesterone:
A comparison of Micronized Vaginal Delivery to
Intramuscular Routes
Presented at the 40th Annual Meeting of the
Pacific Coast Fertility Society
April 8-12, 1992, Indian Wells, California

**Mead Johnson Laboratory/Purvis Martin, M.D.,
Research Award**

Paper entitled: The Route of Administration
Influences the Effect of Estrogen on Insulin Sensitivity in
Postmenopausal Women. Presented at the 41st Annual
Meeting of the Pacific Coast Fertility Society, April 14-18,
1993, Indian Wells, California

Serono Award (1st Prize)

Paper entitled: Serum AoG is a Useful Marker
for the Treatment of Acne in Normoandrogenic Women
Presented at the 42nd Annual Meeting of the
Pacific Coast Fertility Society, April 20-24, 1994.
Indian Wells, California

PUBLICATIONS

Rogerio A. Lobo, M.D.

Peer-Review Journals:

1. Lobo RA, Kletzky OA, Kaptein EM and Goebelsmann U: Prolactin modulation of dehydroepiandrosterone sulfate secretion. *Am J Obstet Gynecol* 138:632-636, 1980.
2. Lobo RA, March CM, Goebelsmann U, Krauss RM and Mishell DR Jr: Sub-dermal estradiol pellets following hysterectomy and oophorectomy. Effect upon serum estrone, estradiol, luteinizing hormone, follicle-stimulating hormone, corticosteroid binding globulin-binding capacity, testosterone-estradiol binding globulin-binding capacity, lipids, and hot flushes. *Am J Obstet Gynecol* 138:714-719, 1980.
3. Lobo RA and Goebelsmann U: Adult manifestation of congenital adrenal hyperplasia due to incomplete 21-hydroxylase deficiency mimicking polycystic ovarian disease. *Am J Obstet Gynecol* 138:720-726, 1980.
4. Lobo RA, Paul WL and Goebelsmann U: Dehydroepiandrosterone sulfate as an indicator of adrenal androgen function. *Obstet Gynecol* 57:69-73, 1981.
5. Lobo RA, Granger L, Goebelsmann U and Mishell DR Jr: Elevations in unbound serum estradiol as a possible mechanism for inappropriate gonadotropin secretion in women with PCO. *J Clin Endocrinol Metab* 52:156-158, 1981.
6. Lobo RA, Paul WL and Goebelsmann U: Serum levels of DHEAS in gynecologic endocrinopathy and infertility. *Obstet Gynecol* 57:607-612, 1981.
7. Lobo RA and Goebelsmann U: Evidence for reduced 3 β -ol-hydroxysteroid dehydrogenase activity in some hirsute women thought to have polycystic ovary syndrome. *J Clin Endocrinol Metab* 53:394-400, 1981.
8. Lobo RA, March CM, Goebelsmann U and Mishell DR Jr: The modulating role of obesity and 17 β -estradiol (E_2) on bound and unbound E_2 and adrenal androgens in oophorectomized women. *J Clin Endocrinol Metab* 54:320-324, 1982.
9. Lobo RA, Gysler M, March CM, Goebelsmann U and Mishell DR Jr: Clinical and laboratory predictors of clomiphene response. *Fertil Steril* 37:168-174, 1982.
10. Lobo RA and Goebelsmann U: Effect of androgen excess on inappropriate gonadotropin secretion as found in the polycystic ovary syndrome. *Am J Obstet Gynecol* 142:394-401, 1982.
11. Lobo RA, Goebelsmann U, Brenner PF and Mishell DR Jr: The effects of estrogen on adrenal androgens in oophorectomized women. *Am J Obstet Gynecol* 142:471-478, 1982.
12. Horton R, Hawks D and Lobo R: 3 α , 17 β -Androstenediol glucuronide in plasma: A marker of androgen action in idiopathic hirsutism. *J Clin Invest* 69:1203-1206, 1982.

13. Lobo RA, Granger LR, Davajan V and Mishell DR Jr: An extended regimen of clomiphene citrate in women unresponsive to standard therapy. *Fertil Steril* 37:762-766, 1982.
14. Lobo RA and Gibbons WE: The role of progestin therapy in breast disease and central nervous system function. *J Reprod Med* 27:515-521, 1982.
15. Lobo RA, Paul W, March CM, Granger L and Kletzky OA: Clomiphene and dexamethasone in women unresponsive to clomiphene alone. *Obstet Gynecol* 60:497-501, 1982.
16. Lahteenmaki P, Lobo R, Marrs RP, Gibbons WE, Nakamura RM and diZerega GS: Characterization of porcine granulosa cells by isopycnic gradient centrifugation. *Biol Reprod* 27:633-640, 1982.
17. Mashchak CA, Lobo RA, Dozono-Takano R, Eggena P, Nakamura RM, Brenner PF and Mishell DR Jr: Comparison of pharmacodynamic properties of various estrogen formulations. *Am J Obstet Gynecol* 144:511-518, 1982.
18. Shaaban MM, Hung TT, Hoffman DI, Lobo RA and Goebelsmann U: β -Endorphin and β -lipotropin concentrations in umbilical cord blood. *Am J Obstet Gynecol* 144:560-568, 1982.
19. Readhead C, Lobo RA and Kletzky OA: The activity of 3β -hydroxysteroid dehydrogenase and $\nabla^{4,5}$ isomerase in human follicular tissue. *Am J Obstet Gynecol* 145:491-495, 1983.
20. Lobo RA, Granger LR, Paul WL, Goebelsmann U and Mishell DR Jr: Psychological stress and increases in urinary norepinephrine metabolites, platelet serotonin, and adrenal androgens in women with polycystic ovary syndrome. *Am J Obstet Gynecol* 145:496-503, 1983.
21. Lobo RA and Kletzky OA: Normalization of androgen and sex hormone-binding globulin levels after treatment of hyperprolactinemia. *J Clin Endocrinol Metab* 56:562-566, 1983.
22. Lobo RA, Kletzky OA, Campeau JD and diZerega GS: Elevated bioactive luteinizing hormone in women with the polycystic ovary syndrome. *Fertil Steril* 39:674-678, 1983.
23. Petrucha RA, Goebelsmann U, Hung TT, Haase HR and Lobo RA: Amniotic fluid β -endorphin and β -lipotropin concentrations during the second and third trimester. *Am J Obstet Gynecol* 146:644-651, 1983.
24. Lobo RA, Brenner P and Mishell DR Jr: Metabolic parameters and steroid levels in postmenopausal women receiving lower doses of natural estrogen replacement. *Obstet*

Gynecol 62:94-98, 1983.

25. Lobo RA, Goebelsmann U and Horton R: Evidence for the importance of peripheral tissue events in the development of hirsutism in polycystic ovary syndrome. *J Clin Endocrinol Metab* 57:393-397, 1983.
26. diZerega GS, Campeau JD, Nakamura RM, Ujita EL, Lobo R and Marrs RP: Activity of a human follicular fluid protein(s) in spontaneous and induced ovarian cycles. *J. Clin Endocrinol Metab* 57:838-846, 1983.
27. Shoupe D, Kumar DD and Lobo R: Insulin resistance in polycystic ovary syndrome. *Am J Obstet Gynecol* 147:588-592, 1983.
28. diZerega GS, Campeau JD, Ujita EL, Kling OR, Marrs RP, Lobo RA and Nakamura RM: The possible role for a follicular protein in the intraovarian regulation of folliculogenesis. *Sem Reprod Endocrinol* 1:309-320, 1983.
29. Lobo RA, McCormick W, Singer F and Roy S: Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. *Obstet Gynecol* 63:1-5, 1984.
30. Lobo RA, Shoupe D, Chang SP and Campeau J: The control of bioactive luteinizing hormone secretion in women with polycystic ovary syndrome. *Am J Obstet Gynecol* 148:423-428, 1984.
31. Shoupe D, and Lobo RA: The influence of androgens on insulin resistance. *Fertil Steril* 41:385-388, 1984.
32. Levitan D, Moser SA, Goldstein DA, Kletzky OA, Lobo RA and Massry SG: Disturbances in the hypothalamic-pituitary-gonadal axis in male patients with acute renal failure. *Am J Nephrol* 4:99-106, 1984.
33. Marrs RP, Lobo R, Campeau JD, Nakamura RM, Brown J, Ujita EL and diZerega GS: Correlation of human follicular fluid inhibin activity with spontaneous and induced follicle maturation. *J Clin Endocrinol Metab* 58:704-709, 1984.
34. Klove KL, Roy S and Lobo RA: The effect of different contraceptive treatments on the serum concentration of dehydroepiandrosterone sulfate. *Contraception* 29:319-324, 1984.
35. Chang SP, Shoupe D, Kletzky OA, Lobo RA: Differences in the ratio of bioactive to immunoreactive serum luteinizing hormone during vasomotor flushes and hormonal therapy in postmenopausal women. *J Clin Endocrinol Metab* 58:925-929, 1984.
36. diZerega GS, Marrs RP, Lobo R, Ujita EL, Brown J and Campeau JD: Correlation of inhibin and follicle regulatory protein activities with follicular fluid steroid levels in anovulatory patients. *Fertil Steril* 41:849-855, 1984.

37. Lobo RA, Shoupe D, Roy S and Paul W: Central and peripheral metabolites of norepinephrine and dopamine in postmenopausal women. *Am J Obstet Gynecol* 149:548-552, 1984.
38. Hoffman DI, Klove K and Lobo RA: The prevalence and significance of elevated dehydroepiandrosterone sulfate levels in anovulatory women. *Fertil Steril* 42:76-81, 1984.
39. Fallis RJ, Fisher M and Lobo RA: A double blind trial of naloxone in the treatment of acute stroke. *Stroke* 15:627-629, 1984.
40. Shoupe D and Lobo RA: Evidence for altered catecholamine metabolism in polycystic ovary syndrome. *Am J Obstet Gynecol* 150:566-571, 1984.
41. Lobo RA, diZerega GS and Marrs RP: Follicular fluid steroid levels in dysmature and mature follicles from spontaneous and hyperstimulated cycles in normal and anovulatory women. *J Clin Endocrinol Metab* 60:81-87, 1985.
42. Shoupe D, Montz FJ and Lobo RA: The effects of estrogen and progestin on endogenous opioid activity in oophorectomized women. *J Clin Endocrinol Metab* 60:178-183, 1985.
43. Serafini P and Lobo RA: Increased 5 α -reductase activity in idiopathic hirsutism. *Fertil Steril* 43:74-78, 1985.
44. Serafini P, Ablan F and Lobo RA: 5 α -Reductase activity in the genital skin of hirsute women. *J Clin Endocrinol Metab* 60:349-355, 1985.
45. Hoffman D and Lobo RA: Serum dehydroepiandrosterone sulfate and the use of clomiphene citrate in anovulatory women. *Fertil Steril* 43:196-199, 1985.
46. Lobo RA, Shoupe D, Serafini P, Brinton D and Horton R: The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. *Fertil Steril* 43:200-205, 1985.
47. Shoupe D and Lobo RA: Prolactin response after gonadotropin-releasing hormone in the polycystic ovary syndrome. *Fertil Steril* 43:549-553, 1985.
48. Hoffman DI, Lobo RA, Campeau JD, Jsai H-M, Holmberg EA, Ono T, Frederick JL, Platt LD and diZerega GS: Ovulation induction in clomiphene-resistant anovulatory women: Differential follicular response to purified urinary follicle-stimulating hormone (FSH) versus purified urinary FSH and luteinizing hormone. *J Clin Endocrinol Metab* 60:922-927, 1985.

49. Lobo RA, Roy S, Shoupe D, Endres DB, Adams JS, Rude RK and Singer FR: Estrogen and progestin effects on urinary calcium and calciotropic hormones in surgically-induced postmenopausal women. *Horm Metab Res* 17:369-372, 1985.
50. Serafini PC, Catalino J and Lobo RA: The effect of spironolactone on genital skin 5α -reductase activity. *J Steroid Biochem* 23:191-194, 1985.
51. Barnes DB, and Lobo RA: Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women. *Obstet Gynecol* 66:216-219, 1985.
52. Barnes RB, and Lobo RA: Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation. *J Clin Endocrinol Metab* 61:779-782, 1985.
53. Mashchak CA and Lobo RA: Estrogen replacement therapy and hypertension. *J Reprod Med (Suppl 10)* 30:805-810, 1985.
54. Chiang RS, Barnes RB, Shoupe D and Lobo RA: Dose-related changes in LH bioactivity with intranasal GnRH agonist administration. *Contraception* 32:342-357, 1985.
55. Serafini P and Lobo RA: The effects of spironolactone on adrenal steroidogenesis in hirsute women. *Fertil Steril* 44:595-599, 1985.
56. Serafini P, and Lobo RA: Prolactin modulates peripheral androgen metabolism. *Fertil Steril* 45:41-46, 1986.
57. Barnes RB, Cha K-Y, Lee DG and Lobo RA: Modulation of luteinizing hormone immunoreactivity and bioactivity by dopamine but not norepinephrine in women. *Am J Obstet Gynecol* 154:445-450, 1986.
58. Gibbons WE, Moyer DL, Lobo RA, Roy S and Mishell DR Jr: Biochemical and histologic effects of sequential estrogen/progestin therapy on the endometrium of postmenopausal women. *Am J Obstet Gynecol* 154:456-461, 1986.
59. Cha KY, Barnes RB, Marrs RP and Lobo RA: Correlation of the bioactivity of luteinizing hormone in follicular fluid with oocyte maturity in the spontaneous cycle. *Fertil Steril* 45:338-341, 1986.
60. Steingold KA, Lobo RA, Judd HL, Lu JKH and Chang RJ: The effect of bromocriptine on gonadotropin and steroid secretion in polycystic ovarian disease. *J Clin Endocrinol Metab* 62:1048-1051, 1986.
61. Barnes RB, Mileikowsky GN, Cha, KY, Spencer CA and Lobo RA: Effects of dopamine

- and metoclopramide in polycystic ovary syndrome. *J Clin Endocrinol Metab* 63:506-509, 1986.
62. Paulson RJ, Serafini PC, Catalino JA and Lobo RA: Measurements of 3α , 17 β -androstenediol glucuronide in serum and urine and the correlation with skin 5α -reductase activity. *Fertil Steril* 46:222-226, 1986.
 63. Paulson RJ, Bernstein GS, Marrs RP and Lobo RA: Idiopathic oligospermia and peripheral androgen metabolism. *Fertil Steril* 46:480-483, 1986.
 64. Serafini P, Silva PD, Paulson RJ, Elkind-Hirsch K, Hernandez M and Lobo RA: Acute modulation of the hypothalamic-pituitary axis by intravenous testosterone in normal women. *Am J Obstet Gynecol* 155:1288-1292, 1986.
 65. Silva PD, Paulsons RJ, Anderson RE and Lobo RA: Ectopic pregnancy in unrepaired distal tubal remnant after contralateral tubal anastomosis. *Fertil Steril* 47:522-523, 1987.
 66. Bernstein L, Ross RK, Lobo RA, Hanisch R, Krailo MD and Henderson BE: The effects of moderate physical activity on menstrual cycle patterns in adolescence: Implications for breast cancer prevention. *Br J Cancer* 55:681-685, 1987.
 67. Kaufman FR, Donnell GN and Lobo RA: Ovarian androgen secretion in patients with galactosemia and premature ovarian failure. *Fertil Steril* 47:1033-1034, 1987.
 68. Barnes, RB, Artal R and Lobo RA: Peripheral dopamine metabolism in polycystic ovary syndrome. *Obstet Gynecol* 70:153-156, 1987.
 69. Silva PD, Gentzschein EEK and Lobo RA: Androstenedione may be a more important precursor of tissue dihydrotestosterone than testosterone in women. *Fertil Steril* 48:419-422, 1987.
 70. Serafini P, Paulson RJ, Francis MM and Lobo RA: Modulation of prolactin responses to gonadotropin releasing hormone by acute testosterone infusions in normal women. *Gynecol Endocrinol* 1:247-253, 1987.
 71. Lobo RA, Paul WL, Gentzschein E, Serafini PC, Catalino JA, Paulson RJ and Horton R: Production of 3α -androstenediol glucuronide in human genital skin. *J Clin Endocrinol Metab* 65:711-714, 1987.
 72. Rosen GF, Vermesh M, d'Ablaing G III, Wachtel S and Lobo RA: The endocrinologic evaluation of a 45,X true hermaphrodite. *Am J Obstet Gynecol* 157:1272-1273, 1987.
 73. Rosen GF and Lobo RA: Further evidence against dopamine deficiency as the cause of inappropriate gonadotropin secretion in patients with polycystic ovary syndrome. *J Clin*

Endocrinol Metab 65:891-895, 1987.

74. Vermesh M, Silva PD and Lobo RA: Endogenous opioids modulate the inhibitory effects of androgen on the hypothalamic-pituitary axis of normal women. J Clin Endocrinol Metab 65:1183-1186, 1987.
75. Shoupe D, Mishell DR Jr, Page MA, Madkour H, Spitz IM and Lobo RA: Effects of antiprogesterone RU 486 in normal women. II. Administration in the late follicular phase. Am J Obstet Gynecol 157:1421-1426, 1987.
76. Vermesh M, Silva PD, Rosen GF, Vijod AG and Lobo RA: Effect of androgen on adrenal steroidogenesis in normal women. J Clin Endocrinol Metab 66:128-130, 1988.
77. Lobo RA, Nguyen HN, Eggena P and Brenner PF: Biologic effects of equilin sulfate in postmenopausal women. Fertil Steril 49:234-238, 1988.
78. Anderson RE, Ben-Rafael Z, Flickinger GL, Meloni F, Barnes RB, Rosen GF and Lobo RA: Secretory dynamics of bioactive and immunoreactive prolactin in polycystic ovary syndrome. Fertil Steril 49:239-243, 1988.
79. Silva PD, Porto M, Moyer DL and Lobo RA: Clinical and ultrastructural findings of an androgenizing Krukenberg tumor in pregnancy. Obstet Gynecol 71:432-434, 1988.
80. Davidson A, Vermesh M, Lobo RA and Paulson RJ: Mouse embryo culture as quality control for human in vitro fertilization: The one-cell versus the two-cell model. Fertil Steril 49:516-521, 1988.
81. Do YS, Sherrod A, Lobo RA, Paulson RJ, Shinagawa T, Chen S, Kjos S and Hseuh WA: Human ovarian theca cells are a source of renin. Proc Natl Acad Sci 85:1957-1961, 1988.
82. Pasupuleti V, Lobo R and Horton R: Conversion of dihydro-testosterone to androstanediol glucuronide by female sexual skin. Steroids 51:269-282, 1988.
83. Rosen GF, Kaplan B and Lobo, RA: Menstrual function and hirsutism in patients with gonadal dysgenesis. Obstet Gynecol 71:677-680, 1988.
84. Henderson BE, Pike MC, Ross RK, Mack TM and Lobo R: Re-evaluating the role of progestogen therapy after the menopause. Fertil Steril (Suppl 5) 49:9-15, 1988.
85. Paulson RJ, Lobo RA, Stein A, Toker R, Moegle A and Macasos T: Gestation of triplets after intrauterine implantation of two embryos. N Eng J Med 318:1339-1340, 1988.
86. Davidson A, Vermesh M, Lobo RA and Paulson RJ: The temporal effects of changes in in vitro fertilization culture media on the one-cell mouse embryo system. J In Vitro

Fertil Embryo Transfer 5:149-152, 1988.

87. Lobo, RA: Lipids, clotting factors, and diabetes: Endogenous risk factors for cardiovascular disease. *Am J Obstet Gynecol* 158:1584-1605, 1988.
88. Silva RD, Richmond JA and Lobo RA: Diagnosis and management of a tuberculous, tuboappendiceal fistula. *Am J Obstet Gynecol* 159:440-441, 1988.
89. Paulson RJ and Lobo RA: Ovarian hyperstimulation complicating the clinical presentation of a pre-existing ectopic pregnancy. *Fertil Steril* 50:670-671, 1988.
90. Rodriguez MH, Platt LD, Medearis AL, Lacarra M and Lobo RA: The use of transvaginal sonography for evaluation of postmenopausal ovarian size and morphology. *Am J Obstet Gynecol* 159:810-814, 1988.
91. Vermesh M, Silva PD, Sauer MV, Vargyas JM and Lobo RA: Persistent tubal ectopic gestation: Patterns of circulating β -human chorionic gonadotropin and progesterone, and management options. *Fertil Steril* 50:584-588, 1988.
92. Lobo RA: The androgenicity of progestational agents. *Int J Fertil (Suppl)* 33:6-12, 1988.
93. Whitehead M and Lobo RA: Progestogen use in postmenopausal women. *The Lancet* II:1243-1244, 1988.
94. Sauer MV, Vermesh M, Anderson RE, Vijod AG, Stanczyk FZ and Lobo RA: Rapid measurement of urinary pregnanediol glucuronide to diagnose ectopic pregnancy. *Am J Obstet Gynecol* 159:1531-1535, 1988.
95. Stanczyk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA and Lobo RA: A randomized comparison of nonoral estradiol delivery in postmenopausal women. *Am J Obstet Gynecol* 159:1540-1546, 1988.
96. Paulson RJ, Do YS, Hsueh WA and Lobo RA: Gradients of prorenin and active renin in ovarian venous and peripheral venous blood samples obtained simultaneously. *Am J Obstet Gynecol* 159:1575-1579, 1988.
97. Shoupe D, Mishell DR Jr, Lacarra M, Lobo RA, Horenstein J, d'Ablaing G and Moyer D: Correlation of endometrial maturation with four methods of estimating day of ovulation. *Obstet Gynecol* 73:88-92, 1989.
98. Bernstein L, Pike MC, Lobo RA, Depue RH, Ross RK and Henderson BE: Cigarette smoking in pregnancy results in marked decrease in maternal hCG and oestradiol levels. *Br J Obstet Gynaecol* 96:92-96, 1989.
99. Lobo RA and Whitehead M: Too much of a good thing? Use of progestogens in the menopause: An international consensus statement. *Fertil Steril* 51:229-231, 1989.

100. Kaufman FR, Xu YK, Ng W, Silva PD, Lobo RA and Donnell G: Gonadal function and ovarian galactose metabolism in classical galactosemia. *Acta Endocrinol* 120:129-133, 1989.
101. Xu Y-K, Ng WG, Kaufman FR, Lobo RA and Donnell GN: Galactose metabolism in human ovarian tissue. *Pediatr Res* 25:151-155, 1989.
102. Ross RK, Pike MC, Henderson BE, Mack TM and Lobo RA: Stroke prevention and oestrogen replacement therapy. *The Lancet* I:505, 1989.
103. Paulson RJ, Do YS, Hsueh WA, Eggena P and Lobo RA: Ovarian renin production in vitro and in vivo: Characterization and clinical correlation. *Fertil Steril* 51:634-638, 1989.
104. Davidson A, Vermesh M, Paulson RJ, Graczykowski JW and Lobo RA: Presence of immunoreactive β -endorphin and calcitonin in human seminal plasma, and their relation to sperm physiology. *Fertil Steril* 51:878-880, 1989.
105. Paulson RJ, Sauer MV and Lobo RA: In vitro fertilization in unstimulated cycles: A new application. *Fertil Steril* 51:1059-1060, 1989.
106. Anderson RE, Cragun JM, Chang RJ, Stanczyk FZ and Lobo RA: A pharmacodynamic comparison of human urinary follicle-stimulating hormone and human menopausal gonadotropin in normal women and polycystic ovary syndrome. *Fertil Steril* 52:216-220, 1989.
107. Sauer MV, Lobo RA and Paulson RJ: Successful twin pregnancy after embryo donation to a patient with XY gonadal dysgenesis. *Am J Obstet Gynecol* 161:380-381, 1989.
108. Pike MC, Ross RK, Lobo RA, Key TJA, Potts M and Henderson, BE: LHRH agonists and the prevention of breast and ovarian cancer. *Br J Cancer* 60:142-148, 1989.
109. Sauer MV, Paulson RJ, Macaso TM, Francis-Hernandez M and Lobo RA: Establishment of a nonanonymous donor oocyte program: Preliminary experience at the University of Southern California. *Fertil Steril* 52:433-436, 1989.
110. Steinleitner A, Stanczyk FZ, Levin JH, d'Ablaing G III, Vijod MA, Shahbazian VL and Lobo RA: Decreased in vitro production of 6-keto-prostaglandin $F_{1\alpha}$ by uterine arteries from postmenopausal women. *Am J Obstet Gynecol* 161:1677-1681, 1989.
111. Matteri RK, Stanczyk FZ, Gentzschein EE, Delgado C and Lobo RA: Androgen sulfate and glucuronide conjugates in nonhirsute and hirsute women with polycystic ovarian syndrome. *Am J Obstet Gynecol* 161:1704-1709, 1989.
112. Sauer MV, Paulson RJ and Lobo RA: Simultaneous establishment of pregnancies in two ovarian failure patients using one oocyte donor. *Fertil Steril* 52:1072-1073, 1989.

113. Stanczyk FZ, Lobo RA, Chiang ST and Woutersz TB: Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. *Contraception* 41:39-53, 1990.
114. Graczykowski JW, Vermesh M, Siegel MS, Davidson A and Lobo RA: Absence of direct effect of beta-endorphin and calcitonin on human sperm motility. *Arch Androl* 24:121-124, 1990.
115. Sauer MV, Paulson RJ and Lobo RA: Successful pre-embryo donation in ovarian failure after treatment for breast carcinoma. *The Lancet* 335:723, 1990.
116. Lobo RA: Cardiovascular implications of estrogen replacement therapy. *Obstet Gynecol (Suppl 4)* 75:18S-25S, 1990.
117. Paulson RJ, Sauer MV and Lobo RA: Embryo implantation after human in vitro fertilization: Importance of endometrial receptivity. *Fertil Steril* 53:870-874, 1990.
118. Carmina E and Lobo RA: Pituitary-adrenal responses to corticotropin-releasing factor in late onset 21-hydroxylase deficiency. *Fertil Steril* 54:79-83, 1990.
119. Anderson RE, Stein AL, Paulson RJ, Stanczyk FZ, Vijod AG and Lobo RA: Effects of norethindrone on gonadotropin and ovarian steroid secretion when used for cycle programming during in vitro fertilization. *Fertil Steril* 54:96-101, 1990.
120. Carmina E, Levin JH, Malizia G and Lobo RA: Ovine corticotropin-releasing factor and dexamethasone responses in hyperandrogenic women. *Fertil Steril* 54:245-250, 1990.
121. Kaufman FR, Stanczyk FZ, Matteri RK, Gentzschein E, Delgado C and Lobo RA: Dehydroepiandrosterone and dehydro-epiandrosterone sulfate metabolism in human genital skin. *Fertil Steril* 54:251-254, 1990.
122. Bernstein L, Yuan J-M, Ross RK, Pike MC, Hanisch R, Lobo R, Stanczyk F, Gao Y-T and Henderson BE: Serum hormone levels in pre-menopausal Chinese women in Shanghai and White women in Los Angeles: Results from two breast cancer case-control studies. *Cancer Causes and Controls* 1:51-58, 1990.
123. Lobo RA: Adult onset 21-hydroxylase deficiency: A significant problem in gynecology? *Gynecol Report* 2:266-272, 1990.
124. Stanczyk FZ, Matteri RK, Kaufman FR, Gentzschein E and Lobo RA: Androstenedione is an important precursor of dihydro-testosterone in the genital skin of women and is metabolized via 5 α -androstenedione. *J Steroid Biochem Molec Biol* 37:129-132, 1990.
125. Paulson RJ, Sauer MV, and Lobo RA: Pregnancy after in vitro fertilization in a patient with stage I endometrial carcinoma treated with progestins. *Fertil Steril* 54:735-736, 1990.

126. Sauer MV, Paulson RJ and Lobo RA: A preliminary report on oocyte donation extending reproductive potential to women over 40. *N Eng J Med* 323:1157-1160, 1990.
127. Paulson RJ, Sauer MV, Francis MM, Macaso TM and Lobo RA: In vitro fertilization in unstimulated cycles: A clinical trial utilizing hCG for timing of follicle aspiration. *Obstet Gynecol* 76:788-791, 1990.
128. Carmina E and Lobo RA: Pituitary-adrenal responses to ovine corticotropin-releasing factor in polycystic ovary syndrome and in other hyperandrogenic patients. *Gynecol Endocrinol* 4:225-232, 1990.
129. Levin JH, Tonetta SA and Lobo RA: Comparison of norethindrone and medroxy-progesterone acetate with natural progesterone and estradiol in stimulating prolactin production from cultured endometrial stromal cells. *Am J Obstet Gynecol* 163:1932-1938, 1990.
130. Cassidenti DL, Vijod AG, Vijod MA, Stanczyk FZ and Lobo RA: Short-term effects of smoking on the pharmacokinetic profiles of micronized estradiol in postmenopausal women. *Am J Obstet Gynecol* 163:1953-1960, 1990.
131. Shoupe D, Mishell DR Jr, Fossum G, Bopp BL, Spitz IM and Lobo RA: Antiprogestin treatment decreases midluteal luteinizing hormone pulse amplitude and primarily exerts a pituitary inhibition. *Am J Obstet Gynecol* 163:1982-1985, 1990.
132. Paulsons RJ, Sauer MV and Lobo RA: Factors affecting embryo implantation after human in vitro fertilization: A hypothesis. *Am J Obstet Gynecol* 163:2020-2023, 1990.
133. Sauer MV, Paulson RJ, Macaso TM, Francis MM and Lobo RA: Oocyte and pre-embryo donation to women with ovarian failure: An extended clinical trial. *Fertil Steril* 55:39-43, 1991.
134. Frederick JL, Francis MM, Macaso TM, Lobo RA, Sauer MV and Paulson RJ: Preovulatory follicular fluid steroid levels in stimulated and unstimulated cycles triggered with human chorionic gonadotropin. *Fertil Steril* 55:44-47, 1991.
135. Carmina E, Stanczyk FZ, Matteri RK, and Lobo RA: Serum androsterone conjugates differentiate between acne and hirsutism in hyperandrogenic women. *Fertil Steril* 55:872-876, 1991.
136. Sauer MV, Kaufman FR, Paulson RJ and Lobo RA: Pregnancy after oocyte donation to a woman with ovarian failure and classical galactosemia. *Fertil Steril* 55:1197-1199, 1991.
137. Cassidenti DL, Paulson RJ, Serafini P, Stanczyk FZ and Lobo RA: Effects of sex steroids on skin 5 α -reductase activity in vitro. *Obstet Gynecol* 78:103-107, 1991.

138. Presser SC, Stanczyk FZ and Lobo RA: Simultaneous measurements of prostacyclin and thromboxane metabolites during the menstrual cycle. *Am J Obstet Gynecol* 165:647-651, 1991.
139. Koonings PP, Al-Marayati L, Schlaerth JB and Lobo RA: Mayer-Rokitansky-Kuster-Hauser syndrome associated with endodermal sinus tumor of the ovary. *Fertil Steril* 56:577-578, 1991.
140. Levin JH, Carmina E and Lobo RA: Is the inappropriate gonadotropin secretion of patients with polycystic ovary syndrome similar to that of patients with adult onset congenital adrenal hyperplasia? *Fertil Steril* 56:635-640, 1991.
141. Ditkoff EC and Lobo RA: Ovarian stimulation. *Curr Opin Obstet Gynecol* 3:635-640, 1991.
142. Lobo RA: Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. *J Clin Endocrinol Metab* 73:925-930, 1991.
143. Carmina E and Lobo RA: Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism. *Obstet Gynecol* 78:845-849, 1991.
144. Ditkoff EC, Crary WG, Crisito M and Lobo RA: Estrogen improves psychological function in asymptomatic post-menopausal women. *Obstet Gynecol* 78:991-995, 1991.
145. Cassidenti DL, Sauer MV, Paulson RJ, Ditkoff EC, Rivier J, Yen SSC and Lobo RA: Comparison of intermittent and continuous use of a gonadotropin-releasing hormone antagonist (Nal-Glu) in in-vitro fertilization cycles: A preliminary report. *Am J Obstet Gynecol* 165:1806-1810, 1991.
146. Ditkoff EC, Cassidenti DL, Paulson RJ, Sauer MV, Paul WL, Rivier J, Yen SSC and Lobo RA: The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women. *Am J Obstet Gynecol* 165:1811-1817, 1991.
147. Bergman A, Stanczyk FZ and Lobo RA: The role of prostaglandins in detrusor instability. *Am J Obstet Gynecol* 165:1833-1836, 1991.
148. Stanczyk FZ, Chang L, Carmina E, Putz Z and Lobo RA: Is 11 β -hydroxyandrostenedione a better marker of adrenal androgen excess than dehydroepiandrosterone sulfate? *Am J Obstet Gynecol* 165:1837-1842, 1991.
149. Shoupe D, Meme D, Mezrow G, Lobo RA: Prevention of endometrial hyperplasia in postmenopausal women with intrauterine progesterone. *N Engl J Med* 325:1811-2, 1991.
150. Lobo RA and Cassidenti DL: Pharmacokinetics of oral 17 β -estradiol. *J Reprod Med* 37:77-84, 1992.

151. Paulson RJ, Sauer MV, Francis MM, Macaso TM and Lobo RA: In vitro fertilization in unstimulated cycles: the University of Southern California experience. *Fertil Steril* 57:290-293, 1992.
152. Lobo RA: Estrogen and the risk of coagulopathy. *Am J Med* 92:283-285, 1992.
153. Lobo RA, Notelovitz M, Bernstein L, Khan FY, Ross RK and Paul WL: Lp (a) lipoprotein: Relationship to cardiovascular disease risk factors, exercise, and estrogen. *Am J Obstet Gynecol* 166:1182-1190, 1992.
154. Cassidenti DL, Paulson RJ, Lobo RA and Sauer MV: The synergistic effects of clomiphene citrate and human menopausal gonadotrophin in the folliculogenesis of stimulated cycles as assessed by the gonadotrophin-releasing hormone antagonist Nal-Glu. *Hum Reprod* 7:344-348, 1992.
155. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC and Henderson BE: 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. *The Lancet* 339:887-889, 1992.
156. Cassidenti DL, Pike MC, Vijod AG, Stanczyk FZ and Lobo RA: A reevaluation of estrogen status in postmenopausal women who smoke. *Am J Obstet Gynecol* 166:1444-1448, 1992.
157. Lobo RA: The role of progestins in hormone replacement therapy. *Am J Obstet Gynecol* 166:1997-2004, 1992.
158. Carmina E, Stanczyk FZ, Chang L, Miles RA and Lobo RA: The ratio of androstenedione: 11 β -hydroxyandrostenedione is an important marker of adrenal androgen excess in women. *Fertil Steril* 58:148-152, 1992.
159. Sauer MV, Paulson RJ and Lobo RA: Reversing the natural decline in human fertility: An extended clinical trial of oocyte donation to women of advanced reproductive age. *JAMA* 268:1275-1279, 1992.
160. Levin JH, Stanczyk FZ and Lobo RA: Estradiol stimulates the secretion of prostacyclin and thromboxane from endometrial stromal cells in culture. *Fertil Steril* 58:530-536, 1992.
161. Paulson RJ, Sauer MV, Francis MM, Macaso TM and Lobo RA: A prospective controlled evaluation of TEST-yolk buffer in the preparation of sperm for human in vitro fertilization in suspected case of male infertility. *Fertil Steril* 58:551-555, 1992.
162. Miles RA, Cassidenti DL, Carmina E, Gentschein E, Stanczyk FZ and Lobo RA:

Cutaneous application of an androstenedione gel as an in vivo test of 5α -reductase activity in women. *Fertil Steril* 58:708-712, 1992.

163. Matteri RK, Stanczyk FZ, Cassidenti DL, Paulson RJ and Lobo RA: The ovarian contribution to peripherally derived serum C^{19} conjugates. *J Clin Endocrinol Metab* 75:768- 772, 1992.
164. Carmina E, Koyama T, Chang L, Stanczyk FZ and Lobo RA: Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? *Am J Obstet Gynecol* 167:1807-1812, 1992.
165. Carmina E, Ditkoff EC, Malizia G, Vijod AG, Janni A and Lobo RA: Increased circulating levels of immunoreactive β -endorphin in polycystic ovary syndrome is not caused by increased pituitary secretion. *Am J Obstet Gynecol* 167:1819-1824, 1992.
166. Lindheim RS, Legro RS, Bernstein L, Stanczyk FZ, Vijod MA, Presser SC and Lobo RA: Behavioral stress responses in premenopausal and postmenopausal women and the effects of estrogen. *Am J Obstet Gynecol* 167:1831-1836, 1992.
167. Ditkoff EC, Levin LH, Paul WL and Lobo RA: Time-resolved fluoroimmunoassay compared with radioimmunoassay of luteinizing hormone. *Fertil Steril* 59:305-310, 1993.
168. Sauer MV, Paulson RJ and Lobo RA: Pregnancy after age 50: Application of oocyte donation to women after natural menopause. *The Lancet* 341:321-323, 1993.
169. Lobo RA: Unexplained infertility. *J Reprod Med* 38:241-249, 1993.
170. Carmina E and Lobo RA: Evidence for increased androsterone metabolism in some normoandrogenic women with acne. *J Clin Endocrinol Metab* 76:1111-1114, 1993.
171. Price TM, Dupuis RE, Carr BR, Stanczyk FZ, Lobo RA and Droegemueller W: Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis. *Am J Gynecol* 168:1400-1406, 1993.
172. Lobo RA: Hormone replacement therapy: Oestrogen replacement after treatment for breast cancer? *The Lancet* 341:1313-1314, 1993.
173. Sullivan JM and Lobo RA: Considerations for contraception in women with cardiovascular disorders. *Am J Obstet Gynecol* 168:2006-2011, 1993.
174. Lindheim SR, Presser SC, Ditkoff EC, Vijod MA, Stanczyk FZ and Lobo RA: A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. *Fertil Steril* 60:664-667, 1993.
175. Kojima T, Lindheim SR, Duffy DM, Vijod MA, Stanczyk FZ and Lobo RA: Insulin

- sensitivity is decreased in normal women by doses of ethinyl estradiol used in oral contraceptives. *Am J Obstet Gynecol* 169:1540-1544, 1993.
176. Carmina E, Janni A and Lobo RA: Physiological estrogen replacement may enhance the effectiveness of the gonadotropin-releasing hormone agonist in the treatment of hirsutism. *J Clin Endocrinol Metab* 78:126-130, 1994.
177. Paulson RJ, Sauer MV and Lobo RA: Addition of a gonadotropin releasing hormone (GnRH) antagonist and exogenous gonadotropins to unstimulated in vitro fertilization (IVF) cycles: Physiologic observations and preliminary experience. *J Assist Reprod Genet* 11:28-32, 1994.
178. Lindheim SR, Legro RS, Morris RS, Wong IL, Tran DQ, Vijod MA, Stanczyk FZ and Lobo RA: The effect of progestins on behavioral stress responses in postmenopausal women. *J Soc Gynecol Invest* 1:79-83, 1994.
179. Lindheim SR, Notelovitz M, Feldman EB, Larsen S, Khan FY and Lobo RA: The independent effects of exercise and estrogen on lipids and lipoproteins in postmenopausal women. *Obstet Gynecol* 83:167-172, 1994.
180. Sauer MV, Paulson RJ, Ary BA and Lobo RA: Three hundred cycles of oocyte donation at the University of Southern California: Assessing the effect of age and infertility diagnosis on pregnancy and implantation rates. *J Assist Reprod Genet* 11:92-96, 1994.
181. Morris RS, Francis MM, Do YS, Hsueh WA, Lobo RA and Paulson RJ: Angiotensin II (AII) modulation of steroidogenesis by luteinized granulosa cells in vitro. *J Assist Reprod Genet* 11:117-122, 1994.
182. Lobo RA and Speroff L: International consensus conference on postmenopausal hormone therapy and the cardiovascular system. *Fertil Steril* 61:592-595, 1994.
183. Lindheim SR, Buchanan TA, Duffy DM, Vijod MA, Kojima T, Stanczyk FZ and Lobo RA: Comparison of estimates of insulin sensitivity in pre-and postmenopausal women using the insulin tolerance test and the frequently sampled intravenous glucose tolerance test. *J Soc Gynecol Invest* 1:150-154, 1994.
184. Legro RS, Shahbahrani B, Lobo RA and Kovacs BW: Size polymorphisms of the androgen receptor among female Hispanics and correlation with androgenic characteristics. *Obstet Gynecol* 83:701-706, 1994.
185. Speroff, L and Lobo RA: Postmenopausal hormone therapy and the cardiovascular system. *Heart Dis Stroke* 3:173-176, 1994.
186. Lobo RA and Stanczyk FZ: New knowledge in the physiology of hormonal contraceptives. *Am J Obstet Gynecol* 170:1499-1507, 1994.

187. Legro RS, Dietz GW, Comings DE, Lobo RA and Kovacs BW: Association of dopamine D₂ receptor gene haplotypes with anovulation and fecundity in female Hispanics. *Hum Reprod* 9:1271-1275, 1994.
188. Paulson RJ, Sauer MV, Francis MM, Macaso TM and Lobo RA: Factors affecting pregnancy success of human in-vitro fertilization in unstimulated cycle. *Hum Reprod* 9:1571-1575, 1994.
189. Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmouh L and Sauer MV: Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: A comparative study. *Fertil Steril* 62:485-490, 1994.
190. Carmina E and Lobo RA: Ovarian suppression reduces clinical and endocrine expression of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Fertil Steril* 62:738-743, 1994.
191. Legro RS, Carmina E, Stanczyk FZ, Gentzschein E and Lobo RA: Alterations in androgen conjugate levels in women and men with alopecia. *Fertil Steril* 62:744-750, 1994.
192. Mezrow G, Shoupe D, Spicer D, Lobo RA, Leung B and Pike M: Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. *Fertil Steril* 62:932-937, 1994.
193. Lindheim SR, Duffy DM, Kojima T, Vijod MA, Stanczyk FZ and Lobo RA: The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women. *Fertil Steril* 62:1176-1180, 1994.
194. Lobo RA, Pickar JH, Wild RA, Walsh B, Hirvonen E and the Menopause Study Group: Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. *Obstet Gynecol* 84:987-995, 1994.
195. Lobo RA and Speroff L: International consensus conference on postmenopausal hormone therapy and the cardiovascular system. *Fertil Steril* 62 (Suppl 2): 176-179S, 1994.
196. Lobo RA: Investigating the cause of hirsutism and acne in women. *Clin Chem* 41:12-13, 1995.
197. Wong IL, Morris RS, Chang L, Spahn M-A, Stanczyk FZ and Lobo RA: A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. *J Clin Endocrinol Metab* 80:233-238, 1995.
198. Luppä P, Müller B, Jacob K, Kimmig R, Strowitzki T, Höss C, Weber MM, Engelhardt D and Lobo RA: Variations of steroid hormone metabolites in serum and urine in

- polycystic ovary syndrome after nafarelin stimulation: Evidence for an altered corticoid excretion. *J Clin Endocrinol Metab* 80:280-288, 1995.
199. Legro RS, Wong IL, Paulson RJ, Lobo RA and Sauer MV: Recipient's age does not adversely affect pregnancy outcome after oocyte donation. *Am J Obstet Gynecol* 172:96-100, 1995.
 200. Ditkoff EC, Fruzzetti F, Chang L, Stanczyk FZ and Lobo RA: The impact of estrogen on adrenal androgen sensitivity and secretion in polycystic ovary syndrome. *J Clin Endocrinol Metab* 80:603-607, 1995.
 201. Carmina E, Gentzschein E, Stanczyk FZ and Lobo RA: Substrate dependency of C₁₉ conjugates in hirsute hyperandrogenic women and the influence of adrenal androgen. *Hum Reprod* 10:299-303, 1995.
 202. Lindheim SR, Legro RS, Morris RS, Vijod MA, Lobo RA, Paulson RJ and Sauer MV: Altered responses to stress in women undergoing in-vitro fertilization and recipients of oocyte donation. *Hum Reprod* 10:320-323, 1995.
 203. Wong IL, Morris RS, Lobo RA, Paulson RJ and Sauer MV: Isolated polycystic morphology in ovum donors predicts response to ovarian stimulation. *Hum Reprod* 10:524-528, 1995.
 204. Sauer MV, Paulson RJ and Lobo RA: Triplet pregnancy in a 51-year-old woman after oocyte donation. *Am J Obstet Gynecol* 172:1044-1045, 1995.
 205. Koopersmith TB and Lobo RA: Insulin sensitivity is unaltered by the use of the Norplant^(®) subdermal implant contraceptive. *Contraception* 51:197-200, 1995.
 206. Morris RS, Carmina E, Vijod MA, Stanczyk FZ and Lobo RA: Alterations in the sensitivity of serum insulin-like growth factor 1 and insulin-like growth factor binding protein-3 to octreotide in polycystic ovary syndrome. *Fertil Steril* 63:742-746, 1995.
 207. Duffy DM, Lindheim SR, Vijod MA, Chang L, Nakamura RM and Lobo RA: Low-dose growth hormone-releasing factor may enhance folliculogenesis in regularly menstruating women: A preliminary study. *Fertil Steril* 63:756-760, 1995.
 208. Legro RS, Muhleman DR, Comings DE, Lobo RA and Kovacs BW: A dopamine D₃ receptor genotype is associated with hyperandrogenic chronic anovulation and resistant to ovulation induction with clomiphene citrate. *Fertil Steril* 63:779-784, 1995.
 209. Legro RS, Wong IL, Paulson RJ, Lobo RA and Sauer MV: Multiple implantation following oocyte donation: A frequent but inefficient event. *Fertil Steril* 63:849-853, 1995.

210. Morris RS, Paulson RJ, Lindheim SR, Legro RS, Lobo RA and Sauer MV: Angiotensin converting enzyme inhibition reverses luteal phase steroid production in oocyte donors. *Fertil Steril* 63:854-858,1995.
211. Morris RS, Paulson RJ, Sauer MV, Lobo RA: Predictive value of serum oestradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome. *Hum Reprod* 10:811-814,1995.
212. Lobo RA: A disorder without identity: "HCA," "PCO," "PCOD," "PCOS," "SLS." What are we to call it? *Fertil Steril* 63:1158-1160,1995.
213. Carmina E, Gonzalez F, Chang L and Lobo RA: Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome. *Obstet Gynecol* 85:971-976,1995.
214. Sauer MV, Paulson RJ, Francis MM, Macaso TM and Lobo RA: Pre-implantation adoption: Establishing pregnancy using donated oocytes and sperm. *Hum Reprod* 10:1419-1422,1995.
215. Sauer MV, Paulson RJ and Lobo RA: Pregnancy after 50 or more years of age: Outcomes of 22 consecutively established pregnancies from oocyte donation. *Fertil Steril* 64:111-115,1995.
216. Stanczyk FZ, Rosen GF, Ditkoff E, Vijod AG, Bernstein L and Lobo RA: Influence of estrogen on prostacyclin and thromboxane balance in postmenopausal women. *Menopause* 2:137-143,1995.
217. Carmina E, Stanczyk FZ, Gentschein E and Lobo RA: Time-dependent changes in serum 3α -androstenediol glucuronide correlate with hirsutism scores after ovarian suppression. *Gynecol Endocrinol* 9:215-220,1995.
218. Duffy DM, Legro RS, Chang L, Stanczyk FZ and Lobo RA: Metabolism of dihydrotestosterone to 5α -androstane- 3α - 17β -diol glucuronide is greater in the peripheral compartment than in the splanchnic compartment. *Fertil Steril* 64:736-739, 1995.
219. Carmina E, Stanczyk FZ, Morris RS, Lee PDK, Savjani G and Lobo RA: Altered regulation of insulin-like growth factor binding protein-1 in patients with polycystic ovary syndrome. *J Soc Gynecol Invest.* 2:743-747, 1995.
220. Morris RS, Wong IL, Hatch IE, Gentschein E, Paulson RJ, Lobo RA: Prorenin is elevated in polycystic ovary syndrome and may reflect hyperandrogenism. *Fertil Steril* 64:1099-1103,1995.
221. Morris RS, Wong IL, Do YS, Hsueh WA, Lobo RA, Sauer MV, Paulson RJ: The pathophysiology of ovarian hyperstimulation syndrome (OHSS). A proposal role of the ovarian derived prorenin to angiotensin cascade (ODPAC) [Review]. *Adv Exp Med Biol*

- 377:391-398, 1995.
222. Lobo RA: Benefits and risks of estrogen replacement therapy. *Am J Obstet Gynecol* 173:982-989, 1995.
223. Lobo RA: Polycystic ovary syndrome/hyperandrogenic chronic anovulation [Review]. *Adv Endocrinol Metab* 6:167-191, 1995.
224. Lobo RA: Estrogen replacement: The evolving role of alternative delivery systems. Introduction. *Am J Obstet Gynecol* 173:981, 1995.
225. Lindheim SR, Sauer MV, Francis MM, Macasos TM, Lobo RA and Paulson RJ: The significance of elevated early follicular phase follicle stimulating hormone (FSH) levels: Observations in unstimulated in vitro fertilization cycles. *J Assist Reprod Genet* 13:49-52, 1996.
226. Sauer MV, Paulson RJ, Lobo RA: Rare occurrence of ovarian hyperstimulation syndrome in oocyte donors. *Int J Gynecol Obstet* 52:259-262, 1996.
227. Lobo RA, Skinner JB, Lippman J and Cirillo SJ: Plasma lipids and desogestrel/ethinyl estradiol: A meta-analysis. *Fertil Steril* 65:1100-1109, 1996.
228. Lobo RA, Ettinger B, Hutchinson KA, Knopp RH, Lindsay R, Nachtigall LE, Santoro N and Studd J: Estrogen Replacement. The Evolving Role of Transdermal Delivery. *J Reprod Med* 41:781-796, No. 10 (Suppl.) 1996.
229. Lobo RA: Treatment of the postmenopausal woman: Basic and clinical aspects [Review]. *South African Medical Journal*, Spring 1996.
230. Wilcox JG, Stanczyk FZ, Morris RS, Gentzschlein E and Lobo RA: Biologic effects of 17 α -dihydroequilin sulfate. *Fertil Steril* 66:748-752, 1996.
231. Gonzalez F, Chang L, Horab T and Lobo RA: Evidence for heterogeneous etiologies of adrenal dysfunction in polycystic ovary syndrome. *Fertil Steril* 66:354-361, 1996.
232. Carmina E, Lo Dico G, Carollo F, Stanczyk FZ and Lobo RA: Serum IGF-1 and the binding proteins 1 and 3 in postmenopausal women and the effects of estrogen. *Menopause* 3:85-89, 1996.
233. Lobo RA: Therapeutic Controversy: Estrogen Replacement in Menopause. *J Clin Endocrinol Metab* 81:3829-3838, 1996.
234. Lindsay R, Bush TL, Grady D, Speroff L and Lobo RA: Therapeutic Controversy. Estrogen Replacement in Menopause. *J Clin Endocr Metab* 81:3829-3838, 1996.
235. Sauer MV, Paulson RJ and Lobo RA: Oocyte donation to women of advanced

- reproductive age: pregnancy results and obstetrical outcomes in patients 45 years and older. *Hum Reprod* 11:2540-2543, 1996.
236. Edwards RG, Lobo R and Bouchard P: Time to revolutionize ovarian stimulation. *Hum Reprod* 11:917-919, 1996.
237. Lobo RA: ART reporting: The American view. *Hum Reprod* 11:1369-1370, 1996.
238. Guess HA, Friedman GD, Sadler MC, Stanczyk FZ, Volgelman JH, Imperato-McGinley J, Lobo RA and Orentreich N: 5α -reductase activity and prostate cancer: A case-control study using stored sera. *Canc Epid Biomark & Prevent* 6:21-24, 1997.
239. Paulson RJ, Sauer MV, Lobo RA: Potential enhancement of endometrial receptivity in cycles using controlled ovarian hyperstimulation with antiprogestins: a hypothesis. *Fertil Steril* 67:321-325, 1997.
240. Wilcox JG, Hatch IE, Gentzschein E, Stanczyk FZ, Lobo RA: Endothelin levels decrease after oral and nonoral estrogen in postmenopausal women with increased cardiovascular risk factors. *Fertil Steril* 67:273-277, 1997.
241. Wilcox JG, Hwang J, Hodis HN, Sevanian A, Stanczyk FZ and Lobo RA: Cardioprotective effects of individual conjugated equine estrogens through their possible modulation of insulin resistance and oxidation of low-density lipoprotein. *Fertil Steril* 67:57-62, 1997.
242. Price TM, Blauer KL, Hansen M, Stanczyk FZ and Lobo RA: Single dose pharmacokinetics of sublingual versus oral administration of micronized 17β -estradiol. *Obstet Gynecol* 89:340-345, 1997.
243. Edwards RG, Lobo RA and Bouchard P: Why delay the obvious need for milder forms of ovarian stimulation? *Hum Reprod* 12:399-401, 1997.
244. Stanczyk FZ, Gentzschein E, Ary BA, Kojima T, Ziogas A and Lobo RA: Urinary progesterone and pregnanediol glucuronide: Use for monitoring progesterone treatment. *J Reprod Med* 42:216-222, 1997.
245. Carmina E and Lobo RA: Gonadotrophin- releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission. *Hum Reprod* 12:663-666, 1997.
246. Paulson RJ, Hatch IE, Lobo RA, Sauer MV: Cumulative conception and live birth rates after oocyte donation: implications regarding endometrial receptivity. *Hum Reprod* 12:835-839, 1997.
247. Carmina E, Wong L, Chang L, Paulson RJ, Sauer MV, Stanczyk FZ and Lobo RA:

- Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. *Hum Reprod* 12:905-909, 1997.
248. Sauer MV, Paulson RJ and Lobo RA: Comparing the clinical utility of GnRH antagonist to GnRH agonist in an oocyte donation program. *Gynecol Obstet Invest* 43:215-218, 1997.
249. Lindheim SR, Sauer MV, Francis MM, Macaso T, Lobo R and Paulson RJ: The utility of a midcycle follicle-stimulating hormone boost in addition to human chorionic gonadotropin for timing of follicle aspiration in unstimulated in vitro fertilization cycles. *Gynecol Obstet Invest* 43:76-78, 1997.
250. Koopersmith TB, Lindheim SR, Lobo RA, Paulson RJ and Sauer MV: Outcomes of high-order multiple implantations in women undergoing ovum donation. *J Matern-Fetal Med* 6:268-272, 1997.
251. Vatten LJ, Ursin G, Ross RK, Stanczyk FZ, Lobo RA, Harvei S and Jellum E: Androgens in serum and the risk of prostate cancer: A nested case-control study from the Janus Serum Bank in Norway. *Canc Epidemiol Biomarkers Prev* 6:967-969, 1997.
252. Lobo RA: New trends in transdermal HRT and aspects on climacteric psychology. *Europ Menopause J* 4:1-4, 1997.
253. Lobo RA: Foreword. CME Activity. Progesterone use in reproductive and gynecologic endocrinology: Current and future perspectives. *Contemporary OB/GYN (Supplement)* 42:3, 1997.
254. Carmina E and Lobo RA: The addition of dexamethasone to antiandrogen therapy for hirsutism prolongs the duration of remission. *Fertil Steril* 69:1075-1079, 1998.
255. Pickar JH, Wild RA, Walsh B, Hirvonen E and Lobo RA: Effects of different hormone replacement regimens on postmenopausal women with abnormal lipid levels. *CLIMACTERIC* 1:26-32, 1998.
256. Carmina E and Lobo RA: Adrenal hyperandrogenism in the pathophysiology of Polycystic Ovary Syndrome. *J Endocrinol Invest* 21:580-588, 1998.
257. Lobo RA: The Perimenopause. *Clin Obstet Gynecol* 41:895-897, 1998.
258. Lobo RA: Perimenopause [Foreword]. *Clin Obstet Gynecol* 41:894, 1998.
259. Lobo RA (Program Chairman and Course Director). CME Activity. Natural Progesterone: Mechanisms, Effects, and Safety. *Contemp OB/GYN*, Sept. 1998.
260. Lobo RA. Low dose therapy. *Contemp Ob/Gyn* 43 (Suppl. 5), May 1998.

261. Carmina E, Gonzalez F, Vidali A, Stanczyk FZ, Ferin M and Lobo RA: The contributions of estrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome. *Hum Reprod* 14:307-11, 1999.
262. Carmina, E and Lobo RA: Do hyperandrogenic women with normal menses have PCOS? *Fertil Steril* 71:319-22, 1999.
263. Fraser IS, Lobo RA: Update on Progestogen Therapy, a Journal Supplement Based on a Consensus Development Conference Sponsored by the College of Physicians and Surgeons of Columbia University, held on October 3 and 4, 1998, in San Francisco, California. *J Reprod Med* 44:139-140 (Suppl. #2), 1999.
264. Lobo RA. Progestogen Metabolism. *J Reprod Med* 44 (2 Suppl):148-152, 1999.
265. Gonzalez F, Chang L, Horab T, Stanczyk FZ, Crickard K, Lobo RA. Adrenal dynamic responses to physiologic and pharmacologic adrenocorticotrophic hormone stimulation before and after ovarian steroid modulation in women with polycystic ovary syndrome. *Fertil Steril* 71:439-44, 1999.
266. Carmina E, Lobo RA. Editorial. COMMENTARY. Polycystic ovary syndrome (PCOS) arguably the most common endocrinopathy is associated with significant morbidity in women. *J Clin Endocrinol Metab* 84:1897-9, 1999.
267. Lindsay R, Cosman F, Lobo RA, Walsh BW, Harris ST, Reagan JE, Liss CL, Melton ME, Byrnes CA. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial. *J Clin Endocrinol Metab* 84:3076-81, 1999.
268. Lobo RA. Commentary. Two-year prospective, randomized trial comparing an innovative twice-a-week progestin regimen with a continuous combined regimen as postmenopausal hormone therapy by Antonio Cano et al. *Fertil Steril* 71:129-136, 1999. JAMA Women's Health web site, 1999 (www.amaassn.org/special/womh).
269. Archer DF, Lobo RA, Land HF, and Pickar JH. A comparative study of transvaginal uterine ultrasound and endometrial biopsy for evaluating the endometrium of postmenopausal women taking hormone replacement therapy. *Menopause* 6:201-8, 1999.
270. Carmina E, Ferin M, and Lobo RA. Evidence that insulin and adrenal androgens participate in the regulation of serum leptin levels in women. *Fertil Steril* 72:926-31, 1999.
271. Legro RS, Blanche P, Krauss RM and Lobo RA. Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovary syndrome: influence of insulin and genetic factors. *Fertil Steril* 72:990-5, 1999.
272. Birken, S, Santoro N, Maydelman Y, Galina MA, Kovalevskaya G, Lobo RA, Freeman

- EW, Warren M, McMahon D and O'Connor J. Differences in urinary excretion patterns of the hLH beta core fragment in premenopausal, perimenopausal and postmenopausal women. *Menopause* 6:290-8, 1999.
273. Lobo RA, Zacur HZ, Caubel P and Lane R. A novel pulsed regimen of norgestimate preserve the beneficial effects of 17β -estradiol on lipids and lipoprotein profiles. *Am J Obstet Gynecol* 182:41-49,2000.
274. Lindheim S, Sauer MV, Carmina E, Chang PL, Zimmermann R, Lobo RA. Circulating leptin levels during ovulation induction: relation to adiposity and ovarian morphology. *Fertil Steril* 73:493-98, 2000.
275. Lobo RA. Maximize the benefit of hormone replacement therapy. *J Reprod Med* 45: No.3/March 243-4,2000 (Suppl.).
276. Chang P, Lindheim SR, Lowre C, Ferin M, Gonzalez F, Berglund L, Carmina E, Sauer MV, Lobo RA. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing. *J Clin Endocr Metab* 85:995-1000, 2000.
277. Lobo RA, Carmina E. Perspective. The importance of diagnosing the polycystic ovary syndrome. *Ann Int Med* 132:989-93, 2000.
278. Dunaif A, Utian WH, Brandenburg SL, Gerhard M, Lobo RA, Caren G, Solomon CG, Sowers JR, Effects of menopause and Estrogen Replacement Therapy or Hormone Replacement Therapy in Women with Diabetes Mellitus: Consensus Opinion of The North American Menopause Society. *Menopause* 7:87-95, 2000.
279. Lobo RA, et al. Current Management of Recurrent Pregnancy Loss. Sponsored by the College of Physicians' and Surgeons of Columbia University. *Contemp OB/GYN* (Suppl) February, 2000.
280. Upmalis DH, Lobo RA, Bradley L, Warren M, Cone FL, Lamia CA. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. *Menopause* 7:236-42,2000.
281. Zimmermann RC, Xiao E, Husami N, Sauer MV, Lobo RA, Kitajewski J, Ferin M. Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the Rhesus monkey. *J Clin Endocrinol Metab* 86:768-72, 2001.
282. Lobo RA. Priorities in polycystic ovary syndrome. *The Med J Australia* 174:554-555,2001.
283. Lobo RA. CME Review Article. Androgens in postmenopausal women: production, possible role and replacement options. *Obstet Gynecol Survey* 56:361-376,2001.

284. Lobo RA, Whitehead MI. Is low-dose hormone replacement therapy for postmenopausal women efficacious and desirable? *Climacteric* 4:110-19,2001.
285. Lobo RA, Bush T, Carr BR, Picar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. *Fertil Steril* 76:13-24,2001.
286. Lobo RA. Dietary Soy and cardiovascular disease risk. *Menopause* 8:303-4, 2001.
287. Lobo RA. Menopause: Approach to therapy. *Precis: Reproductive Endocrinology*, Second Edition. 2001.
288. Cha KY, Wirth DP and Lobo RA. Does prayer influence the success of in vitro fertilization embryo transfer (IVF-ET)? Report of a masked randomized trial. *J Reprod Med* 46:781,2001.
289. Carmina E, Lobo RA. Polycystic ovaries in hirsute women with normal menses. *Am J Med* 111:602, 2001.
290. Lobo RA. Progestogens: New Approaches. *The Female Patient (Suppl.)* October 2001:19-22.
291. Lobo RA. Recent findings in cardiovascular disease. *The Female Patient (Suppl.)* October 2001:3-4.
292. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu C-R, Liu C-H, Azen SP. Estrogen in the prevention of atherosclerosis: A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 135:939-53, 2002.
293. Hodis, HN, Mack WJ, Lobo RA. Postmenopausal hormone replacement therapy as antiatherosclerotic therapy. *Curr Atheroscler Rep.* 4:52-8, 2002.
294. Pinn VW, Lobo RA. Preface. Androgen Insufficiency in Women: The Princeton Conference. Special Supplement. *Fertil Steril.* 77:#4, Suppl.4, S1,2002.
295. Bachmann G, Bancroft J, Braunstein G, Burger, H, Davis S, Dennerstein L, Goldstein I, Guay A, Leiblum S, Lobo RA, Notelovitz M, Rosen R, Sarrel P, Sherwin B, Simon J, Simpson E, Shifren J, Spark R, Traish A. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. *Fertil Steril* 77:660-665, 2002.
296. Carmina E, Godwin AJ, Stanczyk FZ, Lippman JS, Lobo RA. Serum androsterone glucuronide reflects inflammatory lesions in women with adult acne. *J Endocrinol Invest.* 25:765-68, 2002.

297. Hodis HN, Mack WJ, Lobo RA. Antiatherosclerosis interventions in women. *Am J Cardiol* 90:17F-21F, 2002.
298. Carmina E, Lobo RA. A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. *Clin Endocrinology* 57:231-234, 2002.
299. Lobo RA. Editorial. Menopausal medicine. *Best Pract Res Clin Obstet Gynaecol* 16(3):ix-xii, 2002.
300. Grimes DA, Lobo RA. Perspectives on the Women's Health Initiative trial of hormone replacement therapy. *Obstet Gynecol* 100:1344-53, 2002.
301. Dunaif A, Lobo RA. Toward optimal health: the experts discuss polycystic ovary syndrome. *J Womens Health Gend Based Med* 11:579-84, 2002.
302. Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. *Fertil Steril*. 79:91-95, 2003.
303. Lobo RA. News about the Journal of the Society for Gynecologic Investigation. *J Soc Gynecol Investig* 10:1, 2003.
304. Mack WJ, Hameed AB, Xiang M, Roy S, Slater CC, Stanczyk FZ, Lobo RA, Liu C-r, Liu Ci, Hodis, HN. Does elevated body mass modify the influence of postmenopausal estrogen replacement on atherosclerosis progression: results from the estrogen in the prevention of atherosclerosis trial. *Atherosclerosis* 00 (2003) 1-8 (in press).
305. Lobo RA, Rosen RC, Yang H-M, Block BA, Gerritsen R, Hoop Va der. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. *Fertil Steril* (in press, 2003).
306. Lobo RA. Editorial response to the article entitled "Androgen excess is the key element in polycystic ovary syndrome by Ricardo Azziz. *Fertil Steril* 2003 (in press).
307. Lobo RA, Archer DF, Ettinger B, Gambrell RD, Liu JH, Sitruk-Ware R, Stanczyk FZ, Wagner JD. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. *Menopause* 2003 (in press).
308. Carmina E, Longo A, Lobo RA. Does ovarian blood flow distinguish between ovulatory and anovulatory patients with polycystic ovary syndrome? *Am J Obstet Gynecol* (submitted 2003).
309. Carmina, E, Legro R, Stamets J, Lowell J, Lobo RA. The influence of diet on obesity and dyslipidemia in polycystic ovary syndrome. Submitted to *Hum Reprod* (2003).

310. Silfen ME, Denburg MR, Manibo AM, Lobo RA, Jaffe R, Ferin M, Levine LS, Oberfield SE. Early endocrine, metabolic, and sonographic characteristics of polycystic ovarian syndrome (PCOS): Comparison between non-obese and obese adolescents.
311. Carmina E, Lobo RA. Effect of the estrogen dose in the treatment of hirsutism using cyproterone acetate. Submitted to Hum Reprod (2003).
312. Mosca, L, Lobo RA. Management of dyslipidemia for the prevention of heart disease in women. A Clinical Guide for Obstetricians and Gynecologists. Submitted to Am College of Obstet Gynecol Monograph (2003).
313. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Mahrer PR, Faxon DP, et al. Women's estrogen-progestin lipid lowering hormone atherosclerosis regression trial (WELL-HART): A randomized trial. Submitted to N Engl J Med (2003).

Chapters in Books:

1. Lahteenmaki P, Lobo RA, Marrs RP, Gibbons WE, Nakamura RM and diZerega GS: Granulosa cells heterogeneity in women treated with clomiphene and human chorionic gonadotropin. In: Greenwald G and Terranova P (eds), *Proceedings of the IV Ovarian Workshop*, pp. 55-60, 1982. Raven Press, New York, New York.
2. Lobo RA: Androgen excess: Differential diagnosis. In: Mishell DR Jr and Brenner PF (eds), *Management of Common Problems in Obstetrics and Gynecology*, pp. 371-375, 1983. Medical Economics Company, Inc., Oradell, New Jersey.
3. Lobo RA: Androgen excess: Evaluation. In: Mishell DR Jr and Brenner PF (eds), *Management of Common Problems in Obstetrics and Gynecology*, pp. 376-378, 1983. Medical Economics, Inc., Oradell, New Jersey.
4. Lobo RA: Management of hirsutism. In: Mishell DR Jr and Brenner PF (eds), *Management of Common Problems in Obstetrics and Gynecology*, pp. 379-382, 1983. Medical Economics Company, Inc., Oradell, New Jersey.
5. Lobo RA: Adrenal gland reproduction. In: Garcia C-R, Mastroianni L Jr, Amelar RD and Dubin L (eds), *Current Therapy of Infertility 1984-1985*, pp. 46-50, 1984. B.C. Decker, Inc., Toronto, Ontario, Canada.
6. Lobo RA: The role of the adrenal in polycystic ovary syndrome. In: Speroff L (ed), *Semrs in Reproductive in Endocrinology*, Volume 2, pp. 251-262, 1984. Thieme-Stratton, Inc., New York, New York.
7. Lobo RA: Androgen excess and the infertile female. In: Besch PK, Goldzieher JW and Gibbons WE (eds), *The Biochemistry of the Reproductive Years*, pp. 119-136, 1984. Kingsport Press, Kingsport, Tennessee.
8. Lobo R and Horton R: Hirsutism. In: Krieger DT and Bardin CW (eds), *Current Therapy in Endocrinology and Metabolism*, pp. 131-134, 1985. B.C. Decker, Inc., Toronto, Ontario, Canada.
9. Lobo RA: Disturbances of androgen secretion and metabolism in polycystic ovary syndrome. In: Jacobs HS (ed), *Reproductive Endocrinology, Clinics in Obstetrics and Gynaecology*, Volume 12, pp. 633-647, 1985. W.B. Saunders Ltd., London, England.
10. Hoffman DI, Lobo RA and Mishell DR Jr: Treatment of dysfunctional uterine bleeding: In: Baird DT and Michiei EA (eds), *Mechanism of Menstrual Bleeding*, pp. 253-261, 1985. Raven Press, New York, New York.
11. Lobo RA: "Idiopathic hirsutism" - Fact or fiction? In: Speroff L (ed), *Seminars in Reproductive Endocrinology*, Vol 4, pp. 179-187, 1986. Thieme Inc., New York, NY.

12. Horton R and Lobo R: Peripheral androgens and the role of androstanediol glucuronide. In: Horton R and Lobo RA (eds), *Androgen Metabolism in Hirsute and Normal Females, Clinics in Endocrinology and Metabolism*, Volume 15, pp. 293-306, 1986. W.B. Saunders Company, Ltd., London, England.
13. Kletzky OA and Lobo RA: Reproductive Neuroendocrinology. In: Mishell DR Jr and Davajan V (eds), *Infertility, Contraception and Reproductive Endocrinology*, Second Edition, pp. 3-29, 1987. Medical Economics Company, Inc., Oradell, New Jersey.
14. Goebelsmann U and Lobo RA: Androgen excess. In: Mishell DR Jr and Davajan V (eds), *Infertility, Contraception and Reproductive Endocrinology*. Second Edition, pp. 303-317, 1987. Medical Economics Company, Inc., Oradell, New Jersey.
15. Lobo RA: Polycystic ovary syndrome. In: Mishell DR Jr and Davajan V (eds), *Infertility, Contraception and Reproductive Endocrinology*, Second Edition, pp. 319-336, 1987. Medical Economics Company, Inc., Oradell, New Jersey.
16. March CM, Hoffman DI and Lobo RA: Dysfunctional uterine bleeding. In: Mishell DR Jr and Davajana V (eds), *Infertility, Contraception and Reproductive Endocrinology*, Second Edition, pp. 337-351, 1987. Medical Economics Company, Inc., Oradell, New Jersey.
17. Lobo RA and Kletzky OA: Dynamics of hormone testing. In: Mishell DR Jr and Davajan V (eds), *Infertility, Contraception and Reproductive Endocrinology*, Second Edition, pp. 365-377, 1987. Medical Economics Company, Inc., Oradell, New Jersey.
18. Lobo RA: Prevention of postmenopausal osteoporosis. In: Mishell DR Jr (ed), *Menopause: Physiology and Pharmacology*, pp. 165-186, 1987. Year Book Medical Publishers, Inc., Chicago, IL.
19. Baranes RB and Lobo RA: Pharmacology of estrogens. In: Mishell DR Jr (ed), *Menopause: Physiology and Pharmacology*, pp. 301-315, 1987. Year Book Medical Publishers, Inc., Chicago, IL.
20. Lobo RA and Horton R: Hirsutism. In: Bayless TM, Brain MC and Cherniack RM (eds), *Current Therapy in Internal Medicine- 2*, pp. 506-508, 1987. B.C. Decker, Inc., Toronto, Ontario, Canada.
21. Lobo RA, Hirsutism. In: Sciarra JJ, Speroff L and Simpson JL (eds), *Gynecology and Obstetrics*, Volume 5, pp. 1-15, 1987. *Reproductive Endocrinology, Infertility and Genetics*. J.B. Lippincott Company, Philadelphia, Pennsylvania.

22. Lobo RA: Absorption and metabolic effects of different types of estrogens and progestogens. In: Gambrell RD Jr (ed), *The Menopause, Clinics in Obstetrics and Gynecology of North America*, Vol. 14:143-167, 1987. W.B. Saunders Company, Philadelphia, PA.
23. Barnes RB and Lobo RA: Endogenous opioids in polycystic ovary syndrome. In: Speroff L (ed), *Seminars in Reproductive Endocrinology*, Vol. 5, pp. 185-189, 1987. Thieme Medical Publishers, Inc., New York, NY.
24. Shoupe D and Lobo RA: Endogenous opioids in the menopause. In: Speroff L (ed), *Seminars in Reproductive Endocrinology*, Volume 5, pp. 199-206, 1987. Thieme Medical Publishers, Inc., New York, NY.
25. Lobo RA: Androgen excess and the infertile woman. In: Kempers RD (ed), *The Infertile Woman, Clinics in Obstetrics and Gynecology of North America*, Volume 14, pp. 955-977, 1987. W.B. Saunders Company, Philadelphia, PA.
26. Lobo RA: Prolactin secretion in polycystic ovary syndrome. In: Blackwell RE and Chang RJ (eds), *Prolactin-Related Disorders*, pp. 137-149, 1987. Macmillan Healthcare Information, Inc., Florham Park, New Jersey.
27. Lobo RA: Effects of oestrogens and progestogens on the cardiovascular system in post-menopausal women. In: Zichella L, Whitehead MI and van Keep PA (eds), *The Climacteric and Beyond*, pp. 95-107, 1987. The Parthenon Publishing Group Ltd, Lancaster, England.
28. Lobo RA: Polycystic ovary syndrome and hirsutism. In: Imura H, Shizume K and Yoshida S (eds), *Progress in Endocrinology 1988*, Volume 2, pp. 1467-1472, 1988. Elsevier Science Publishers BV, Amsterdam, The Netherlands.
29. Lobo RA: The menopause. In: Rakel RE (ed), *Conn's Current Therapy*, Fortieth Edition, pp. 929-930, 1988. W.B. Saunders Company, Philadelphia, PA.
30. Lobo RA: Androgen excess: Differential diagnosis. In: Mishell DR Jr. and Brenner PF (eds), *Management of Common Problems in Obstetrics and Gynecology*, Second Edition, pp. 495-500, 1988. Medical Economics Company, Inc., Oradell, New Jersey.
31. Lobo RA: Androgen excess: Evaluation. In: Mishell DR Jr and Brenner PF (eds), *Management of Common Problems in Obstetrics and Gynecology*, Second Edition, pp. 501-504, 1988. Medical Economics Company, Inc., Oradell, New Jersey.
32. Lobo RA: Management of hirsutism. In: Mishell DR Jr. and Brenner PF (eds), *Management of Common Problems in Obstetrics and Gynecology*, Second Edition, pp. 505-509, 1988. Medical Economics Company, Inc., Oradell, New Jersey.
33. Lob RA: Therapy of polycystic ovary syndrome. In: Mishell DR Jr and Brenner PF

- (eds), Management of Common Problems in Obstetrics and Gynecology, Second Edition, pp. 510-514, 1988. Medical Economics Company, Inc., Oradell, New Jersey.
34. Lobo RA: The role of neurotransmitters and opioids in polycystic ovarian syndrome. In: Mahajan DK (ed), Polycystic disease, Endocrinology and Metabolism Clinics of North America, pp. 667-683, 1988. W.B. Saunders Company, Philadelphia, PA.
35. Lobo RA: Endocrine therapy of hyperandrogenism. In: Barbieri RL and Schiff I (eds), Reproductive Endocrine Therapeutics, pp. 101-126, 1988. Alan R. Liss, Inc., New York, NY.
36. Lobo RA: Functional variations of the female genital tract. In: Wren BG and Lobo RA (eds), Handbook of Obstetrics and Gynaecology, Third Edition, pp. 299-322, 1989. Chapman and Hall Ltd., London, England.
37. Lobo RA: Androgen excess in women: The enigma of the hirsute female. In: Soules MR (ed), Controversies in Reproductive Endocrinology and Infertility, pp. 59-77, 1989. Elsevier Science Publishing Company, Inc., New York, New York.
38. Lobo RA: Cardiovascular disease, menopause, and the influence of hormonal replacement therapy. In: Hammond CB, Haseltine FP and Schiff I (eds), Menopause: Evaluation, Treatment and Health Concern, pp. 313-332, 1989. Alan R. Liss, Inc., New York, New York.
39. Lobo RA: Hirsutism, alopecia, and acne. In: Becker KL and Rebar RW (eds), Principles and Practice of Endocrinology and Metabolism, pp. 834-848, 1990. J.B. Lippincott Company, Philadelphia, Pennsylvania.
40. Lobo RA: Androgen excess of adrenal origin. In: Quilligan EJ and Zuspan FP (eds), Current Therapy in Obstetrics and Gynecology, Third Edition, pp. 3-7, 1990. W.B. Saunders Company, Philadelphia, Pennsylvania.
41. Lobo RA: Estrogen and cardiovascular disease. In: Flint M, Kronenberg F and Utian W (eds), Multidisciplinary Perspectives on Menopause, Volume 592, pp. 286-294, 1990. Annals of the New York Academy of Sciences, New York, New York.
42. Cassidenti DL and Lobo RA: Ovulatory disturbances in the hyperandrogenic woman. In: Diamond MP, DeCherney AH and Yee B (eds), Ovulation Induction, Infertility and Reproductive Medicine Clinics of North America, pp. 101-119, 1990. W.B. Saunders Company, Philadelphia, Pennsylvania.
43. Kletzky OA and Lobo RA: Reproductive neuroendocrinology, In: Mishell DR Jr, Davajan V and Lobo RA (eds), Infertility, Contraception and Reproductive Endocrinology, Third Edition, pp. 3-33, 1991. Blackwell Scientific Publications, Cambridge, Massachusetts.

44. Lobo RA: The menstrual cycle. In: Mishell DR Jr, Davajan V and Lobo RA (eds), *Infertility, Contraception and Reproductive Endocrinology*, Third Edition, pp. 104-124, 1991. Blackwell Scientific Publications, Cambridge, Massachusetts.
45. Lobo RA: Endocrinology of pregnancy. In: Mishell DR Jr, Davajan V and Lobo RA (eds), *Infertility, Contraception and Reproductive Endocrinology*, Third Edition, pp. 150-179, 1991. Blackwell Scientific Publications, Cambridge, Massachusetts.
46. Mishell DR Jr and Lobo RA: Disorders of sexual differentiation. In: Mishell DR Jr, Davajan V and Lobo RA (eds), *Infertility, Contraception and Reproductive Endocrinology*, Third Edition, pp. 317-335, 1991. Blackwell Scientific Publications, Cambridge, Massachusetts.
47. Lobo RA: Androgen excess. In: Mishell DR Jr, Davajan V and Lobo RA (eds), *Infertility, Contraception and Reproductive Endocrinology*, Third Edition, pp. 422-446, 1991. Blackwell Scientific Publications, Cambridge, Massachusetts.
48. Lobo RA: The syndrome of hyperandrogenic chronic anovulation. In: Mishell DR Jr, Davajan V and Lobo RA (eds), *Infertility, Contraception and Reproductive Endocrinology*, Third Edition, pp. 447-487, 1991. Blackwell Scientific Publications, Cambridge, Massachusetts.
49. Lobo RA and Kletzky OA: Dynamics of hormone testing. In: Mishell DR Jr, Davajan V and Lobo RA (eds), *Infertility, Contraception and Reproductive Endocrinology*, Third Edition, pp. 518-534, 1991. Blackwell Scientific Publications, Cambridge, MA.
50. Lobo RA, Hirsutism in polycystic ovary syndrome (PCO): Current concepts. In: Chang RJ (ed), *Clinical Obstetrics and Gynecology*, Volume 34, pp. 817-826, 1991. J.B. Lippincott Company, Philadelphia, Pennsylvania.
51. Lobo RA: Ovarian hyperandrogenism and androgen producing tumors. In: Strauss JF III (ed), *Steroid Hormones: Synthesis, Metabolisms, and Action in Health and Disease*, Volume 20, pp. 773-805, 1991. *Endocrinology and Metabolism Clinics of North America*. W.B. Saunders Company, Philadelphia, Pennsylvania.
52. Lobo RA: Androgen secretion in the syndrome of hyperandrogenic chronic anovulation. In: Dunaif A, Givens JR, Haseltine FP and Merriam GR (eds), *Polycystic Ovary Syndrome (Current Issues in Endocrinology and Metabolism series)*, pp. 319-332, 1992. Blackwell Scientific Publications, Cambridge, Massachusetts.
53. Lobo RA: Hirsutism and Virilism. In: Carr DR and Blackwell RE (eds), *Textbook of Reproductive Medicine*, pp. 371-387, 1993. Appleton & Lange, Norwalk, Connecticut.
54. Lobo RA: Hormones, hormone replacement therapy, and heart disease. In: Douglas PS (ed), *Cardiovascular Health and Disease in Women*, pp. 153-173, 1993. W.B. Saunders

Company, Philadelphia, Pennsylvania.

55. Lobo RA: Treatment of the postmenopausal woman: Where we are today. In: Lobo RA (ed), Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, pp. 427-432, 1994. Raven Press, New York, New York.
56. Lobo RA: Androgen excess: Differential diagnosis. In: Mishell DR Jr and Brenner PF (eds), Management of Common Problems in Obstetrics and Gynecology, Third Edition, pp. 619-625, 1994. Blackwell Scientific Publications, Cambridge, Massachusetts.
57. Lobo RA: Androgen excess: Evaluation. In: Mishell DR Jr and Brenner PF (eds), Management of Common Problems in Obstetrics and Gynecology, Third Edition, pp. 626-630, 1994. Blackwell Scientific Publications, Cambridge, Massachusetts.
58. Lobo RA: Management of hirsutism. In: Mishell DR Jr and Brenner PF (eds), Management of Common Problems in Obstetrics and Gynecology, Third Edition, pp. 631-636, 1994. Blackwell Scientific Publications, Cambridge, Massachusetts.
59. Lobo RA: Therapy of polycystic ovary syndrome. In: Mishell DR Jr and Brenner PF (eds), Management of Common Problems in Obstetrics and Gynecology, Third Edition, pp. 637-642, 1994. Blackwell Scientific Publications, Cambridge, Massachusetts.
60. Lobo RA: Androgen excess of adrenal origin. In: Zuspan FP and Quilligan EJ (eds), Current Therapy in Obstetrics and Gynecology, Fourth Edition. pp. 3-7, 1994. W.B. Saunders Company, Philadelphia, Pennsylvania.
61. Legro RS and Lobo RA: Androgen insensitivity syndrome. In: Zuspan FP and Quilligan EJ (eds), Current Therapy in Obstetrics and Gynecology, Fourth Edition, pp. 7-9, 1994. W.B. Saunders Company, Philadelphia, Pennsylvania.
62. Lobo RA: Chronic anovulation and polycystic ovary syndrome: Treatment for infertility. In: Keye WR Jr, Chang RJ, Rebar RW and Soules MR (eds), Infertility: Evaluation and Treatment, pp. 168-177, 1995. W.B. Saunders Company, Philadelphia, Pennsylvania.
63. Lobo RA: Polycystic ovary syndrome/hyperandrogenic chronic anovulation. In: Mazzaferri EL, Bar RS and Kreisberg RA (eds), Advances in Endocrinology and Metabolism (R), Volume 6, pp. 167-191, 1995. Mosby-Year Book, Inc., St. Louis, MO.
64. Morris RS, Wong IL, Do YS, Hsueh WA, Lobo RA, Sauer MV and Paulson RJ: The pathophysiology of ovarian hyperstimulation syndrome (OHSS): A proposal role of the ovarian derived prorenin to angiotensin cascade (OPAC), pp. 391-398, 1995. In: Mukhopadhyay AK and Raizada MK (eds), Tissue Renin Angiotensin Systems. Plenum Press, New York, New York.
65. Lobo RA: Hirsutism, alopecia, and acne. In: Becker KL and Rebar RW (eds), Principles

- and Practice of Endocrinology and Metabolism, Second Edition, pp. 924-940, 1995. J.B. Lippincott Company, Philadelphia, Pennsylvania.
66. Wong IL and Lobo RA: Ovarian androgen-producing tumors. In: Adashi EY, Rock JA and Rosenwaks Z (eds), Reproductive Endocrinology, Surgery, and Technology, Volume 2, pp. 1571-1598. Lippincott-Raven Publishers, Philadelphia, Pennsylvania.
 67. Lobo RA: Cardiovascular disease in women: Influence of hormonal replacement therapy. In: Zanchetti A, Safar M, Stimpel M (eds), Hypertension in Postmenopausal Women. Springer-Verlag, Heidelberg, Germany.
 68. Lobo RA: A unifying concept for polycystic ovary syndrome. In: Chang RJ (ed), Polycystic Ovary Syndrome. Serono Symposia USA, Springer-Verlag New York, Inc. pp 334-352.
 69. Lobo RA: Estrogen Replacement: The Evolving Role of Transdermal Delivery. A Symposium in Print. October 1995. Sponsored by Professional Postgraduate Services, Secaucus, NJ.
 70. Lobo RA: Steroid Supplementation of GnRH Analog in Ovarian Hyperandrogenism. Symposium held in Bologna September 15-16, 1995.
 71. Carmina E and Lobo RA: Steroid supplementation of GnRH analog in ovarian hyperandrogenism. In: Treatment with GnRH Analogs: Controversies and Perspectives. The Proceedings of a Satellite Symposium of the 15th World Congress on Fertility and Sterility held in Bologna, Italy, 15-16 September 1995. Marco Filicori and Carlo Flamigni (eds). Parthenon Publishing Group, International Publishers in Medicine, Science & Technology, New York/London 1996, Chapter 14, pp. 115-121
 72. Shoupe D and Lobo RA: Reproductive Neuroendocrinology. In: Mishell's Textbook of Infertility, Contraception, and Reproductive Endocrinology, Fourth Edition. R.A. Lobo, D.R. Mishell, R.J. Paulson and D. Shoupe (eds). Blackwell Scientific Publications, Malden, Massachusetts. 1997, pp 3-25.
 73. Lobo R.A. The Menstrual Cycle. In: Mishell's Textbook of Infertility, Contraception, and Reproductive Endocrinology, Fourth Edition. R.A. Lobo, D.R. Mishell, R.J. Paulson and D. Shoupe (eds). Blackwell Scientific Publications, Malden, Mass., 1997, pp. 124-140.
 74. Lobo R.A. Endocrinology of Pregnancy. In: Mishell's Textbook of Infertility, Contraception, and Reproductive Endocrinology, Fourth Edition. R.A. Lobo, D.R. Paulson and D. Shoupe (eds). Blackwell Scientific Publications, Malden, Massachusetts 1997, pp. 183-206.
 75. Lobo R.A. and Carmina E. Polycystic Ovary Syndrome. In: Mishell's Textbook of

Infertility, Contraception, and Reproductive Endocrinology, Fourth Edition. R.A. Lobo, D. R. Paulson and D. Shoupe (eds). Blackwell Scientific Publications, Malden, Massachusetts 1997, pp. 363-383.

76. Lobo R.A. and Carmina E. Androgen Excess. In: Mishell's Textbook of Infertility, Contraception, and Reproductive Endocrinology. Fourth Edition. R.A. Lobo, D. R. Paulson and D. Shoupe (eds). Blackwell Scientific Publications, Malden, Massachusetts 1997, pp. 342-362.
77. Carmina E. and Lobo RA: Dynamic Tests for Hormone Evaluation. In: Mishell's Textbook of Contraception, and Reproductive Endocrinology. Fourth Edition. R.A. Lobo, D. R. Paulson and D. Shoupe (eds). Blackwell Scientific Publications, Malden, Massachusetts 1997, pp. 471-483.
78. Lobo RA: The Postmenopausal State and Estrogen Deficiency. In: Estrogens and Anti-estrogens: Basic and Clinical Aspects. Robert Lindsay, David W. Dempster, and V. Craig Jordan (eds). Lippincott-Raven Publishers 1997, Chapter 6, pp. 63-72.
79. Lobo RA: What is the Perimenopause? Sero Symposia USA, Inc. In: Perimenopause: R.A. Lobo (Ed), Springer-Verlag New York 1997, pp 1-3.
80. Lobo RA: Hirsutism and Virilism. In: Carr DR and Blackwell RE (eds), Textbook of Reproductive Medicine: Second Edition, 1998. Appleton & Lange, Norwalk, Connecticut, Chapter 20, 405-423.
81. Lobo RA: Hirsutism and Virilization. In: Preci- an update in obstetrics and gynecology. Reproductive Endocrinology. The American College of Obstetricians and Gynecologist Women's Health Care Physicians 1998, pp 48-50.
82. Lobo RA: Estrogen Replacement Therapy. In: Knobil E and Neill JD (eds). Encyclopedia of Reproduction, Vol. 2. 1998. Academic Press, San Diego, CA, pp 101-108.
83. Lobo RA: Designer estrogens: clinical aspects. In: R.D. Kempers, J. Cohen, A.F. Haney and J.B. Younger. Fertility and Reproductive Medicine. Proceedings of the XVI World Congress on Fertility and Sterility, San Francisco, 4-9 October, 1998. pp 555-562. Elsevier, Amsterdam-New York-Oxford.
84. Lobo RA: Polycystic Ovary Syndrome (PCOS). In: Fraser IS, Jansen RPS, Lobo RA and Whitehead MI (eds). Estrogens and Progestogens in Clinical Practice. Churchill-Livingstone, London, 1998, pp 405-417.
85. Lobo RA: Primary and Secondary Amenorrhea. In: Fraser IS, Jansen RPS, Lobo RA and Whitehead MI (eds). Estrogens and Progestogens in Clinical Practice. Churchill-Livingstone, London, 1998, pp 357-363.

86. Lobo RA: Assisted Reproductive Technologies. In: Fraser IS, Jansen RPS, Lobo RA and Whitehead MI (eds). Estrogens and Progestogens in Clinical Practice. Churchill-Livingstone, London, 1998, pp 507-520.
87. Lobo RA: Estrogen Replacement Therapy. Encyclopedia of Reproduction Vol. 2, 1999. Academic Press, San Diego, California, pp 101-108.
88. Lobo RA: Menopause. In: Goldman L, Bennett JC, et al: Cecil Textbook of Medicine, 21st edition. W.B. Saunders Company, Philadelphia, PA. 1999.
89. Lobo RA. The Perimenopause. Chapter 5. In: Lobo RA (ed). Treatment of the Postmenopausal Woman, 2nd Edition. Lippincott Williams & Wilkins, New York, NY, 1999.
90. Lobo RA. Hormonal Replacement: Routes of Administration. Chapter 13. In: Lobo RA (ed). Treatment of the Postmenopausal Woman, 2nd Edition. Lippincott Williams & Wilkins, New York, NY, 1999.
91. Lobo RA. Treatment of the Postmenopausal Woman: Where We Are Today. Chapter 62. In: Lobo RA (ed). Treatment of the Postmenopausal Woman, 2nd Edition. Lippincott Williams & Wilkins, New York, New York. 1999.
92. Lobo RA. Prevalence and Clinical Impact of PCOS. Update for the online version of McGraw-Hill's Harrison's Principles of Internal Medicine, 14e, Anthony Fauci et al., (eds), 1999.
93. Lobo RA. Progestogens. Chapter 30, pp. 429. Menopause: Biology and Pathobiology. In: Lobo RA, Marcus R & Kelsey J (Eds.). The Academic Press, San Diego, CA. 2000.
94. Carmina E, Lobo RA. Hirsutism, Alopecia, and Acne. Chapter 101. In: Becker K.J. Principles and Practice of Endocrinology and Metabolism, Third Edition. J.B. Lippincott Williams & Wilkins, Philadelphia, 2001.
95. Lobo RA. Treatment of hyperandrogenism. Ch. 23, pp 327-348. In: Chang J, Heindel J Dunaif A. Polycystic Ovary Syndrome. Marcel-Dekker, New York, NY 2002.
96. Lobo RA. Menopause. In: Cecil Textbook of Medicine 22nd edition. Edited by Lee Goldman and Dennis Ausiello. Ch. 256. W.B. Saunders, Philadelphia, PA. 2002.
97. Lobo RA. Recent findings in cardiovascular disease. Chapter 14. HRT and Cardiovascular Disease: A New Approach. In: Lobo RA, Crosignani PG, Paoletti R and Bruschi F (Eds). Kluwer Academic Publishers, Dordrecht/Boston/London, 2002, pp. 137-141.
98. Lobo RA. Progestogens: New Approaches. In: Lobo RA, Crosignani PG, Paoletti R and Bruschi F (Eds). Kluwer Academic Publishers, Dordrecht/Boston/London, 2002, pp.

167-173.

- 99 Samsioe G, Doren M, Lobo RA (eds). In: **Menopause. Rapid Reference to Menopause.** Mosby, London 2002.

Book Editorships:

1. Horton R and Lobo RA: Androgen metabolism in normal and hirsute females. In: Clinics in Endocrinology and Metabolism, Volume 15:2, 1986. W.B. Saunders Company, Ltd., London, England.
2. Lobo RA: Role of opioid peptides in reproductive endocrinology. In: Seminars in Reproductive Endocrinology, Volume 5:2, 1987. Thieme Medical Publishers, Inc., New York, N.Y.
3. Wren BG, and Lobo RA: Handbook of Obstetrics and Gynaecology, Third Edition, 1989. Chapman and Hall Ltd., London, England.
4. Lobo RA and Whitehead MI: Consensus Development Conference on Progestogens. International Proceedings Journal, Volume 1, Number 1, 1989. Worldwide Medical Group, New York, N.Y.
5. Mishell DR Jr, Paulsen CA and Lobo RA: 1989 Year Book of Infertility. Year Book Medical Publishers, Chicago, Illinois.
6. Mishell DR Jr, Paulen CA and Lobo RA: 1990 Year Book of Infertility. Mosby-Year Book, Inc., Chicago, Illinois.
7. Mishell DR Jr, Davajan V and Lobo RA: Infertility, Contraception and Reproductive Endocrinology, Third Edition, 1991. Blackwell Scientific Publication, Cambridge, Massachusetts.
8. Mishell DR Jr, Paulsen CA and Lobo RA: 1991 Year Book of Infertility. Mosby-Year Book, Inc., Chicago, Illinois.
9. Lobo RA and Naftolin F: Progesterone in Hormonal Replacement Therapy, 1992. The Parthenon Publishing Group Inc., Park Ridge, New Jersey.
10. Mishell DR Jr, Paulsen CA and Lobo RA: 1992 Year Book of Infertility. Mosby-Year Book, Inc., Chicago, Illinois.
11. Mishell DR Jr, Sokol RZ and Lobo RA: 1993 Year Book of Infertility. Mosby-Year Book, Inc., Chicago, Illinois.
12. Lobo RA: Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, 1994. Raven Press, New York, NY.
13. Mishell DR Jr, Sokol RZ and Lobo RA: 1994 Year Book of Infertility. Mosby-Year Book, Inc., Chicago, Illinois.

14. Lobo RA and Speroff L: Menopausal Medicine. 1993-1995. The American Fertility Society, Birmingham, Alabama.
15. Mishell DR Jr, Sokol RZ and Lobo RA: 1995 Year Book of Infertility. Mosby-Year Book, Inc., Chicago, Illinois.
16. Mishell DR Jr, Lobo RA and Sokol RZ: 1996 Year Book of Infertility and Reproductive Endocrinology. Mosby-Year Book, Inc., Chicago, Illinois.
17. Lobo RA, Mishell DR Jr, Paulson RJ and Shoupe D: 1997. Mishell's Textbook of Infertility, Contraception and Reproductive Endocrinology, Fourth Edition. Blackwell Scientific Publication, Malden, Massachusetts.
18. Lobo RA: Perimenopause. Serono Symposia USA, Springer-Verlag, New York, Inc. 1997.
19. Pitkin, RM, Scott JR (Eds), Duff P and Lobo, RA (Guest Eds): Clinical Obstetrics & Gynecology, Vol. 41, # 4, 1998, Lippincott Williams & Wilkins, Philadelphia, PA.
20. Fraser I, Jansen RPS, Lobo RA and Whitehead MI: Estrogens and Progestogens in Clinical Practice. Churchill Livingstone, London, 1998.
21. Lobo RA. Treatment of the Postmenopausal Woman, 2nd Edition. Lippincott Williams & Wilkins, New York, NY 1999.
22. Lobo RA, Marcus R, Kelsey J. Menopause: Biology and Pathobiology. The Academic Press, San Diego, CA, 2000.
23. Lobo RA. Menopausal Medicine. Guest Editor. Bailliere's Best Practice & Research. Clinical Obstetrics and Gynaecology. In: S. Arulkumaran (Ed). Vol. 16 #3, June 2002.
24. Lobo RA, Crosignani PG, Paoletti R, Bruschi F. Women's Health and Menopause - New Strategies Improved Quality of Life. Vol. 17 Medical Science Symposia Series. Kluwer Academic Publishers, Dordrecht/Boston/London, 2002.

EDUCATIONAL SERVICE

1. Lobo RA, Notelovitz M. Estrogen Replacement: The Evolving Role of Transdermal Delivery. Symposium in print, CME activity, October 1995.
2. Lobo RA. Genetic Control of Gametogenesis. Special Report: Women's Reproductive Health. Biomedical Frontiers, Advances in Science, Technology, and Medicine at Columbia Presbyterian Medical Center Vol. 5, Issue 1, Fall 1997.
3. Lobo RA. Foreword. CME Activity. Progesterone use in reproductive and gynecologic endocrinology: Current and future perspectives. A Supplement to Contemporary OB/GYN 42 #10 October 1997.
4. Lobo RA. Appraisal of the protective therapeutic effects of transdermal hormone replacement therapy. Symposium in Copenhagen, August 1997, on "New Trends in Transdermal HRT and Aspects on Climacteric Psychology.
5. Lobo RA.(Moderator). Polycystic Ovary Syndrome. An educational service of The American College of Obstetricians and Gynecologists. ACOG Update Vol. 24, July 1998.
6. Lobo RA, Mishell D, Speroff L. New Approaches to Addressing Women's Health Issues. Scientific Forum organized by Parke-Davis Women's Healthcare, Big Sky, Montana, August 20-23, 1998.
7. Lobo RA (Program Chairman and Course Director). CME Activity. Natural Progesterone: Mechanisms, Effects, and Safety. Contemporary OB/GYN (Suppl), Sept. 1998.
8. Lobo RA: Future directions in the treatment of hyperandrogenic anovulation. ACCME Update in Obstetrics and Gynecology/CLIER, October 2-3, 1998, Chicago, Illinois.
9. Lobo RA: Estrogens and antiestrogens for postmenopausal women. ACCME Update in Obstetrics and Gynecology /CLIER, October 2-3, 1998, Chicago, Illinois.
10. Lobo RA: Hirsutism and Virilization. *Precis*, Reproductive Endocrinology: an update in obstetrics and gynecology. The American College of Obstetricians and Gynecologists, Danvers, MA, 1998.
11. Adashi EY, Bates W, Berenson AB, Blackwell RE, Bronson RA, Carr BR, Carson SA, Dawood MY, Diamond MP, Dodson WC, Lobo RA et al (contributors). *Precis* an update in obstetrics and gynecology. Reproductive Endocrinology. In:Holzman GB, Rinehart RD, Moghissi KS (eds). 1998.

12. Lobo RA: The risks and benefits of hormone replacement therapy (HRT). Presented at The 53rd Annual Assembly of Southern California on February 3-7, 1999 in Los Angeles. Obstetrical and Gynecological Assembly of Southern California, 1999.
13. Lobo RA: The role of SERMs in women's health. Presented at The 53rd Annual Assembly of Southern California on February 3-7, 1999 in Los Angeles. Obstetrical and Gynecological Assembly of Southern California, 1999.
14. Lobo RA: Is there a new way to treat PCOS? Presented at The 53rd Annual Assembly of Southern California on February 3-7, 1999 in Los Angeles. Obstetrical and Gynecological Assembly of Southern California, 1999.
15. Lobo RA: What is new in ovulation induction? Presented at The 53rd Annual Assembly of Southern California on February 3-7, 1999 in Los Angeles. Obstetrical and Gynecological Assembly of Southern California, 1999.
16. ART: Where we are today. Presented at The 53rd Annual Assembly of Southern California on February 3-7, 1999 in Los Angeles. Obstetrical and Gynecological Assembly of Southern California, 1999.
17. Lobo, RA. Commentary: Cano et al: Two-year prospective, randomized trial comparing an innovative twice-a-week progestin regimen with a continuous combined regimen as postmenopausal hormone therapy. *Fertil Steril* 1999;71:129-136. Library of Women's Health Web Site. JAMA Women's Health Web Site 1999. (www.amaassn.org/special/womh).
18. Lobo RA. Fertility issues in PCOS: An overview. Syllabi for PCOS Course during the ASRM Conjoint Annual Meeting of the American Society for Reproductive Medicine and the Canadian Fertility and Andrology Society. ASRM/CFAS 1999, Toronto, Canada.
19. Lobo RA, Steroidogenesis in PCOS. Syllabi for PCOS Course during the ASRM Conjoint Annual Meeting of the American Society for Reproductive Medicine and the Canadian Fertility and Andrology Society. ASRM/CFAS 1999, Toronto, Canada.
20. Lobo RA. Diagnostic and follow up studies (GYN). Syllabi for PCOS Course during the ASRM Conjoint Annual Meeting of the American Society for Reproductive Medicine and the Canadian Fertility and Andrology Society. ASRM/CFAS 1999, Toronto, Canada.
21. Lobo RA and Fraser IS. Introduction. Update on Progestogen Therapy: Endometrial Protection Vol. 2, 1999. A CME monograph highlighting presentations from an educational symposium held during a Consensus Development conference October 1998. MPE Communications, The Healthcare Resource, 1999.

22. Lobo RA and Fraser IS. Introduction. Dr. Thomas B. Clarkson's monograph entitled "Update on Progestogen Therapy: Cardiovascular Considerations." MPE Communications, The Healthcare Resources, 1999.
23. Rogerio A. Lobo. Menopause Management for the Millennium. Valid for CME until December 13, 2000. <http://www.medscape.com/Medscape/WomensHealth/ClinicalMagmt/CM.v01/public/index.CM.v01.htm>.
24. Lobo RA. Clinical Management Module/Menopause. Medscape Women's Health Website, 2000.
25. Lobo RA (Program Chair), Branch DW, Reindollar RH, Carson SA (Panel) CME Activity. Current Management of Recurrent Pregnancy Loss. Contemp OB/GYN (Suppl.), February 2000.
26. Lobo RA. Hormone Replacement Therapy in the New Millennium. *The State of HRT in the New Millennium - Estrogen Deficiency and the Menopause -Home Study Program* sponsored by Wyeth-Ayerst Global Pharmaceuticals and Dowden Health Media Inc., 2000.
27. Lobo, RA HRT Casebook 1- *II-Bleeding Patterns and Adherence*. Therapeutic options when considering the impact of progestogens on cardiovascular risk factors. A CME Monograph. R.A. Lobo (editor). Sponsored by the College of Physicians and Surgeons of Columbia University, New York, NY. MPE Communications, Fair Lawn, New Jersey, Solvay Pharmaceuticals Inc., 2001.
28. Lobo RA. APGO educational module, "Improving Quality of Life During Menopause: The Role for Hormone Replacement Therapy." Current Therapeutics Inc., Beachwood, OH. 2001.
25. Lobo RA. Approach to therapy. *Precis: Reproductive Endocrinology*, Second Edition. 2002.
26. Barbieri RL, Lobo RA, Walsh BW, Santoro NF (Editorial Board). Improving quality of Life During Menopause. The Role of Hormone Replacement Therapy. Association of Professors of Gynecology and Obstetrics (APGO) Educational Series on Women's Health Issues, Current Therapeutics Inc., Beachwood, OH, 2002.
27. Lobo RA, et al. Female sexuality and hormone replacement therapy. A Focus on Androgen Insufficiency. CME Monograph based on Proceedings of the 4th Task Force on Female Sexuality held in New York City in February 2002. Sponsored by Medical Education Resources and is supported by an unrestricted educational grant from Solvay Pharmaceuticals.
28. Lobo RA. HRT and Menopausal Health. Clinical Implications of Recent Data. CME

Audio CD presentation 2002. Sponsored by Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing.

Abstracts

1. Lobo RA, Kletzky OA, Kapteini EM and Goebelsmann U: Effects of alterations of plasma prolactin (PRL) levels upon circulating dehydroepiandrosterone sulfate (DHEA-S). Presented at the 61st Annual Meeting of The Endocrine Society, June 13-15, 1979, Anaheim, California.
2. Lobo RA, Paul W and Goebelsmann U: Clinical correlation between plasma dehydroepiandrosterone sulfate (DHEA-S) and urinary 17-ketosteroids (17KS) in gynecologic endocrinopathy. Presented at the American College of Obstetricians and Gynecologists, District VIII, Annual Meeting, September 16-20, 1979, Seattle, Washington.
3. Lobo RA, Paul W and Goebelsmann U: The role of DHEA-S in the evaluation of hirsute women. Presented at the 27th Annual Meeting of the Pacific Coast Fertility Society, October 17-21, 1979, Rancho Mirage, California.
4. Lobo RA and Goebelsmann U: Response of androgens and 17-hydroxyprogesterone (17OHP) to ACTH in normal and hirsute women, patients with postpubertal manifestation of congenital adrenal hyperplasia (CAH) and their family members. Presented at the 27th Annual Meeting of the Society for Gynecologic Investigation, March 19-22, 1980, Denver, Colorado.
5. Lobo RA and Goebelsmann U: Evidence for reduced 3 β -ol- hydroxysteroid dehydrogenase (3 β -ol-HD) activity in some hirsute women. Presented at the 27th Annual Meeting of the Society for Gynecologic Investigation, March 19-22, 1980, Denver, Colorado.
6. Mashchak CA, Lobo RA, Brenner PF and Mishell DR Jr: Comparison of pharmacodynamic properties of various estrogen formulations. Presented at the 27th Annual Meeting of the Society for Gynecologic Investigation, March 19-22, 1980, Denver, Colorado.
7. Lobo RA, March CM, Goebelsmann U and Mishell DR Jr: Subdermal estradiol (E_2) pellets: Effects on serum E_2 , estrone (E_1), LH, FSH, binding protein, lipids and postmenopausal symptoms. Presented at the 27th Annual Meeting of the Society for Gynecologic Investigation, March 19-22, 1980, Denver, Colorado.
8. Lobo RA, March CM and Mishell DR Jr: Subdermal 17 β -estradiol (E_2) pellet replacement therapy in premenopausal normal and obese women. Presented at the 62nd Annual Meeting of The Endocrine Society, June 18-20, 1980, Washington, D.C.
9. Lobo RA and Goebelsmann U: Incomplete 21-hydroxylase (21OH-ase) and 3-beta-ol-hydroxysteroid dehydrogenase (3 β -ol-HD) deficiencies in hirsute women. Presented at the 62nd Annual Meeting of The Endocrine Society, June 18-20, 1980, Washington, D.C.

10. Lobo RA, Gysler M, March CM, Goebelsmann U and Mishell DR Jr. Clinical and laboratory predictors of clomiphene response. Presented at the 28th Annual Meeting of the Pacific Coast Fertility Society, October 15-19, 1980, Scottsdale, Arizona.
11. Lobo RA, Granger L, Goebelsmann U and Mishell DR Jr: Elevations in unbound serum estradiol as a possible mechanism for inappropriate gonadotropin secretion in women with PCO. Presented at the 28th Annual Meeting of the Pacific Coast Fertility Society, October 15-19, 1980, Scottsdale, Arizona.
12. Lobo, RA, Paul W, Kletzky OA and March CM: Ovulatory and anovulatory hormonal profiles in women treated with high-dose clomiphene citrate (Clomid) with and without the addition of dexamethasone. Presented at the 37th Annual Meeting of The American Fertility Society, March 14-18, 1981, Atlanta, Georgia.
13. Lobo RA and Goebelsmann U: Effect of androgen excess on inappropriate gonadotropin secretion (IGS) as found in the polycystic ovary syndrome. Presented at the 28th Annual Meeting of the Society for Gynecologic Investigation, March 18-21, 1981, St. Louis, Missouri.
14. Readhead CW, Lobo RA, Goebelsmann U, Kletzky O and Mishell DR Jr: 3 β -ol-hydroxysteroid dehydrogenase-isomerase enzymatic activity. Presented at the 28th Annual Meeting of the Society for Gynecologic Investigation, March 18-21, 1981, St. Louis, Missouri.
15. Lobo RA, Goebelsmann U, Brenner PF and Mishell DR Jr: Effect of estrogens on adrenal androgens in oophorectomized women. Presented at the 63rd Annual Meeting of The Endocrine Society, June 17-19, 1981, Cincinnati, Ohio.
16. Readhead C, Lobo RA, Shultz AW and Kletzky OA: LH-stimulated 3 β -hydroxysteroid dehydrogenase-isomerase (3 β -HSD) activity. Presented at the 63rd Annual Meeting of The Endocrine Society, June 17-19, 1981, Cincinnati, Ohio.
17. Granger LR, Lobo RA and Mishell DR Jr: An extended regimen of clomiphene citrate in women unresponsive to standard therapy. Presented at the 29th Annual Meeting of the Pacific Coast Fertility Society, October 14-18, 1981, Rancho Mirage, California.
18. Lobo RA, Granger LR, Paul WL, Goebelsmann U and Mishell DR Jr: The relationship between psychological stress, neuro-transmitters and androgen secretion in women with PCO. Presented at the 29th Annual Meeting of the Pacific Coast Fertility Society, October 14-18, 1981, Rancho Mirage, California.
19. Lahteenmaki P, Lobo R, Marrs RP, Gibbons WE, Nakamura RM and diZerega GS: folliculogenesis in response to clomiphene therapy: Allochronic follicular maturation.

Presented at the 29th Annual Meeting of the Pacific Coast Fertility Society, October 14-18, 1981, Rancho Mirage, California.

20. Horton R, Lobo R and Hawks D: Plasma androstenediol glucuronide (3α -diol G), a marker of peripheral androgen action in hirsutism. Presented at the Annual Meeting of the American Federation for Clinical Research, Western Society for Clinical Research, February 16-19, 1982, Carmel, California.
21. Horton R, Lobo R and Hawks D: Androstenediol glucuronide (3α -diol G) in plasma: A measure of peripheral androgen action. Presented at the 7th Annual Meeting of The American Society of Andrology, February 23-26, 1982, Hilton Head Island, Southern California.
22. Lobo RA, Kletzky OA and diZerega GS: Elevated serum bioactive luteinizing hormone (LH) concentrations in women with polycystic ovary syndrome (PCO). Presented at the 38th Annual Meeting of The American Fertility Society, March 20-24, 1982, Las Vegas, Nevada.
23. Lobo RA and Kletzky OA: Elevated androgen levels and decreased SHBG in hyperprolactinemia. Presented at the 29th Annual Meeting of the Society for Gynecologic Investigation, March 24-27, 1982, Dallas, Texas.
24. Gibbons WE, Lobo RA, Roy S and Mishell DR Jr: Estrogen receptor levels in the endometria of post-menopausal women on estrogen and progestin replacement. Presented at the 29th Annual Meeting of the Society for Gynecologic Investigation, March 24-27, 1982, Dallas, Texas.
25. Lobo RA, Hung TT, diZerega GS, Kletzky OA and Goebelsmann U: Control of adrenal androgen secretion in women with PCO. Presented at the 29th Annual Meeting of the Society for Gynecologic Investigation, March 24-27, 1982, Dallas, Texas.
26. Lobo RA, Goebelsmann U and Horton R: 5α -androstane- 3α , 17β -diol-3-glucuronide (3α -AG), an index of increased peripheral androgen action in hirsutism. Presented at the 29th Annual Meeting of the Society for Gynecologic Investigation, March 24-27, 1982, Dallas, Texas.
27. Lobo RA, Hung TT, Roy S and Goebelsmann U: Estrogen therapy raises serum dehydroepiandrosterone sulfate (DHEA-S) in oophorectomized (OO) women through mechanisms independent of ACTH or β -EP). Presented at the 29th Annual Meeting of the Society for Gynecologic Investigation, March 24-27, Dallas, Texas.
28. Petrucha RA, Hung TT, Lobo RA and Goebelsmann U: Amniotic fluid (AF) β -endorphin β -lipotropin (β -EP) and β -LPH concentrations during the second and third trimester.

Presented at the 29th Annual Meeting of the Society for Gynecologic Investigation, March 24-27, 1982, Dallas, Texas.

29. Goebelsmann U, Shaaban MM, Hung TT, Hoffman DI and Lobo RA: Beta-endorphin (β -EP) and β -lipotropin (β -LPH) in human. Presented at the 29th Annual Meeting of the Society for Gynecologic Investigation, March 24-27, 19982, Dallas, Texas.
30. Horton R, Lobo R and Hawks D. Androstanediol glucuronide in plasma, a marker of androgen action in men and women. Presented at the 74th Annual Meeting of the American Federation for Clinical Research, American Society for Clinical Investigation, May 8-10, 1982, Washington, D.C.
31. Lahteenmaki P, Lobo R, Marrs R, Gibbons W, Nakamura R and diZerega G: Characterization of porcine granulosa cells by isopycnic gradient centrifugation. Presented at the 64th Annual Meeting of The Endocrine Society, June 16-18, 1982, San Francisco, California.
32. Lobo RA, Goebelsmann U and Horton R: Hirsutism in polycystic ovary syndrome (PCO). Presented at the 30th Annual Meeting of the Pacific Coast Fertility Society, October 13-17, 1982, Scottsdale, Arizona.
33. Montoro M, Kletzky OA, Lobo R and Nicoloff JT: Altered pituitary function in women and men with pituitary hypothyroidism. Presented at the 30th Annual Meeting of the Pacific Coast Fertility Society, October 13-17, 1982, Scottsdale, Arizona.
34. Moghissi E, Lobo R, Hawks D and Horton R: Evidence for peripheral factors in the hirsutism of the polycystic ovary syndrome. Presented at the Annual Meeting of the American Federation for Clinical Research, Western Society for Clinical Research, February 9-11, 1983, Carmel, California.
35. Fallis R, Fisher M and Lobo R: A double-blind trial of naloxone in acute stroke. Presented at the Eight International Joint Conference on Stroke and Cerebral Circulation, February 10-12, 1983, San Diego, California.
36. Lobo R and Shoupe D; Evidence for decreased dopaminergic control of LH secretion in polycystic ovary syndrome (PCO): Presented at the 30th Annual Meeting of the Society for Gynecologic Investigation, March 17-20, 1983, Washington, D. C.
37. Shoupe D, Campeau J and Lobo RA: Differences in bioactive (bio) LH and immunoreactive (I) LH secretion in women. Presented at the 30th Annual Meeting of the Society for Gynecologic Investigation, March 17-20, 1983, Washington, D.C.
38. Marrs RP, Lobo R, Campeau JD, Brown J and diZerega GS: Correlation of human follicular fluid inhibin activity with spontaneous and induced follicular development. Presented at the 30th Annual Meeting of the Society for Gynecologic Investigation, March

17-20, 1983, Washington, D.C.

39. Vargyas J and Lobo R: The role of non-SHBG bound estradiol (E2), total E2, progesterone (P) and the E2/P ratio in the premenstrual syndrome (PMS). Presented at the 30th Annual Meeting of the Society for Gynecologic Investigation, March 17-20, 1983, Washington, D.C.
40. Gibbons WE, Lobo RA, Moyer DL, Roy S and Mishell DR Jr; A comparison of biochemical and morphological events mediated by estrogen \pm progestin in the endometrium of postmenopausal women. Presented at the 30th Annual Meeting of the Society for Gynecologic Investigation, March 17-20, 1983, Washington, D.C.
41. Shoupe D, Kumar D and Lobo R: Insulin resistance in polycystic ovary syndrome (PCO). Presented at the 30th Annual Meeting of the Society for Gynecologic Investigation, March 17-20, 1983, Washington, D.C.
42. Lobo RA, Goebelsmann U and Horton R: Evidence for peripheral factors in the development of hirsutism in polycystic ovary syndrome. Presented at the 39th Annual Meeting of The American Fertility Society, April 16-20, 1983, San Francisco, California.
43. Shoupe D and Lobo RA: Insulin resistance in polycystic ovary syndrome (PCO). Presented at the 39th Annual Meeting of The American Fertility Society, April 16-20, 1983, San Francisco, California.
44. Hoffman DI and Lobo RA: The prevalence and significance of elevated DHEA-S levels in anovulatory women. Presented at the 39th Annual Meeting of The American Fertility Society, April 16-20, 1983, San Francisco, California.
45. Shoupe D and Lobo RA: Decreased dopaminergic control of LH secretion in polycystic ovary syndrome (PCO) yet differences in the control of immunological (I) LH and bioactive (bio) LH. Presented at the 65th Annual Meeting of The Endocrine Society, June 8-10, 1983, San Antonio, TX.
46. Marrs RP, Vargyas JM and Lobo R: Comparison of the intrafollicular hormone milieu with fertilization of human oocytes in vitro. Presented at the 65th Annual Meeting of The Endocrine Society, June 8-10, 1983, San Antonio, Texas.

47. Lobo RA, Vargyas JM and Marrs RP: Androgen levels in follicular fluid (FF) and its relationship to the maturity of the oocyte and its ability to be fertilized in vitro. Presented at the 31st Annual Meeting of the Pacific Coast Fertility Society, October 12-16, 1983, Rancho Mirage, California.
48. Ablan F, Moghissi M, Hoopes M, Lobo RA and Horton R: Origin of androstanediol glucuronide in plasma of men and women with polycystic ovary syndrome. Presented at the annual Meeting of the American Federation for Clinical Research, Western Society for Clinical Research, February 8-10, 1984, Carmel, California.
49. Serafini P and Lobo R: Androgenicity in women; Tissue 5 α -reductase activity (5 α -RA) and serum androgen levels. Presented at the 31st Annual Meeting of the Society for Gynecologic Investigation, March 21-24, 1984, San Francisco, California.
50. Serafini P and Lobo R: Hirsutism in postmenopausal women (PoW): Androgen/estrogen ratios and 5 α -reductase activity (5 α -RA). Presented at the 31st Annual Meeting of the Society for Gynecologic Investigation, March 21-24, 1984, San Francisco, California.
51. Shoupe D, Chang SP, Kletzky OA and Lobo R: Differences in the ratio of bioactive to immunoreactive serum LH during vasomotor flushes and hormonal therapy in postmenopausal women. Presented at the 31st Annual Meeting of the Society for Gynecologic Investigation, March 21-24, 1984, San Francisco, California.
52. Shoupe D, Montz FJ and Lobo R: LH and PRL-evoked naloxone (Nal) responses and plasma β -EP in oophorectomized women (Ow) before and after estrogen (E) and progestin (P) treatment. Presented at the 31st Annual Meeting of the Society for Gynecologic Investigation, March 21-24, 1984, San Francisco, California.
53. Serafini P, Goebelsmann UT and Lobo RA: Increased 5 α -reductase activity in hirsutism. Presented at the 40th Annual Meeting of The American Fertility Society, April 2-7, 1984, New Orleans, Louisiana.
54. Lobo R, Shoupe D, Serafini P, Brinton D and Horton R: Serum androgens and the clinical response to spironolactone therapy. Presented at the 40th Annual Meeting of The American Fertility Society, April 2-7, 1984, New Orleans, Louisiana.
55. Shoupe D and Lobo RA: PRL responses after GnRH in PCO. Presented at the 40th Annual Meeting of The American Fertility Society, April 2-7, 1984, New Orleans, Louisiana.
56. Serafini P, Ablan F, Horton R and Lobo R: The effects of spironolactone and progesterone on in vitro 5 α -reductase activity in hirsute women. Presented at the International Symposium on Regulation of Androgen Action, June 29-July 1, 1984, Montreal, Quebec, Canada.

57. Serafini P, Ablan F and Lobo R: Increased in vitro production of DHT-glucuronide (G) and 3α - androstenediol (3α -diol) G from the skin of hirsute women. Presented at the 7th International Congress of Endocrinology, July 1-7, 1984. Quebec City, Quebec, Canada.
58. Shoupe D, Barnes RB, Montz FJ, Brazal SD and Lobo R: Bioactive (bio) LH and the bio: immunoreactive (i) LH ratio after naloxone (nal) as a probe for endogenous central opioid activity (COA) in women. Presented at the 7th International Congress of Endocrinology, July 1-7, 1984, Quebec City, Quebec, Canada.
59. Barnes R, Shoupe D and Lobo R: Endogenous opioid activity in polycystic ovary syndrome. Presented at the 7th International Congress of Endocrinology, July 1-7, 1984, Quebec City, Quebec, Canada.
60. Hoffman D, Lobo R, Platt L and diZerega G: Differential follicular response in anovulatory patients to purified urinary FSH versus purified urinary FSH and LH. Presented at the Vth Reinier de Graaf Symposium: Gamete Quality and Fertility Regulation, August 23-25, 1984, Nijmegen, The Netherlands.
61. Serafini P and Lobo R: The effects of spironolactone on adrenal steroidogenesis in hirsute women. Presented at the 32nd Annual Meeting of the Pacific Coast Fertility Society, September 19-23, 1984, Rancho Mirage, California.
62. Barnes R, Shoupe D, Chiang J and Lobo R: Central opioid activity in polycystic ovary syndrome. Presented at the 32nd Annual Meeting of the Pacific Coast Fertility Society, September 19-23, 1984, Rancho Mirage, California.
63. Vargyas J, Lobo R and Mishell D: Brain opioid activity in the premenstrual cycle. Presented at the 32nd Annual Meeting of the Pacific Coast Fertility Society, September 19-23, 1984.
64. Hoffman DI, Lobo R, Moyer D, Roy S and Platt L: Evaluation of early follicular phase administration of a potent gonadotropin-releasing hormone agonist (Wy-40, 972, Wyeth). Presented at the 32nd Annual Meeting of the Pacific Coast Fertility Society, September 19-23, 1984, Rancho Mirage, California.
65. Steingold KA, Lobo R, Andrews L, Lu JKH, Judd HL and Chang RJ: The effect of bromocriptine on gonadotropin secretion in polycystic ovary disease. Presented at the 32nd annual Meeting of the Pacific Coast Fertility Society, September 19-23, 1984, Rancho Mirage, California.
66. Lobo RA and Serafini PC: Peripheral androgen metabolism (PAM) in postmenopausal (PM) women and the complaint of hirsutism. Presented at The Fourth International Congress on the Menopause, October 28-November 2, 1984, Orlando, Florida.

67. Barnes R, Roy S and Lobo R: Plasma lipid and serum androgen levels in postmenopausal (PM) women treated with depo-medroxyprogesterone acetate (DMPA). Presented at The Fourth International Congress on the Menopause, October 28-november 2, 1984, Orlando, Florida.
68. Serafini P; Paulson F, Elkind-Hirsch K, Hernandez M and Lobo R: Acute modulation of the hypothalamic pituitary axis (HPA) by testosterone (T) in normal women. Presented at the 32nd Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1985, phoenix, Arizona.
69. Baranes R, Cha K and Lobo R: Altered dopaminergic control of PRL in polycystic ovary syndrome (PCO). Presented at the 32nd Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1985, Phoenix, Arizona.
70. Barnes R, Lee D and Lobo R: Dopamine but not norepinephrine influences the bioactivity of LH in normal women. Presented at the 32nd Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1985, Phoenix, Arizona.
71. Paulson R, Serafini P, Catalino J and Lobo R: Serum and urinary 3 α -androstenediol glucuronide 3 α -diol G) and their correlations with genital skin 5 α -reductase activity (5 α RA) and 3 α -diol G formation. Presented at the 32nd Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1985, Phoenix, Arizona.
72. Baranes RB, Chiang JH, Cha KY, Shoupe D and Lobo R: Responses of bio and iLH and FSH to 2 doses of a nasal GnRH agonist. Presented at the 33rd Annual Meeting of the Pacific Coast Fertility Society, April 24-28, 1985, Las Vegas, Nevada.
73. Paulson RJ, Bernstein GS and Lobo RA: Idiopathic oligospermia and peripheral androgen metabolism. Presented at the 33rd Annual Meeting of the Pacific Coast Fertility Society, April 24-28, 1985, Las Vegas, Nevada.
74. Serafini PC and Lobo RA: Prolactin (PRL) modulates peripheral androgen metabolism (PAM). Presented at the 33rd Annual Meeting of the Pacific Coast Fertility Society, April 24-28, 1985, Las Vegas, Nevada.
75. Serafini P, Paulson R, Francis M and Lobo R: Testosterone elicits divergent PRL and LH responses after GnRH in normal women. Presented at the 67th Annual Meeting of The Endocrine Society, June 19-21, 1985, Baltimore, Maryland.
76. Barnes R, Artal R and Lobo R: Altered catecholamine metabolism in polycystic ovary syndrome (PCO). Presented at the 67th Annual Meeting of The Endocrine Society, June 19-21, 1985, Baltimore, Maryland.
77. Greep N, Hoopes M, Lobo R and Horton R: Evidence for a role of androstenedione as precursor of plasma DHT and androstenediol glucuronide in normal hirsute women.

- Presented at the 67th Annual Meeting of The Endocrine Society, June 19-21, 1985, Baltimore, Maryland.
78. Lobo RA, Serafini PC and Paulson RJ: Genital skin 5 α -reductase activity (5 α RA): A marker of androgenicity in women. Presented at the 4th Annual Meeting of The American Gynecological and Obstetrical Society, September 4-7, 1985, Hot Springs, Virginia.
 79. Mileikowsky G, Anderson R, Chen D, Siegel M and Lobo R: Radionuclide hysterosalpingo tomography (RHST) for the evaluation of the reproductive tract in infertility. Presented at the 41st Annual Meeting of The American Fertility Society, September 27-October 2, 1985, Chicago, Illinois.
 80. Barnes R, Spencer C and Lobo R: Responses of LH, PRL and TSH to dopaminergic blockade in polycystic ovary syndrome (PCO): Lack of evidence for decreased dopaminergic activity. Presented at the 41st Annual Meeting of The American Fertility Society, September 27-October 2, 1985, Chicago, Illinois.
 81. Cha K, Barnes R, Marrs R and Lobo R: Oocyte maturity in the spontaneous cycle correlates with follicular fluid (FF) progesterone (Prog) levels and LH of greater biological activity. Presented at the 41st Annual Meeting of The American Fertility Society, September 27-October 2, 1985, Chicago, Illinois.
 82. Paulson R, Serafini P and Lobo R: Effect of sex steroids on 5 α -reductase activity (5 α RA) in vitro. Presented at the 41st Annual Meeting of The American Fertility Society, September 27-October 2, 1985, Chicago, Illinois.
 83. Hoffman D, Lobo R, Campeau J and diZerega G: Increased prolactin (PRL) levels in gonadotropin-stimulated cycles. Presented at the 41st Annual Meeting of The American Fertility Society, September 27-October 2, 1985, Chicago, Illinois.
 84. Cha K, Campeau J, Marrs R, Nakamura R and Lobo R: Follicular fluid (FF) LH bioactivity and oocyte maturity (OM) in spontaneous (S) and stimulated (STIM) cycles. Presented at the 33rd Annual Meeting of the Society for Gynecologic Investigation, March 19-22, 1986, Toronto, Ontario, Canada.
 85. Paulson RJ, Paulson YJ, Silva PD, Cha KY, Lobo RA, Yee B and Marrs RP: Hormonal dynamics of hCG-triggered ovulation: Bio-hCG and steroid response. Presented at the 33rd Annual Meeting of the Society for Gynecologic Investigation, March 19-22, 1986, Toronto, Ontario, Canada.
 86. Shoupe D, Spitz I, Osborn C, Page M, Mishell D Jr and Lobo R: Effects of progesterone (P) antagonism on gonadotropins at midcycle and during the luteal phase. Presented at the 33rd Annual Meeting of the Society for Gynecologic Investigation, March 19-22, 1986, Toronto, Ontario, Canada.

87. Silva P, Paulson R, Serafini P, Francis M and Lobo R: Acute effects of testosterone (T) on immunoreactive luteinizing hormone (ILH) and bioreactive LH (BLH) in normal women. Program book of the 33rd Annual Meeting of the Society for Gynecologic Investigation, March 19-22, Toronto, Ontario, Canada.
88. Paulson R, Gentzschein E, Nguyen H and Lobo R: Differences between genital skin (G) and pubic (P) skin 5 α -reductase activity (5 α RA). Program book of the 33rd Annual Meeting of the Society for Gynecologic Investigation, March 19-22, 1986, Toronto, Ontario, Canada.
89. Silva P, Gentzschein E, Paulson R, Horton R and Lobo R: Androstenedione (A) as precursor for DHT: Evidence for dissociated blood and tissue DHT production (P). Program book of the 33rd Annual Meeting of the Society for Gynecologic Investigation, March 19-22, 1986, Toronto, Ontario, Canada.
90. Paulson RJ, Silva PD, Paulson YJ, Cha KY, Yee B, Lobo RA and Marrs RP: The effects of different doses of intramuscular hCH on follicular fluid (FF) steroid and hCG levels and on oocyte maturity (OM). Presented at the 34th Annual Meeting of the Pacific Coast Fertility Society, April 9-13, 1986, San Diego, California.
91. Rosen GF, Vermesh M, Gentzschein E and Lobo RA: Clinical heterogeneity in Turner's syndrome. Presented at the 34th Annual Meeting of the Pacific Coast Fertility Society, April 9-13, 1986, San Diego, California.
92. Silva PD, Porto M, Moyer DL and Lobo RA: Expression of androgenicity in a nonsteroid secreting tumor in pregnancy. Presented at the 34th Annual Meeting of the Pacific Coast Fertility Society, 9-13, 1986, San Diego, California.
93. Rosen GF and Lobo RA: Further evidence against dopamine (DA) deficiency as a cause of inappropriate gonadotropin secretion (IGS) in polycystic ovary syndrome (PCO). Presented at the 42nd Annual Meeting of The American Fertility Society/Canadian Fertility and Andrology Society, September 27-October 2, 1986, Toronto, Ontario, Canada.
94. Silva PD and Lobo RA: Androstenedione (A) is the major precursor of tissue dihydrotestosterone (DHT)-production (P) in women. Presented at the 42nd Annual Meeting of The American Fertility Society/Canadian Fertility and Andrology Society, September 27- October 2, 1986, Toronto, Ontario, Canada.
95. Rosen GF, Cha K-Y, Marrs RP and Lobo RA: Effects of pure FSH (Metrodin) and HCG on hormonal characteristics on follicular fluid (FF) and their correlation with oocyte maturity (OM). Presented at the 42nd Annual Meeting of The American Fertility Society/Canadian Fertility and Andrology Society, September 27-October 2, 1986, Toronto, Ontario, Canada.
96. Xu YK, Ng, WG, Kaufman F, Lobo R and Donnell GN: Galactose metabolism in human

ovary. Presented at the Annual Meeting of the American Federation for Clinical Research, Western Society for Pediatric Research, February 3-6, 1987, Carmel, California.

97. Pasupuleti V, Lobo R and Horton R: Formation of androstenediol glucuronide by human sexual skin. Presented at the Annual Meeting of the American Federation for Clinical Research, Western Society for Clinical Research, February 3-6, 1987, Carmel, California.
98. Lobo R, Gentzschlein E, Pasupuleti V and Horton R: Differential pathways of 3α -diol G formation in human skin. Presented at the 34th Annual Meeting of the Society for Gynecologic Investigation, March 18-21, 1987, Atlanta, Georgia.
99. Vermesh M, Silva PD and Lobo R: Opiates modulate the inhibitory effect of androgen on the hypothalamic-pituitary axis (HPA) of normal women. Presented at the 34th Annual Meeting of the Society for Gynecologic Investigation, March 18-21, 1987, Atlanta, Georgia.
100. Davidson A, Vermesh M, Vijod A, Paulson RJ and Lobo R: Presence of immunoreactive β -endorphin (β EP) in seminal plasma (SP) and its possible involvement in sperm motility. Presented at the 34th Annual Meeting of the Society for Gynecologic Investigation, March 18-21, 1987, Atlanta, Georgia.
101. Kaufman F, Xu Y, Ng W, Donnell G and Lobo R: Characterization of ovarian failure in galactosemia (G) and galactose (gal) metabolism in the ovary. Presented at the 34th Annual Meeting of the Society for Gynecologic Investigation, March 18-21, 1987, Atlanta, Georgia.
102. Lobo R, Nguyen H, Eggena P and Brenner P: Biological effects of equilin sulfate (EqS): Differences in hepatic and bone resorbing effects. Presented at the 34th Annual Meeting of the Society for Gynecologic Investigation, March 18-21, 1987, Atlanta, Georgia.
103. Paulson RJ, Do Y, Hsueh W, Eggena P and Lobo R: Prorenin (PR), renin activity (RA) and renin substrate (RS) in follicular fluid (FF): Correlation with oocyte maturity (OM) and FF steroids. Presented at the 34th Annual Meeting of the Society for Gynecologic Investigation, March 18-21, 1987, Atlanta, Georgia.
104. Shoupe D, Roy S and Lobo RA: Psychological function (Psy) and peripheral and central opioid activity (COA) in postmenopausal women (PM): Estrogen and progestin effects. Presented at the 34th Annual Meeting of the Society for Gynecologic Investigation, March 18-21, 1987, Atlanta, Georgia.
105. Vermesh M, Silva PD, Rosen GF and Lobo R: Induction of partial 21-hydroxylase deficiency by androgen in normal women. Program book of the 34th Annual Meeting of the Society for Gynecologic Investigation, March 18-21, 1987, Atlanta, Georgia.

106. Davidson A, Vermesh M, Toker R, Braxton P, Lobo R and Paulson R: Mouse embryo culture as quality control for human IVF: The once cell (1C) vs. two cell (2C) model. Presented at the Vth World Congress - In Vitro Fertilization and Embryo Transfer, April 5-10, 1987, Norfolk, Virginia.
107. Lobo RA, Cristo M and Crary W: Effects of estrogen on psychological function in asymptomatic postmenopausal women. Presented at the Fifth International Congress on the Menopause, April 6-10, 1987, Sorrento, Italy.
108. Nguyen HN, Eggena P and Lobo RA: Biological effects of equilin sulfate; Differences in hepatic and bone resorbing effects. Presented at the Fifth International Congress on the Menopause, April 6-10, 1987, Sorrento, Italy.
109. Morton J, Fraser D, Whitehead MI and Lobo R: Is failure of progesterone action upon the endometrium due to poor end-organ response or to poor absorption/rapid metabolism of the progestogen? Presented at the Fifth International Congress on the Menopause, April 6-10, 1987, Sorrento, Italy.
110. Anderson RE, Ben-Rafael Z, Meloni L, Flickinger M, Barnes RB, Rosen GF and Lobo RA: Secretory dynamics of bioactive and immunoreactive PRL in PCO. Presented at the 35th Annual Meeting of the Pacific Coast Fertility Society, May 6-10, 1987, Palm Springs, California.
111. Davidson A, Vermesh M, Lobo RA and Paulson RJ: The temporal effects of changes in IVF culture media on the one-cell (1C) mouse embryo system. Presented at the 35th Annual Meeting of the Pacific Coast Fertility Society, May 6-10, 1987, Palm Springs, California.
112. Davidson A, Vermesh M, Vijod AG, Paulson RJ and Lobo RA: The presence of calcitonin in seminal plasma. Presented at the 35th Annual Meeting of the Pacific Coast Fertility Society, May 6-10, 1987, Palm Springs, California.
113. Silva PD, Paulson RJ, Anderson RE, Werlin LB, Stein AL and Lobo RA: Ectopic pregnancy in contralateral tubal remnants after unilateral tubal anastomosis: Preventable and unpreventable causes. Presented at the 35th Annual Meeting of the Pacific Coast Fertility Society, May 6-10, 1987, Palm Springs, California.
114. Stein A, Manoogian C, Vijod A and Lobo R: Adrenal androgen excess resulting in virilization and PCO-like features. Presented at the 35th Annual Meeting of the Pacific Coast Fertility Society, May 6-10, 1987, Palm Springs, California.
115. Vermesh M, Silva PD, Rosen GF and Lobo RA: Adrenal effects of short-term administration of testosterone in normal women. Presented at the 35th Annual Meeting of the Pacific Coast Fertility Society, May 6-10, 1987, Palm Springs, California.

116. Stanczyk FZ, Kaufman FR, Gentzschein E and Lobo RA: Androstenedione (A) is an important precursor of dihydro-testosterone (DHT) in the skin of women and is metabolized via 5α -androstenedione (5α -A). Presented at the 69th Annual Meeting of The Endocrine Society, June 10-12, 1987, Indianapolis, Indiana.
117. Shoupe D, Mishell DR Jr, Tonetta SA, Spitz IM, Madkour H and Lobo RA: Suppression of ovulation by follicular phase administration of the antiprogesterin RU 486 and evidence for suppression of ovarian steroidogenesis. Presented at the 69th Annual Meeting of The Endocrine Society, June 10-12, 1987, Indianapolis, Indiana.
118. Pasupuleti V, Lobo R and Horton R: Conversion of dihydrotestosterone to androstenediol glucuronide by skin. Presented at the 69th Annual Meeting of The Endocrine Society, June 10-12, 1987, Indianapolis, Indiana.
119. Davidson A, Vermesh M, Lobo RA and Paulson RJ: The temporal effects of changes in IVF culture media on the one-cell (1C) mouse embryo system. Presented at the 43rd Annual Meeting of The American Fertility Society, September 28-30, 1987, Reno, Nevada.
120. Stein AL and Lobo RA: Factors determining clitoral hypertrophy (CH) in hyperandrogenism. Presented at the 43rd Annual Meeting of The American Fertility Society, September 28-30, 1987, Reno, Nevada.
121. Anderson R, Cragun J, Chang RJ, Bhasin S, Stanczyk F, Vijod M and Lobo RA: Pharmacodynamics of human urinary FSH (hFSH) and human menopausal gonadotropin hMG) in PCO and normal women. Presented at the 35th Annual Meeting of the Society for Gynecologic Investigation, March 17-20, 1988, Baltimore, Maryland.
122. Shoupe D, Mishell DR Jr and Lobo R: Evidence that oxytocin increases cortisol secretion and decreases LH pulsatility in normal women. Presented at the 35th Annual Meeting of the Society for Gynecologic Investigation, March 17-20, 1988, Baltimore, Maryland.
123. Matteri RK, Stanczyk FZ, Kaufman FR, Vijod AG, Anderson RE and Lobo RA: Measurement and comparison of circulating C19 sulfates and glucuronides in normal and hirsute women and men. Presented at the 35th Annual Meeting of the Society for Gynecologic Investigation, March 17-20, 1988, Baltimore, Maryland.
124. Paulson RJ, Do Y, Hsueh W and Lobo R: Prorenin (PR) and renin activity (RA) in ovarian venous (OV) and peripheral venous (PV) blood: Gradients and correlations with ovarian steroids. Presented at the 35th Annual Meeting of the Society for Gynecologic Investigation, March 17-20, 1988, Baltimore, Maryland.
125. Kaufman FR, Matteri RK, Stanczyk FZ, Gentzschein E, Delgado C and Lobo RA: Characterization of dehydroepiandrosterone (DHEA) and DHEA-sulfate (S) metabolism

in

human genital skin. Presented at the 35th Annual Meeting of the Society for Gynecologic Investigation, March 17-20, 1988, Baltimore, Maryland.

126. Stanczyk FZ, Shoupe D, Nunez V and Lobo RA: A randomized comparison of non-oral estradiol (E2) delivery in post-menopausal women (PM). Presented at the 35th Annual Meeting of the Society for Gynecologic Investigation, March 17-20, 1988, Baltimore, Maryland.
127. Matteri RK, Stanczyk FZ, Kaufman FR, Chenette PE, Anderson RE, Gentzschein E and Lobo RA: Androgen sulfates as markers of peripheral androgen action in hirsutism. Presented at the 36th Annual Meeting of the Pacific Coast Fertility Society, April 13-17, 1988, Palm Springs, California.
128. Anderson RE, Stein AL, Paulson RJ and Lobo RA: Effects of norethindrone (NET) used to program oocyte retrieval for in vitro fertilization. Presented at the 36th Annual Meeting of the Pacific Coast Fertility Society, April 13-17, 1988, Palm Springs, California.
129. Shoupe D, Mishell DR, Lobo RA, Lacarra M, Horenstein J, d'Ablainig G, Moyer D: Correlation of endometrial maturation with 4 methods of estimating day of ovulation. Presented at the 36th Annual Meeting of the Pacific Coast Fertility Society, April 13-17, 1988, Palm Springs, California.
130. Graczykowski JW, Vermesh M, Siegel MS and Lobo RA: The effect of beta-endorphin (β -EP) and calcitonin (CT) on sperm movement characteristics in vitro. Presented at the 36th Annual Meeting of the Pacific Coast Fertility Society, April 13-17, 1988, Palm Springs, California.
131. Matteri RK, Stanczyk FZ, Kaufman FR, Delgado C, Gentzschein E and Lobo RA: Production of C19 sulfates and glucuronides in human genital skin. Presented at the 70th Annual Meeting of The Endocrine Society, June 8-11, 1988, New Orleans, Louisiana.
132. Carmina E, Malizia G, Janni A and Lobo RA: Comparison of adrenal responses with ACTH and ovine (O) CRF in normal and hyperandrogenic women. Presented at the 70th Annual Meeting of The Endocrine Society, June 8-11, 1988, New Orleans, Louisiana.
133. Matteri R, Hatch I, Delgado C, Paulson R, Stanczyk F and Lobo R: Influence of the ovary on androgens of peripheral origin. Presented at the 44th Annual Meeting of The American Fertility Society, October 8-13, 1988, Atlanta, Georgia.
134. Anderson RE, Paulson RJ, Sauer MV and Lobo RA: Evidence supporting the routine use of a GnRH agonist (GnRH-a) during ovarian stimulation for in vitro fertilization (IVF). Presented at the 4th Annual Meeting of The American Fertility Society, October 8-13, 1988, Atlanta, Georgia.
135. Vermesh M, Silva PD, Rosen GF, Stein AL, Fossum GT, Anderson RE, Sauer MV,

- Vargyas JM, Lobo RA and Mishell DR Jr: Management of unruptured ectopic pregnancy (UEP) by linear salpingostomy (LS). An extended, prospective clinical trial of laparoscopy (LSC) versus laparotomy. Presented at the 44th Annual Meeting of the American Fertility Society, October 8-13, 1988, Atlanta, Georgia.
136. Levin JH, Anderson RE, Stanczyk FZ and Lobo RA: Characteristics of progestin (P) inhibition of gonadotropin secretion in normal women. Presented at the 36th Annual Meeting of the Society for Gynecologic Investigation, March 15-18, 1989, San Diego, California.
 137. Matteri RK, Stanczyk FZ, Lee DG, Delgado C, Gentzschein E and Lobo RA: C-19 conjugates reflect both ovarian and peripheral androgen metabolism. Presented at the 36th Annual Meeting of the Society for Gynecologic Investigation, March 15-18, 1989, San Diego, California.
 138. Matteri RK, Stanczyk FZ, Gentzschein E, Vijod AG and Lobo RA: Δ^5 androstenediol and its conjugates in pre and post-menopausal women and men. Presented at the 36th Annual Meeting of the Society for Gynecologic Investigation, March 15-18, 1989, San Diego, California.
 139. Stanczyk FZ, Nadler J, Vijod AG, Krikorian L, Rosen GF, Steinleitner A and Lobo RA: Influence of estrogen and the effect of smoking on prostacyclin (PGI_2) and thromboxane A_2 (TXA_2) balance in postmenopausal women. Presented at the 36th Annual Meeting of the Society for Gynecologic Investigation, March 15-18, 1989, San Diego, California.
 140. Steinleitner A, Stanczyk FZ, Levin JH, Vijod MA, Nakamura RM and Lobo RA: Decreased production of 6-keto-prostaglandin ($\text{F}_{1\alpha}$) ($6\text{KPGF}_{1\alpha}$) by postmenopausal uterine arteries. Presented at the 36th Annual Meeting of the Society for Gynecologic Investigation, March 15-18, 1989, San Diego, California.
 141. Steinleitner A, Stanczyk FZ, Paulson RJ and Lobo RA: Characterization of proopiomelanocortin (POMC) peptides in porcine and human follicular fluid. Presented at the 36th Annual Meeting of the Society for Gynecologic Investigation, March 15-18, 1989, San Diego, California.
 142. Paulson RJ, Hernandez MF, Do YS, Hsueh WA and Lobo RA: Angiotensin II (AII) modulation of steroidogenesis by luteinized granulosa cells in vitro. Presented at the 36th Annual Meeting of the Society for Gynecologic Investigation, March 15-18, 1989, San Diego, California.
 143. Carmina E, Levin JH, Malizia G and Lobo RA: Decreased responses of ACTH to ovine corticotropin-releasing factor (oCRF) and increased adrenal insensitivity in hyperandrogenic women. Presented at the 37th Annual Meeting of the Pacific Coast Fertility Society, April 12-16, 1989, Palm Springs, California.
 144. Paulson RJ, Francis-Hernandez M, Macaso TM, Lobo RA and Sauer MV: Embryo

implantation following human in vitro fertilization (IVF): Relative contributions of embryo quality (EQ) and endometrial receptivity (ER). Presented at the 37th Annual Meeting of the Pacific Coast Fertility Society, April 12-16, 1989, Palm Springs, California.

145. Sauer MV, Macaso TM, Francis-Hernandez M, Lobo RA and Paulson RJ: Establishment of a non-anonymous donor oocyte program: Preliminary experience at the University of Southern California. Presented at the 37th Annual Meeting of the Pacific Coast Fertility Society, April 12-16, 1989, Palm Springs, California.
146. Carmina E, Levin JH and Lobo RA: Clinical similarities between late onset congenital adrenal hyperplasia and polycystic ovary syndrome. Presented at the 71st Annual Meeting of The Endocrine Society, June 21-24, 1989, Seattle, Washington.
147. Matteri RK, Kaufman FR, Stanczyk FZ, Gentzschein E, Vijod AG and Lobo RA: Androgens of peripheral origin increase during adrenarche in boys. Presented at the 71st Annual Meeting of The Endocrine Society, June 21-24, 1989, Seattle, Washington.
148. Matteri RK, Levin JH, Stanczyk FZ, Paulson RJ and Lobo RA: Androgens are elevated with gonadotropin therapy despite GnRH-agonist suppression. Presented at the 45th Annual Meeting of The American Fertility Society, November 11-16, 1989, San Francisco, California.
149. Carmina E, Stanczyk FZ, Matteri RK and Lobo RA: Androsterone glucuronide signifies the presence and severity of acne (A) among hyperandrogenic hirsute women (HHW). Presented at the 37th Annual Meeting of the Society for Gynecologic Investigation, March 21-24, 1990, St. Louis, Missouri.
150. Lee DG, Pike MC, Stanczyk FZ and Lobo RA: A reevaluation of the effects of smoking on estrogen status. Presented at the 37th Annual Meeting of the Society for Gynecologic Investigation, March 21-24, 1990, St. Louis, Missouri.
151. Presser SC, Stanczyk FZ and Lobo RA: The simultaneous measurements of prostacyclin and thromboxane metabolites during the menstrual cycle and in postmenopausal women. Presented at the 37th Annual Meeting of the Society for Gynecologic Investigation, March 21-24, 1990, St. Louis, Missouri.
152. Levin, JH, Tonetta SA, Hickey MJ and Lobo RA; Growth factors modulate prolactin (PRL) production by isolated, dispersed human endometrial stromal cells in culture. Presented at the 37th Annual Meeting of the Society for Gynecologic Investigation, March 21-24, 1990, St. Louis, Missouri.
153. Levin JH, Tonetta SA, Stanczyk FZ and Lobo RA: Differential regulation of prolactin (PRL) and prostacyclin production by human endometrial stromal cells in culture.

Presented at the 37th Annual Meeting of the Society for Gynecologic Investigation, March 21-24, 1990, St. Louis, Missouri.

154. Levin JH, Hickey MJ and Lobo RA: Mechanisms of clomiphene citrate (CC) resistance in polycystic ovary syndrome (PCO). Presented at the 37th Annual Meeting of the Society for Gynecologic Investigation, March 21-24, 1990, St. Louis, Missouri.
155. Stanczyk FZ, Moltz L, Schwartz U and Lobo RA: Dexamethasone (DEX) suppressibility and adrenal and ovarian venous effluents of 5 α -reduced C19 conjugates in women. Presented at the 37th Annual Meeting of the Society for Gynecologic Investigation, March 21-24, 1990, St. Louis, Missouri.
156. Steinleitner A, Stanczyk FZ and Lobo RA: Production of POMC peptides under gonadotropin stimulation and modulation of ovarian steroidogenesis by POMC peptides in cultured porcine granulosa cells (pGC). Presented at the 37th Annual Meeting of the Society for Gynecologic Investigation, March 21-24, 1990, St. Louis, Missouri.
157. Sauer MV, Paulson RJ and Lobo RA: Oocyte donation: Extending reproductive potential to women over forty. Presented at the 37th Annual Meeting of the Society for Gynecologic Investigation, March 21-24, 1990, St. Louis, Missouri.
158. Paulson RJ, Sauer MV and Lobo RA: Factors affecting embryo implantation (EI) following human in vitro fertilization (IVF). Presented at the 37th Annual Meeting of the Society for Gynecologic Investigation, March 21-24, 1990, St. Louis, Missouri.
159. Paulson RJ, Sauer MV, Francis MM, Macaso TM and Lobo RA: In vitro fertilization (IVF) in unstimulated cycles. Presented at the 37th Annual Meeting of the Society for Gynecologic Investigation, March 21-24, 1990, St. Louis, Missouri.
160. Price T, Dupuis R, Pollack G, Mattern W, Stanczyk F, Lobo R, Dotters D and Droegemueller W: Single dose pharmacokinetics of a 35 μ g ethinyl estradiol, 1 mg norethindrone combination oral contraceptive in women with chronic renal failure on continuous ambulatory peritoneal dialysis. Presented at the 37th Annual Meeting of the Society for gynecologic Investigation, March 21-24, 1990, St. Louis, Missouri.
161. Kovacs BW, Kornafel K, Shahbahrani B, Curtain J and Lobo R: Molecular alterations in endometrial hyperplasias and cancers. Presented at the 37th Annual Meeting of the Society for Gynecologic Investigation, March 21-24, 1990, St. Louis, Missouri.
162. Sauer MV, Paulson RJ, Macaso TM, Francis MM and Lobo RA: Nonanonymous oocyte donation: A successful treatment for infertility in women with ovarian failure. Presented at the 38th Annual Meeting of the Pacific Coast Fertility Society, April 25-29, 1990, Scottsdale, Arizona.
163. Frederick JL, Paulson RJ, Sauer MV, Francis MM, Macaso TM and Lobo RA: In vitro fertilization (IVF) in unstimulated cycles: Analysis of follicular fluid (FF) steroids.

Presented at the 38th Annual Meeting of the Pacific Coast Fertility Society, April 25-29, 1990, Scottsdale, Arizona.

164. Paulson RJ, Sauer MV, Francis MM, Macaso TM and Lobo RA: Use of test-yolk buffer (TYB) to enhance fertilization during human in vitro fertilization (IVF) in cases of suspected male infertility. Presented at the 38th Annual Meeting of the Pacific Coast Fertility Society, April 25-29, 1990, Scottsdale, Arizona.
165. Levin JH, Tonetta SA and Lobo RA: Human chorionic gonadotropin (hCG) enhances progestin stimulation of prolactin (PRL) production by human endometrial stromal cells in culture: Evidence for trophoblast-endometrial paracrine interaction. Presented at the 38th Annual Meeting of the Pacific Coast Fertility Society, April 25-29, 1990, Scottsdale, Arizona.
166. Levin JH, Tonetta SA and Lobo RA: Leuprolide acetate (LA) does not alter progestin stimulation of prolactin (PRL) production by human endometrial stromal cells in culture. Presented at the 38th Annual Meeting of the Pacific Coast Fertility Society, April 25-29, 1990, Scottsdale, Arizona.
167. Carmina E and Lobo RA: Serum levels of 5 androgen metabolites in hirsutism. Presented at the XXIII Congresso Della Societa Italiana di Endocrinologia, May 27-29, 1990, Porto Conte-Alghero, Italy.
168. Carmina E and Lobo RA: Effect of long term dexamethasone (DEX) or spironolactone (S) administration on clinical presentation and peripheral androgen metabolites in hirsutism. Presented at the 2nd European Congress of Endocrinology, July 1-6, 1990, Ljubljana, Yugoslavia.
169. Stanczyk FZ, Matteri RK and Lobo RA: An assessment of serum C₁₉ sulfates and glucuronides as markers of peripheral androgen metabolism in women. Presented at the VIII International Congress on Hormonal Steroids, September 16-21, 1990, The Hague, The Netherlands.
170. Paulson RJ, Sauer MV, Francis MM, Macaso TM and Lobo RA: Norethindrone (NET) blocks the initial agonistic response to leuprolide acetate (LA). Presented at the 46th Annual Meeting of The American Fertility Society, October 13-18, 1990, Washington, D.C.
171. Ditkoff EC, Cassidenti DL, Paulson RJ, Sauer MV, Paul WL and Lobo RA: The GnRH antagonist, Nal-Glu, acutely blocks the LH surge but allows for resumption of folliculogenesis in normal women and in women undergoing hyperstimulation. Presented at the 38th Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1991,

San Antonio, Texas.

172. Cassidenti DL, Sauer MV, Paulson RJ, Ditkoff EC and Lobo RA: A proposed protocol for the use of the GnRH-antagonist (Nal-Glu) in IVF cycles and its comparison to the GnRH-agonist (A). Presented at the 38th Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1991, San Antonio, Texas.
173. Miles RA, Cassidenti DL, Carmina E, Gentzsch E, Stanczyk FZ and Lobo RA: Percutaneous androstenedione as an in vivo test of inherent 5 α -reductase activity (5 α -RA). Presented at the 38th Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1991, San Antonio, Texas.
174. Cassidenti DL, Stanczyk FZ and Lobo RA: The relationship between insulin resistance, IGF-1 levels, adrenal androgens and peripheral androgen metabolism in polycystic ovary syndrome (PCO). Presented at the 38th Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1991, San Antonio, Texas.
175. Stanczyk FZ, Chang L, Carmina E and Lobo RA: Is 11 β -hydroxyandrostenedione (11 β -OHA) a better marker of adrenal androgen excess than dehydroepiandrosterone (DS)? Presented at the 38th Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1991, San Antonio, Texas.
176. Levin JH, Stanczyk FZ, Vijod MA and Lobo RA: Growth factors stimulate prostaglandin production from human endometrial stromal cells in culture. Presented at the 38th Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1991, San Antonio, Texas.
177. Chang L, Stanczyk FZ, Cassidenti DL, Putz Z and Lobo RA: Is the ovary a source of 11 β -hydroxyandrostenedione among hyperandrogenic women? Presented at the 38th Annual Meeting of the Soc. for Gynecol Invest. March 20-23, 1991, San Antonio, Texas.
178. Presser SC, Stanczyk FZ, Delgado C and Lobo RA: Insulin sensitivity in postmenopausal women and the effects of estrogen. Presented at the 38th Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1991, San Antonio, Texas.
179. Paulson RJ, Sauer MV, Francis MM, Macaso TM and Lobo RA: Factors affecting success of human in vitro fertilization (IVF) in unstimulated cycles. Presented at the 38th Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1991, San Antonio, Texas.
180. Bergman A, Lobo R and Stanczyk FZ: Role of prostaglandins in detrusor instability. Presented at the 38th Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1991, San Antonio, Texas.
181. Dodds WG, Friedman CI, Lobo R, Goldberg J and Kim MH: Low dose daily verses

- alternate day dexamethasone therapy in adrenal hyperandrogenism. Presented at the 38th Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1991, San Antonio, Texas.
182. Meme D, Shoupe D and Lobo R: Use of progesterone (P) releasing intrauterine device for protection of the endometrium in menopausal hormone replacement: A pilot study. Presented at the 38th Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1991, San Antonio, Texas.
183. Cassidenti DL, Paulson RJ, Lobo RA and Sauer MV: The synergistic effects of clomiphene citrate and human menopausal gonadotropins in folliculogenesis of hyperstimulated cycles as assessed by GnRH antagonist (Nal-Glu). Presented at the 39th Annual Meeting of the Pacific coast Fertility Society, April 10-14, 1991, Indian Wells, California.
184. Presser SC, Stanczyk FZ, Sauer MV, Delgado C and Lobo RA: Insulin induced stress responses and the effects of estrogen and progestin in postmenopausal women (PMW). Presented at the 39th Annual Meeting of the Pacific Coast Fertility Society, April 10-14, 1991, Indian Wells, California.
185. Carmina E, Stanczyk FZ, Chang L, Miles RA and Lobo RA: The ratio of androstenedione (A)/11 β -hydroxyandrostenedione (11 β -A) is an important marker of adrenal androgen excess in women. Presented at the 39th Annual Meeting of the Pacific Coast Fertility Society, April 10-14, 1991, Indian Wells, California.
186. Cassidenti DL, Matteri RK, Vijod AG and Lobo RA: Lack of correlation between the suppression of androgen levels and the ovulatory response in clomiphene resistant patients with polycystic ovary syndrome (PCO). Presented at the 39th Annual Meeting of the Pacific Coast Fertility Society, April 10-14, 1991, Indian Wells, California.
187. Paulson RJ, Sauer MV, Francis MM, Macaso M and Lobo RA: Embryo implantation after in vitro fertilization (IVF) in unstimulated cycles. Presented at the 39th Annual Meeting of the Pacific Coast Fertility Society, April 10-14, 1991, Indian Wells, CA.
188. Ditkoff EC, Levin JH, Paul WL, and Lobo RA: Time-related fluorimmunoassay (FIA): A better clinical indication of LH biological activity. Presented at the 47th Annual Meeting of The American Fertility Society, October 19-24, 1991, Orlando, Florida.
189. Carmina E, Ditkoff EC, Vijod AG, Janni A and Lobo RA: Increased circulating levels of β -endorphin in PCO are not due to increased pituitary secretion. Presented at the 39th Annual Meeting of the Society for Gynecologic Investigation, March 18-21, 1992, San Antonio, Texas.
190. Millar LK, Goodwin TM, Stanczyk FZ, Lobo RA and Paul RH: Effect of 6 hour

infusion of the oxytocin antagonist atosiban on uterine activity and plasma PGFM.
Presented at the 39th Annual Meeting of the Society for Gynecologic Investigation,
March 18-21, 1992, San Antonio, Texas.

191. Ng S, Shoupe D and Lobo R: Peripheral vasodilatory effect of conjugated equine estrogens in postmenopausal women. Presented at the 39th Annual Meeting of the Society for Gynecologic Investigation, March 18-21, 1992, San Antonio, Texas.
192. Lindheim SR, Legro RS, Stanczyk FZ, Vijod MA and Lobo RA: Stress responses in pre- and postmenopausal women and the effects of estrogen. Presented at the 39th Annual Meeting of the Society for Gynecologic Investigation, March 18-21, 1992, San Antonio, Texas.
193. Ditkoff EC, Kornafel KL, Carmina E, Shoupe D, Stanczyk FZ and Lobo RA: Corticotropin-releasing factor decreases fasting insulin levels in patients with PCO. Presented at the 39th Annual Meeting of the Society for Gynecologic Investigation, March 18-21, 1992, San Antonio, Texas.
194. Carmina E, Getzschein E and Lobo RA: Evidence for increased androsterone metabolism in nonhyperandrogenic acne. Presented at the 39th Annual Meeting of the Society for Gynecologic Investigation, March 18-21, 1992, San Antonio, Texas.
195. Ditkoff EC, Fruzzetti F, Chang L, Stanczyk FZ and Lobo RA: Ovarian influence on adrenal androgen sensitivity and secretion in PCO. Presented at the 39th Annual Meeting of the Society for Gynecologic Investigation, March 18-21, 1992, San Antonio, Texas.
196. Price T, Carr B, Dupulis R, Stanczyk F and Lobo R: Multiple dose pharmacokinetics of
a 35 µg ethinyl estradiol, 1 mg norethindrone oral contraceptive in women with chronic renal failure on peritoneal dialysis. Presented at the 39th Annual Meeting of the Society for Gynecologic Investigation, March 18-21, 1992, San Antonio, Texas.
197. Miles RA, Lobo RA, Paulson RJ and Sauer MV: The use of testolactone to prevent ovarian hyperstimulation syndrome (OHSS) after gonadotropin therapy. Presented at the 39th Annual Meeting of the Society for Gynecologic Investigation, March 18-21, 1992, San Antonio, Texas.
198. Carmina E, Koyma T, Chang L, Stanczyk FZ and Lobo RA: Ethnic variability in polycystic ovary syndrome (PCO): Insight into pathophysiology. Presented at the 39th Annual Meeting of the Society for Gynecologic Investigation, March 18-21, 1992, San Antonio, Texas.
199. Paulson RJ, Sauer MV, Francis MM, Macaso TM and Lobo RA: Toward ultimate in vitro fertilization (IVF): Addition of the GnRH antagonist Nal-Glu and pure FSH to unstimulated IVF cycles. Presented at the 39th Annual Meeting of the Society for Gynecologic Investigation, March 18-21, 1992, San Antonio, Texas.

200. Miles RA, Lobo RA, Gentzchein E, Moyer D, Presser MF, Koopersmith T, Paulson RJ and Sauer MV: Assessing the pharmacodynamic properties of exogenously administered progesterone: A comparison of micronized vaginal delivery to intramuscular routes. Presented at the 40th Annual Meeting of the Pacific Coast Fertility Society, April 8-12, 1992, Indian Wells, California.
201. Miles RA, Gentzschein E, Goedert L, Stanczyk FZ and Lobo RA: Assessment of androgen suppression using androstenedione gel. Presented at the 40th Annual Meeting of the Pacific Coast Fertility Society, April 8-12, 1992, Indian Wells, California.
202. Lindheim SR, Ditkoff EC, Presser SC, Vijod MA, Stanczyk FZ and Lobo RA: A biomodal effect of estrogen on insulin resistance in postmenopausal women and a potential attenuating effect of progestin. Presented at the 40th Annual Meeting of the Pacific Coast Fertility Society, April 8-12, 1992, Indian Wells, California.
203. Lindheim SR, Legro RS, Chang L, Vijod MA, Shoupe D, Stanczyk FZ and Lobo RA; Enhanced reactivity to induced behavioral stress in polycystic ovary syndrome. Presented at the 40th Annual Meeting of the Pacific Coast Fertility Society, April 8-12, 1992, Indian Wells, California.
204. Carmina E, Janni A and Lobo RA: Physiologic hormonal replacement enhances the effect of GnRH-agonist treatment for hirsutism in patients with ovarian hyperandrogenism. Presented at the 74th Annual Meeting of The Endocrine Society, June 24-27, 1992, San Antonio, Texas.
205. Stanczyk FZ, Carmina E, Gentzschein E and Lobo RA: Specific elevations in C19 conjugate levels in hyperandrogenic women with hirsutism. Presented at the 74th Annual Meeting of The Endocrine Society, June 24-27, 1992, San Antonio, Texas.
206. Cassidenti DL, Ary BA and Lobo RA: Leuprolide acetate (LA) followed by clomiphene citrate (CC) induces ovulation in clomiphene resistant patients with polycystic ovary syndrome (PCO). Presented at the 48th Annual Meeting of The American Fertility Society, October 31-November 5, 1992, New Orleans, Louisiana.
207. Lindheim SR, Legro RS, Vijod MA, Stanczyk FZ and Lobo RA: Does racial background influence the effect of estrogens on the hormonal response to stress? Presented at the 48th Annual Meeting of The American Fertility Society, October 31-November 5, 1992, New Orleans, Louisiana.
208. Lindheim SR, Kades WW, Wassilv VM, Chang L, Kojima T, Saad MF and Lobo RA: Effects of IGF-1 and insulin in PCO. Presented at the 40th Annual Meeting of the Society for Gynecologic Investigation, March 31-April 3, 1991, Toronto, Ontario, Canada.
209. Carmina E, Gentzschein E, Stanczyk FZ and Lobo RA: Substrate dependency of C19

- conjugates in hyperandrogenic women and the influence of adrenal androgen. Presented at the 40th Annual Meeting of the Society for Gynecologic Investigation, March 31-April 3, 1993, Toronto, Ontario, Canada.
210. Lindheim SR, Sauer MV, Francis MM, Macaso TM, Lobo RA and Paulson RJ; Elevated early follicular phase FSH levels in unstimulated cycles: Effects on follicular dynamics and oocyte maturation. Presented at the 40th Annual Meeting of the Society for Gynecologic Investigation, March 31-April 3, 1993, Toronto, Ontario, Canada.
211. Duffy DM, Lobo RA, Paulson RJ and Sauer MV: Follicular and endometrial response to fixed dose regimens of estrogen and progesterone among cycling women preparing for oocyte donation. Presented at the 40th Annual Meeting of the Society for Gynecologic Investigation, March 31-April 3, 1993, Toronto, Ontario, Canada.
212. Stanczyk FZ, Gentschein E, Kojima T, Ary BA, Ziogas A and Lobo RA: Comparison of urinary unconjugated progesterone with urinary pregnanediol glucuronide as a marker of luteal activity. Presented at the 40th Annual Meeting of the Society for Gynecologic Investigation, March 31-April 3, 1993, Toronto, Ontario, Canada.
213. Legro RS, Carmina E, Gentschein E, Stanczyk FZ and Lobo RA: Evidence for decreased androgen glucuronidation in balding men and androgenic alopecia. Presented at the 40th Annual Meeting of the Society for Gynecologic Investigation, March 31-April 3, 1993, Toronto, Ontario, Canada.
214. Lindheim SR, Buchanan TA, Duffy DM, Vijod MA, Kojima T and Lobo RA: Estimates of insulin resistance in postmenopausal women: Comparison of the ITT and the IVGTT. Presented at the 40th Annual Meeting of the Society for Gynecologic Investigation, March 31-April 3, 1993, Toronto, Ontario, Canada.
215. Legro RS, Shahbarami B, Lobo RA and Kovacs B: Size polymorphisms of the androgen receptor among female Hispanics and correlation with peripheral hyperandrogenism. Presented at the 40th Annual Meeting of the Society for Gynecologic Investigation, March 31-April 3, 1993, Toronto, Ontario, Canada.
216. Legro RS, Muhleman D, Comings D, Lobo RA and Kovacs B: D3 receptor polymorphisms associated with oligo-ovulation among female Hispanics. Presented at the 40th Annual Meeting of the Society for Gynecologic Investigation, March 31-April 3, 1993, Toronto, Ontario, Canada.
217. Lindheim SR, Legro RS, Wong IL, Tran DQ, Chang L and Lobo RA: Attenuating effects of progestin on adaptation to behavioral stress in postmenopausal women. Presented at the 40th Annual Meeting of the Society for Gynecologic Investigation, March 31-April 3, 1993, Toronto, Ontario, Canada.
218. Wong IL, Chang L, Spahn M-A F, Lindheim SR, Stanczyk FZ and Lobo RA; Characterization of the ovarian steroidogenic abnormality in PCO. Presented at the 40th

Annual Meeting of the Society for Gynecologic Investigation, March 31-April 3, 1993, Toronto, Ontario, Canada.

219. Legro RS, Blanche P, Krauss RM and Lobo RA: Alterations in atherogenic lipoproteins among hyperandrogenic women: Influence of insulin and genetic factors. Presented at the 40th Annual Meeting of the Society for Gynecologic Investigation, March 31-April 3, 1993, Toronto, Ontario, Canada.
220. Ary BA, Stanczyk FZ, Fahy MA and Lobo RA: 6-sulfatoxymelatonin levels in ovulatory women. Presented at the 40th Annual Meeting of the Society for Gynecologic Investigation, March 31-April 3, 1993, Toronto, Ontario, Canada.
221. Lindheim SR, Kojima T, Duffy DM, Vijod MA, Stanczyk FZ and Lobo RA: Insulin sensitivity is decreased in normal women by doses of ethinyl estradiol used in oral contraceptives. Presented at the 41st Annual Meeting of the Pacific Coast Fertility Society, April 14-18, 1993, Indian Wells, California.
222. Lindheim SR, Duffy DM, Kojima T, Vijod MA, Stanczyk FZ and Lobo RA: The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women. Presented at the 41st Annual Meeting of the Pacific Coast Fertility Society, April 14-18, 1993, Indian Wells, California.
223. Lindheim SR, Sauer MV, Francis MM, Macaso TM, Lobo RA and Paulson RJ: In vitro fertilization (IVF) in unstimulated cycles: Utility of a midcycle FSH boost in addition to HCG for timing of follicle aspiration. Presented at the 41st Annual Meeting of the Pacific Coast Fertility Society, April 14-18, 1993, Indian Wells, California.
224. Carmina E and Lobo RA: Ovarian suppression reduces clinical and endocrine expression of late onset congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. Presented at the 75th Annual Meeting of The Endocrine Society, June 9-12, 1993, Las Vegas, Nevada.
225. Morris RS, Carmina E, Vijod MA, Stanczyk FZ and Lobo RA: Alterations in the sensitivity of serum IGF-1 and IGF-BP3 to octreotide in polycystic ovary syndrome (PCO). Presented at the 75th Annual Meeting of The Endocrine Society, June 9-12, 1993, Las Vegas, Nevada.
226. Ary BA, Chang L, Gentzschein E, Vijod M, Stanczyk FZ and Lobo RA: Comparison of GRF and clonidine as probes for the GH axis in normal and clomiphene resistant women with PCO. Presented at the conjoint meeting of The American Fertility Society and The Canadian Fertility and Andrology Society, October 9-14, 1993, Montreal, Quebec, Canada.
227. Duffy DM, Lindheim SR, Ary BA, Saad M, Vijod MA, Chang L and Lobo RA: The effects of growth hormone releasing factor (GRF) and insulin-like growth factor-1 (IGF-

- 1) on folliculogenesis in normal women. Presented at the conjoint meeting of The American Fertility Society and The Canadian Fertility and Andrology Society, October 9-14, 1993, Montreal, Quebec, Canada.
228. Morris RS, Duffy DM, Lindheim SR, Gentzsch E, Spahn M-A, Chang L, Espinoza TB, Anderson PW and Lobo RA: Angiotensin converting enzyme (ACE) inhibition during the normal menstrual cycle. Presented at the conjoint meeting of The American Fertility Society and The Canadian Fertility and Andrology Society, October 9-14, 1993, Montreal, Quebec, Canada.
229. Lindheim SR, Legro RS, Morris RS, Lobo RA, Paulson RJ and Sauer MV: Altered stress responses in women undergoing in vitro fertilization and in recipients of oocyte donation. Presented at the conjoint meeting of The American Fertility Society and The Canadian Fertility and Andrology Society, October 9-14, 1993, Montreal, Quebec, Canada.
230. Morris RS, Wong IL, Hatch IE, Paulson RJ and Lobo RA: Prorenin is elevated in PCO and may reflect hyperandrogenism. Presented at the 41st Annual Meeting of the Society for Gynecologic Investigation, March 22-26, 1994, Chicago, Illinois.
231. Wilcox JG, Morris RS, Gentzsch E, Stanczyk FZ and Lobo RA: The biological effects of 17α -dihydroequilin sulfate and its possible modulation of hepatic production. Presented at the 41st Annual Meeting of the Society for Gynecologic Investigation, March 22-26, 1994, Chicago, and Illinois.
232. Wong IL, Morris RS, Chang L, Spahn MA, Stanczyk FZ and Lobo RA: A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. Presented at the 41st Annual Meeting of the Society for Gynecologic Investigation, March 22-26, 1994, Chicago, Illinois.
233. Duffy DM, Legro RS, Stanczyk FZ and Lobo RA: Comparisons between dihydrotestosterone (DHT) metabolism in blood and skin in men, women and polycystic ovary syndrome. Presented at the 41st Annual Meeting of the Society for Gynecologic Investigation, March 22-26, 1994, Chicago, Illinois.
234. Carmina E, Stanczyk FZ, Morris RS, Vijod MA, Lee PDK, Savjani G and Lobo RA: Altered regulation of IGFBP-1 and BP-3 in patients with PCO. Presented at the 41st Annual Meeting of the Society for Gynecologic Investigation, March 22-26, 1994, Chicago, Illinois.
235. Carmina E, Chang L, Gonzalez F and Lobo RA: Does the ovary explain elevated levels of DHEAS and 11β -A in polycystic ovary syndrome (PCO)? Presented at the 41st Annual Meeting of the Society for Gynecologic Investigation, March 22-26, 1994, Chicago, Illinois.

236. Hatch IE, Carmina E, Vijod MA, Gentzschein E, Stanczyk FZ and Lobo RA: Inhibition of the IGF axis and 5-alpha reductase activity by 13-cis retinoic acid in normal women. Presented at the 41st Annual Meeting of the Society for Gynecologic Investigation, March 22-26, 1994, Chicago, Illinois.
237. Wong IL, Morris RS, Paulson RJ, Lobo RA and Sauer MV: Isolated polycystic morphology in ovum donors predicts response to controlled hyperstimulation. Presented at the 41st Annual Meeting of the Society for Gynecologic Investigation, March 22-26, 1994, Chicago, Illinois.
238. Morris RS, Wong IL, Lobo RA and Paulson RJ: Angiotensin converting enzyme (ACE) inhibition for the prevention of OHSS in rabbits: A randomized, prospective, double blinded trial. Presented at the 41st Annual Meeting of the Society for Gynecologic Investigation, March 22-26, 1994, Chicago, Illinois.
239. Legro RS, Wong IL, Paulson RJ, Lobo RA and Sauer MV: Uterine aging does not adversely affect endometrial receptivity to embryo implantation in recipients of oocyte donation. Presented at the 41st Annual Meeting of the Society for Gynecologic Investigation, March 22-26, 1994, Chicago, Illinois.
240. Legro RS, Wong IL, Paulson RJ, Lobo RA and Sauer MV: The natural history of multiple implantation following oocyte donation: A frequent but inefficient event. Presented at the 41st Annual Meeting of the Society for Gynecologic Investigation, March 22-26, 1994, Chicago, Illinois.
241. Gonzalez F, Chang L, Horab T and Lobo RA: Further assessment of the role of ovarian steroids in the development of adrenal dysfunction. Presented at the 41st Annual Meeting of the Society for Gynecologic Investigation, March 22-26, 1994, Chicago, Illinois.
242. Hatch IE, Carmina E, Stanczyk FZ and Lobo RA: Serum AoG is a useful marker for the treatment of acne in normoandrogenic women. Presented at the 42nd Annual Meeting of the Pacific Coast Fertility Society, April 20-24, 1994, Indian Wells, California.
243. Duffy DM, Koch C, Gentzschein E, Stanczyk FZ, Paulson RJ and Lobo RA: A re-evaluation of the importance of luteinizing hormone (LH) for follicle growth and oocyte maturity. Presented at the 42nd Annual Meeting of the Pacific Coast Fertility Society, April 20-24, 1994, Indian Wells, California.
244. Duffy DM, Bass D, Stanczyk FZ, Gentzschein E and Lobo RA: The single FSH value: Evaluation of assay method, time interval, and operator differences. Presented at the 42nd Annual Meeting of the Pacific Coast Fertility Society, April, 20-24, 1994, Indian Wells, CA.

245. Morris RS, Wong IL, Gentszchein E, Sauer MV, Lobo RA and Paulson RJ: Angiotensin converting enzyme (ACE) inhibition for the prevention of ovarian hyperstimulation syndrome (OHSS): A randomized, prospective, placebo controlled, double blind trial. Presented at the 42nd Annual Meeting of the Pacific Coast Fertility Society, April 20-24, 1994, Indian Wells, California.
246. Morris RS, Wong IL, Sauer MV, Lobo RA and Paulson RJ: Predictive value of serum estradiol (E_2) levels and oocyte number in the prediction of severe ovarian hyperstimulation. Presented at the 42nd Annual Meeting of the Pacific Coast Fertility Society, April 20-24, 1994, Indian Wells, California.
247. Carmina E, Stanczyk FZ, Gentszchein E and Lobo RA: Time-dependent changes in serum 3α -androstenediol glucuronide (3α -diol G) correlate with hirsutism scores after ovarian suppression. Presented at the 76th Annual Meeting of The Endocrine Society, June 15-18, 1994, Anaheim, California.
247. Stanczyk FZ, Skinner EC, Spahn MF, Chang L, Mertes S, Ross R and Lobo RA; Effect of finasteride on serum unconjugated and conjugated androgen levels in men with prostate cancer. Presented at the 76th Annual Meeting of The Endocrine Society, June 15-18, 1994, Anaheim, California.
248. James WM, Morris RS, Gentszchein E, Carmina E and Lobo RA: The effects of octreotide on the adrenal response to corticotropin releasing factor (CRF) in polycystic ovary syndrome (PCO). Presented at the 50th Annual Meeting of The American Fertility Society, November 5-10, 1994, San Antonio, Texas.
250. Duffy DM, Chang L, Gentszchein E and Lobo RA: The use of corticotropin-releasing factor (CRF) to identify the mechanism of oral contraceptive (OC) induced adrenal suppression. Presented at the 50th Annual Meeting of The American Fertility Society, November 5-10, 1994, San Antonio, Texas.
251. Wong IL, Morris RS, Koopersmith TB, and Lobo RA: The effect of finasteride on ovulation function in normal women. Presented at the 50th Annual Meeting of The American Fertility Society, November 5-10, 1994, San Antonio, Texas.
252. Wilcox JG, Hodis HN, Hwang J, Sevanian A, Stanczyk FZ and Lobo RA: The biological effects of individual estrogen components in conjugated equine estrogens (CEE) and their possible modulation of insulin resistance and oxidation of LDL. Presented at the 42nd Annual Meeting of the Society for Gynecologic Investigation, March 15-18, 1995, Chicago, Illinois.
253. Paulson RJ, Sauer MV and Lobo RA: Luteal phase antiprogestin administration improves endometrial receptivity in hyperstimulated cycles: A hypothesis. Presented at the 42nd Annual Meeting of the Society for Gynecologic Investigation, March 15-18, 1995, Chicago, Illinois.

254. Gonzalez F, Chang L, Horab T, Stanczyk FZ, Crickard K and Lobo RA: Adrenal dysfunction in polycystic ovary syndrome (PCO) as assessed by physiologic and pharmacologic adrenal dynamic responses in the presence and absence of ovarian steroids Presented at the 42nd Annual Meeting of the Society for Gynecologic Investigation, March 15-18, 1995, Chicago, Illinois.
255. Hatch IE, Spahn MA, Wilcox JG, Stanczyk FZ and Lobo RA: Opiate regulation of insulin sensitivity and the IGF-1 axis in polycystic ovary syndrome (PCO). Presented at the 42^d Annual Meeting of the Society for Gynecologic Investigation, March 15-18, 1995, Chicago, Illinois.
256. Paulson RJ, Hatch I, Lobo RA and Sauer MV: Lack of decrease of efficiency of oocyte donation substantiates lack of an intrinsic endometrial defect in embryo implantation. Presented at the 42nd Annual Meeting of the Society for Gynecologic Investigation, March 15-18, 1995, Chicago, Illinois.
257. Hendershott CM, Millar LK, Hindle WH, Moyer D, Lobo RA and Felix JC: Hormone levels and proliferative activity in breast tissue throughout the menstrual cycle. Presented at the 42nd Annual Meeting of the Society for Gynecologic Investigation, March 15-18, 1995, Chicago, Illinois.
258. Thornton MH, Najmabadi S, Hatch IE, Acacio B and Lobo RA: Evaluation of inappropriate gonadotropin secretion in polycystic ovary syndrome. Presented at the 42nd Annual Meeting of the Society for Gynecologic Investigation, March 15-18, 1995, Chicago, Illinois.
259. Fruzzetti F, Lobo RA, De Lorenzo D, Parrini D, Ricci C, Ferrara A and Genazzani AR: Comparisons between various antiandrogens in the treatment of hirsutism: Differences between androgen suppression and peripheral effects. Presented at the 42nd Annual Meeting of the Society for Gynecologic Investigation, March 15-18, 1995, Chicago, Illinois.
260. Hatch IE, Nicoloff JT, Spencer CA and Lobo RA: The effect of 13-cis retinoic acid (13-CIS RA) in normal cycling women: An explanation for the diverse endocrine mediated effects of 13-CIS RA. Presented at the 42nd Annual meeting of the Society for Gynecologic Investigation, March 15-18, 1995, Chicago, Illinois.
261. Price T, Blauer K, Hansen M, Stanczyk F, Lobo R and Bates GW: Pharmacokinetics of sublingual vs oral administration of micronized 17 β -estradiol. Presented at the 42nd Annual Meeting of the Society for Gynecologic Investigation, March 15-18, 1995, Chicago, Illinois.

262. Carmina E, Lo Dico G, Lee P, Saviani G, Gentzschein E, Spahn MA, Stanczyk FZ and Lobo RA: Oral estrogen administration increases serum IGFBP-1 and reduces "free" IGF-1. Presented at the 42nd Annual Meeting of the Society for Gynecologic Investigation, March 15-18, 1995, Chicago, Illinois.
263. Mezrow G, Koopersmith T, Shoupe D and Lobo RA: Estrogen replacement therapy using micronized vaginal progesterone. Presented at the 42nd Annual Meeting of the Society for Gynecologic Investigation, March 15-18, 1995, Chicago, Illinois.
264. Paulson RJ, Hatch IE, Lobo RA and Sauer MV: Cumulative success rates after oocyte donation: Life table analysis. Presented at the IXth World Congress on In Vitro Fertilization and Assisted Reproduction, April 3-7, 1995, Vienna, Austria.
265. Hatch IE, Kim MK and Lobo RA: Glucose intolerance in polycystic ovary syndrome (PCOS): Occult findings and risks of pregnancy. Presented at the 43rd Annual Meeting of the Pacific Coast Fertility Society, April 26-30, 1995, San Diego, California.
266. Hatch IE, Sauer MV, Lobo RA and Paulson RJ: Embryo implantation after repetitive cycles of oocyte donation. Presented at the 43rd Annual Meeting of the Pacific Coast Fertility Society, April 26-30, 1995, San Diego, California.
267. Thornton MH, Carmina E, Sauer MV, Paulson RJ, Najmabadi S, Stanczyk FZ, Spahn M-A and Lobo RA: Ovarian production of IGF-BP1 and its role in women with polycystic ovaries. Presented at the 43rd Annual Meeting of the Pacific Coast Fertility Society, April 26-30, 1995, San Diego, California.
268. Wilcox JG, Hatch IE, Gentzschein EK, Stanczyk FZ and Lobo RA: Possible modulation of endothelin levels in postmenopausal women receiving oral versus non-oral hormone replacement therapy. Presented at the 43rd Annual Meeting of the Pacific Coast Fertility Society, April 26-30, 1995, San Diego, California.
269. Koopersmith TB, Sauer MV and Lobo RA: Programmed cycles for frozen embryo transfer: A simplified approach. Presented at the 43rd Annual Meeting of the Pacific Coast Fertility Society, April 26-30, 1995, San Diego, California.
270. Paulson RJ, Sauer MV and Lobo RA: Manipulation of the window of implantation in the human: A proposal. Presented at the 43rd Annual Meeting of the Pacific Coast Fertility Society, April 26-30, 1995, San Diego, California.
271. Adler MA and Lobo RA: Estrogen replacement therapy alters immune competence in postmenopausal women. Presented at the 43rd Annual Meeting of the Pacific Coast Fertility Society, April 26-30, 1995, San Diego, California.
272. Carmina E, Wong IL, Thornton MH, Stanczyk FZ, Paulson RJ, Sauer MV and Lobo RA: Androgen profiles of ovulatory women with polycystic appearing ovaries and alterations in serum IGF-BP1. Presented at the 77th Annual Meeting of The Endocrine

Society, June 14-17, 1995, Washington, D.C.

273. Stanczyk FZ, Carmina E, Skinner EC, Mertes S, Spahn MF, Lee PDK, Savjani G, Ross RK and Lobo RA: Influence of androgen, specifically of 5-reductase activity, but not age on serum IGFBP-1 levels in men. Presented at the 77th Annual Meeting of The Endocrine Society, June 14-17, 1995, Washington, D.C.
274. Carmina E and Lobo RA: GnRH-agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission: Presented at the 51st Annual Meeting of the American Society for Reproductive Medicine, October 7-12, 1995, Seattle, Washington.
275. Thornton MH, Wang C-Y, Spahn M-A, Stanczyk FZ and Lobo RA: Changes in the IGF-1 axis with clomiphene citrate in ovulatory women with PCOS. Presented at the 51st Annual Meeting of the American Society for Reproductive Medicine, October 7-12, 1995, Seattle, Washington.
276. Graczykowski JW, Chang L, Stanczyk FZ and Lobo RA: Does chronic estrogen administration influence pharmacokinetic profiles and does progestin attenuate estrogen bio-availability? Presented at the 51st Annual Meeting of the American Society for Reproductive Medicine, October 7-12, 1995, Seattle, Washington.
277. Koopersmith TB, Gray D, Horowitz D and Lobo RA: Modulation of cytokine and immunoglobulin levels by sex steroids in women. Presented at the 51st Annual Meeting of the American Society for Reproductive Medicine, October 7-12, 1995, Seattle, Washington.
278. Graczykowski JW, Wang C-Y, Stanczyk FZ and Lobo RA. The effect of medroxy-progesterone acetate on insulin sensitivity in postmenopausal women on estrogen replacement therapy. Presented at the 43rd Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1996, Philadelphia, Pennsylvania.
279. Wilcox JG, Hwang J, Gentzschlein EK, Hodis HN, Sevanian A, Stanczyk FZ and Lobo RA. Effects of combined estrogen and progestin therapy in postmenopausal women on endothelin levels and oxidation of LDL. Presented at the 43rd Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1996. Philadelphia, Pennsylvania.
280. Wang C-Y, Stanczyk FZ and Lobo RA. Quantitative measurement of mRNAs encoding type I and type II 5 α -reductase genes in hirsute and non-hirsute women. Presented the 43rd Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1996, Philadelphia, Pennsylvania.

281. Carmina E and Lobo RA. Baseline characteristics of hyperandrogenic women influencing the choice of therapy for hirsutism and whether the agent influences the length of remission. Presented at the 43rd Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1996, Philadelphia, Pennsylvania.
282. Najmabadi S, Thornton MH, Acacio BD and Lobo RA. An assessment of differences in luteinizing hormone (LH) dynamics in patients with polycystic ovary syndrome (PCOS) who have normal or elevated LH. Presented at the 43rd Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1996, Philadelphia, Pennsylvania.
283. Wilcox JG, Najmabadi S, Gentzchein EK, Acacio BD, Stanczyk FZ and Lobo RA. Metformin improves the hormonal profiles of patients with polycystic ovary syndrome. Presented at the 43rd Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1996, Philadelphia, Pennsylvania.
284. Wang C-Y, Jacob C, Graczykowski JW, Kolb BA, Stanczyk FZ, Paulson RJ, Reichardt JKV, Tao I, Gentzchein E and Lobo RA. Length polymorphism of the type II 5 α -reductase gene is associated with hirsutism. Presented at the 43rd Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1996, Philadelphia, Pennsylvania.
285. Najmabadi S, Acacio BD, Thornton MH, Krauss RM and Lobo RA. Effects of transdermal estradiol on serum lipids/lipoproteins and glucose tolerance in postmenopausal hypercholesterolemic women. Presented at the 43rd Annual Meeting of the Society for Gynecologic Investigation, March 20-23, 1996, Philadelphia, Pennsylvania.
286. Hwang J, Wilcox JG, Hodis HN, Lobo RA, Sevanian A: Inhibition of low density lipoprotein oxidation in postmenopausal women receiving combined estrogen therapy. Presented at the American Heart Association, 69th Scientific Sessions, 1996.
287. Wang C-Y, Carmina E, Chang L, Wong IL, Stanczyk FZ, Lobo RA: Effect of finasteride on circulating levels of insulin-like growth factors (IGFs), testosterone, dihydrotestosterone, and their binding proteins in hirsute women. Presented at the 44th Annual Meeting of The Pacific Coast Fertility Society, April 17-21, 1996.
288. Chang PL, Lindheim SR, Carmina E, Vidali A, Ferin M, Sauer MV, Lobo RA: Do normal ovulatory women of normal weight who have polycystic ovaries have features of polycystic ovary syndrome. Presented at 44th Annual Meeting of the Society of Gynecologic Investigation, San Diego, March 19-22, 1997, Abs. # 46.
289. Carmina E, Gonzalez F, Ashok M, Stanczyk FZ, Lobo RA: Influence of insulin and components of the IGF-axis on adrenal hyperandrogenism in PCOS. Presented at 44th Annual Meeting of the Society of Gynecologic Investigation, San Diego, March 19-22, 1997, Abs. # 176.
290. Carmina E, Gonzalez F, Vidali A, Ferin M and Lobo RA: High leptin and low IGF-

BP1 circulating levels in a subgroup of normoweight women with polycystic ovary syndrome (PCOS). Presented at the 79th Annual Meeting of The Endocrine Society, June 11- 14, 1997.

291. Lindheim SR, Chang PL, Ferin M, Lobo RA and Sauer MV: The utility of serum progesterone and inhibin A in monitoring unstimulated IVF-ET cycles. 53rd Annual Meeting of the American Society for Reproductive Medicine, October 18-22, 1997, Cincinnati, Ohio.
292. Lobo RA: Diagnostic dilemmas in PCOS. ASRM symposia Highlights on New Perspectives in Polycystic Ovary Syndrome. 53rd Annual Meeting of the American Society for Reproductive Medicine, October 18-22, 1997, Cincinnati, Ohio. Medical Association Communications and American Society for Reproductive Medicine, 1997.
293. Carmina E, Ferin M. and Lobo R: Evidence that adrenal androgens inhibit and insulin stimulates serum leptin concentrations in women with polycystic ovaries. Presented at the 45th Annual Meeting of the Society of Gynecologic Investigation, Atlanta, Georgia, March 11-14, 1998.
294. Carmina E, Lobo R: Prevalence and characteristics of ovulation occurring in hyperandrogenic women. Presented at the 45th Annual Meeting of the Society of Gynecologic Investigation, Atlanta, Georgia, March 11-14, 1998.
295. Lobo RA: Diagnostic Dilemmas in PCOS. New Perspective in Polycystic Ovary Syndrome. At a session held during ASRM's 53rd Annual Meeting, October 18-22, 1997, in Cincinnati, Ohio. American Society for Reproductive Medicine (ASRM). 1997 Annual Meeting - Symposia Highlights. Medical Association Communications and the American Society for Reproductive Medicine, 1998.
296. Lobo RA: How to Determine the Role of Androgens. North American Menopause Society (NAMS) 9th Annual Meeting, September 16, 1998.
297. Lobo RA. Managing physiological changes of induced menopause. Satellite Symposium on Clinical Management of Women Following Induced Menopause". The 9th Annual Meeting of The American Menopause Society, September 16-19, 1998.
298. Lindheim SR, Sauer MC, Carmina E, Zimmerman R, Chang, P and Lobo RA. Circulating leptin during ovulation induction has no relationship to adiposity and ovarian morphology. The 46th Annual Meeting of the Society of Gynecologic Investigation, Atlanta, Georgia, March 10-13, 1999.
299. Chang P, Lindheim SR, Ferin M, Carmina E, Lowry C, Sauer MV and Lobo RA. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin releasing hormone-agonist (GnRH-a) testing. The 46th Annual

- Meeting of the Society of Gynecologic Investigation, Atlanta, Georgia, March 10-13, 1999.
300. Wang C-Y, Stanczyk FZ, Zheng WX, Felix J and Lobo RA. Localization of human type I and type II 5α -reductase mRNAs in genital skin of hirsute and non-hirsute women. 46th Annual Meeting of the Society of Gynecologic Investigation, Atlanta, Georgia, March 10-13, 1999 (A376).
 301. Carmina E and Lobo RA. The association of hyperandrogenism and ovulatory status with insulin resistance and lipoprotein levels in women. SGI 2000- A Millennial Milestone in Reproductive Sciences: Celebrating the Promise. 47th Annual Meeting of the Society for Gynecologic Investigation, Chicago, Illinois, March 23-26, 2000 (A923).
 302. Carmina E, Lippman J, Godwin A and Lobo RA. Androsterone glucuronide is a useful marker for acne lesions and correlates with the effectiveness of treatment. SGI 2000- A Millennial Milestone in Reproductive Sciences: Celebrating the Promise. 47th Annual Meeting of the Society for Gynecologic Investigation, Chicago, IL, March 23-26, 2000. (A441).
 303. Carmina E, Lobo RA. The prevalence and clinical importance of diagnosing PCOS in ovulatory hirsute women. ENDO 2000 The Endocrine Society 82nd Annual Meeting. Toronto, Ontario, Canada, June 21-24, 2000 (A2334).
 304. Lobo, RA. Physiology of Androgens in Women. Androgens in Women: Physiology, Deficiency, and Emerging Therapeutic Potentials. CMES Ancillary Symposium. The Endocrine Society Annual Meeting. ENDO 2000, Toronto, Canada, June 22, 2000.
 305. Lobo RA. Estrogen agonists and antagonists. The Annual Meeting of the ESHRE, Bologna (Italy), June 25-28, 2000.
 306. Lobo RA. Bone metabolism and progestin hormonal contraception. New two-rod levonorgestrel implants for contraception. Leiras Oy, Jadelle Symposium at the XVI FIGO World Congress of Gynecology and Obstetrics in Washington, September 7, 2000. The Parthenon Publishing Group, International Publishers in Medicine, Science & Technology, Carnforth, Lancs, United Kingdom.
 307. Archer DA, Lobo RA, Utian WH, Pickar JH. Improved amenorrhea, favorable vasomotor and lipid effects, and endometrial safety with lower doses of conjugated estrogens (CE) and medroxyprogesterone acetate (MPA). "Late Breaking News," American Society for Reproductive Medicine (ASRM), 2000.
 308. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu CR, Liu CH, Azen SP. Estrogen in the prevention of atherosclerosis trial. Circulation

102:II. 837 (Abstract).

309. Carmina E, Lobo RA. A comparison of the relative efficacy of antiandrogen therapy for acne and alopecia in hyperandrogenic women. The 48th Annual Society for Gynecological Investigation (SGI) Meeting, March 15, 2001 (A151).
310. Carmina E, Legro R, Stamets K, Lowell J, Lobo RA. The influence of diet on the obesity and metabolic alterations in polycystic ovary syndrome. The Endocrine Society June 2001 Annual Meeting, (A37801).
311. Lobo RA, Bush T, Carr BR, Picar JH. Effects of lower doses of conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA) on plasma lipids. The American Society for Reproductive Medicine (ASRM) meeting 2001 (A1186).
312. Carmina, E, Longo A, Lobo RA. Does ovarian blood flow distinguish between ovulatory and anovulatory patients with polycystic ovary syndrome. The Endocrine Society's 84th Annual Meeting. Abs. # 851188, 2002.
313. Ruman J, Rennaer R, Chung W, Thornton M, Zimmermann R, Sauer MV, Lobo RA and Zeitoun K. The Endocrine Society's 84th Annual Meeting. Abs. # 853627, 2002.
314. Carmina E, Lobo RA. Does metformin induce ovulation in normoandrogenic anovulatory women? The Endocrine Society's 85th Annual Meeting, June 19-22, 2003. Abs. # 851730, 2003.